784 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00002 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 6 M |
| dbacp00011 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00020 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00099 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00108 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00117 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00151 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00184 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00218 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00253 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00262 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 6 M |
| dbacp00271 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00293 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00319 | [A18K]OCN-3N | GIFDVLKNLAKGVITSLKS | Derivatives of ocellatin-3N | Membranolytic mechanism | Not specified | A549 | Lung adenocarcinoma | LC50 : 12-20 μM |
| dbacp00433 | [D4K,A18K]OCN-3N | GIFKVLKNLAKGVITSLKS | Derivatives of ocellatin-3N | Membranolytic mechanism | Not specified | A549 | Lung adenocarcinoma | LC50 : 12-20 μM |
| dbacp00436 | [D4K]OCN-3N | GIFKVLKNLAKGVITSLAS | Derivatives of ocellatin-3N | Not specified | Lactate dehydrogenase (LDH) assay | A549 | Lung adenocarcinoma | LC50 : 12-20 μM |
| dbacp00439 | [G11k, N15K] alyteserin-2a | ILGKLLSTAAGLLSNL | Common midwife toad | Cell-penetrating mechanism | Cytotoxicity assay | A549 | Lung adenocarcinoma | LC50 : 13 µM |
| dbacp00616 | [ribosomal protein uS5]-alanine N-acetyltransferase | MPHTPSRLLAEGPRVGIRHFTLADGPEFTARARESKDLHHPWLFPPDSPQTYEAYAARLIEDRTKAGFLVCERDTAGTSEGTRGGGPIAGFVNINNIVEGGFLSGALGYGAFAHAAGRGLMREGLDLVVRYAFGPMRLHRLEINVQPGNAASIALARACGFHLEGFSPRMLHIDGAWRDHQRWALTAETAASG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00716 | 2,3-dihydroxybenzoate-AMP ligase | MTETQPTWSEAESARYRAAGHWQGVTFGARLRQAGAEHAQRVALVDGNRRWTYADLDAEADRVAAGLRGLGVERGDRVVLQLPNCAEFVLAWFGLQRLGAVPVHAMPGHRSREIGHLVRLSDAVACVVPDLHARFDHRRLMSDVRAELGPDGPLRHVVVVGDPGPYDGFVPFDALRESGGRGPSAPVSDSDSADPDPGGLALLLLSGGTTGLPKLIPRTHDDYAYNARACAGVCALDTRSVYLAVLPLGFNFTFACPGVLGTLMAGGTVVIAPDPSPQTAFALIEREGVTLTSLTPPLVPHWTDEAASGSWDLGSLAVVQVGGARLPEDHARRLGPALGARVQQVFGMAEGLINLTRLDDAEDLVCTTQGRPASPDDEILVVDAGGRPVPDGTAGELLTRGPYTLRGYYRAEAHNRTAFTPDGYYRSGDVVRRLPSGHLVVVGRIKDQINRGGEKIPAVEVEEELLTHPAVTAAALVGVPDERWGERSVAFVVCTGTAPGAREVAAHLASRGLAGYKAPDEIVQVPGLPLTAVGKVDKAALARRSEG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00765 | A specific Eps8/EGFR Inhibitor Peptide 327 | EFLDCFQKF | A specific Eps8/EGFR Inhibitor Peptide 327 | Immune response to tumor cell recognition | Lactate dehydrogenase (LDH)-release assay | A549 | Human lung cancer | IC50 : 119.84 ± 16.01 μM |
| dbacp00773 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 11.1 µMo/L |
| dbacp00778 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.4 µMo/L |
| dbacp00781 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.7 µMo/L |
| dbacp00786 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.1 µMo/L |
| dbacp00789 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.2 µMo/L |
| dbacp00794 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.7 µMo/L |
| dbacp00797 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 8.7 µMo/L |
| dbacp00802 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.9 µMo/L |
| dbacp00806 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | C4-2B | Lung cancer | IC50 : 29.05 μM |
| dbacp00808 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | A549 | Lung cancer | IC50 : 14.97 μM |
| dbacp00810 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | U87 | Lung cancer | IC50 : 14.8 μM |
| dbacp00812 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | MCF-7 | Lung cancer | IC50 : 14.16 μM |
| dbacp00821 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | NCI-H460 | Human lung adenocarcinoma | MIC : 10−4 to 10−9 M |
| dbacp00829 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | NCI-H460 | Human lung adenocarcinoma | MIC : 10−4 to 10−9 M |
| dbacp00839 | ABC transporter ATP-binding protein | MTPPKDSTMDPLVRLDGVHVRHRARSGGLLRRDSVHALTDVGLEVRRGEILGLVGESGCGKSTLARVVTGLQRPTEGRVSFRGRDLWTMSGAERRTGFGAAVGVVFQDASTALNPRLPVRRILRDPLDVHDRGTRAEREERVEELLDLVGLPGHTLQALPGQLSGGQRQRVAIARALALEPELIVADEPTSALDVSVRAQILNLLVDLRARLGLGMVFISHDVQTVRHLADRVAVLYLGRVVEEGGASEVLGASRHPYTEALLSATPSLLERPERIVLHGPVPSATNPPSGCPFRTRCWKADDACATAFPAAAEGPGGHRWHCVHPRESGVPREATSAK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00844 | ABC transporter ATP-binding protein | MTTTGPPTRSDADTPALDVEGLCVELSTPSGTVRAVDGVSFSVRRGRTLALLGESGCGKSMTALSVVGLLDPAAAVTGGAVRVRGDDTLRMSPAQRRRLAGPVLSIVFQDALTALNPVQPVGRQIGEPFRIHRRLSRRQAREKAIELMTRVGIPEPRQRARSYPHQFSGGMRQRLLIAMAVALAPDVLIADEPTTALDVTVQAQIMRLLRDLQDERDMAVVLITHDLAVVAQRADDVVVMYAGTVVENGPVRDVFAAPRHPYTRGLLDSVPEDSVRGRPLPAVPGSPPELSAVPAGCVFQARCPLVRERCVRERPVPRPAGEGRSAACHFSEELDRA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00849 | ABC transporter ATP-binding protein | MTTQTKPEEAPAAAAGNAFLSVRDLKVHFSTEGGVVKAVDGLSFDLERGKTLGIVGESGSGKSVTNLAVLGLHDRRKTAVDGSITLDGQELTDASEKQLETLRGKKMAMIFQDALTALSPYYTVGRQIGEPFMKHNGASKKDARVRAIDLLQKVGIPHPQKRVDDYPHQFSGGMRQRAMIAMALSCDPDLLIADEPTTALDVTVQAQILDLLKDLQQEFGSAIIMITHDLGVVGnMADDILVMYAGRAVERGSVREVLKTPQHPYTWGLLSSMPNLSSDVNEPLMPIPGSPPSLMNPPSGCAFHPRCGFTDLVPGGRCSGERPTLDLGRGAACHLTGDQRQQVFIEKIQPRLG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00854 | ABC transporter ATP-binding protein | MLLEVRDLHVEFHTRDGVAKAVNGVSYGVDAGETLAVLGESGSGKSVTAQTVMGILDVPPGRITAGEILFEGRDLLKLKEEERRKVRGAEMAMIFQDALSALNPVLTVGAQLAEMFTVHRGMSRKDAHAKAVELMDRVRIPAARERVRQYPHQFSGGMRQRIMIAMAMALEPKLIIADEPTTALDVTVQAQVMDLLAELQRELRMGLILITHDLGVVADVADKIAVMYAGRIVETAPVHDIYKAPAHPYTRGLLESIPRLDQKGQELYAIKGLPPNLTRIPPGCAFHPRCPMAQDVCRTDVPPLYDVTESDAERGSACHFWRECLHA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00859 | ABC transporter ATP-binding protein | MTEPSKSGAAVGEPTGDAPGSNAFLEVRDLKVHFPTDDGLVKSVDGLSFQLERGKTLGIVGESGSGKSVTSLGIMGLHTAGQYGRRKAQISGEIWLDGTELLSADPDHVRKLRGRQMAMIFQDPLSALHPYYTIGKQIVEAYRIHHDVDKKTARRRAVEMLDRVGIPQPDKRVDSYPHEFSGGMRQRAMIAMSLVNNPELLIADEPTTALDVTVQAQILDLIRDLQKEFGSAVIVITHDLGVVAELADDLLVMYGGRCVERGPAEKVFYEPRHPYTWGLLDSMPRLDRDQQERLIPVKGSPPSLINLPSGCAFNPRCPYADVPKDDVTRTVRPELTEIGSKHWAACHMSQEQRERIWTEEIAPKL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00864 | ABC transporter ATP-binding protein | MSAVRPPAAPAPDGGHILDLDDLGVVFTTETGTVRAVRGVSLHVAPGETLALVGESGSGKSTVALAAMGLLAGNARATGRAVVDGTDIVGADEEQLSGLRGKTVSMVFQEPATALDPLTRVGRQIAEVIRNHRRVSAADAAAHAVELLRRVGIPEPEQRARAYPFQLSGGQRQRVVIAMAIANEPALLIADEPTTALDVTVQAEILDLLRRLAAETGTGVLLVTHnMGVVADFADRVAVMYQGAVVETGPVEDVLLRPTHDYTKRLLSAVPRLSVSEAAGAGDTAEPAGAGSAGAGSAGAESVEEPAVELRDVSVVFGRGKQAVHALRGVSFAVRPGETLGLVGESGSGKSTASRVALGLVAPTAGSVTLFGADLARTRARARRALRAGVGVVLQDPVASLDPRMTVGECVAEPLRVHRRTLSGRERESLVGDVLDRVRLPREVARRAPRELSGGQRQRVSLARALVLGPRLLVADEPTSALDVSVQEAVLEVIGELQEELGFACLFVSHDLAVVQQFARRVVVMRAGRAEEQGLTSATLLNPETDYTRRLLAAVPVPDPVVQRGRRAERLATLAAGRTEEQG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00869 | ABC transporter ATP-binding protein | MSLVEVTGLSVAFGSVRAVEDLSFRLEKGAALGLVGESGSGKSTVASALLGLHRGTGAVVDGSVRVAGTDVGAASERELRGLRGGKAAMVFQDPLSSLDPYYAVGDQIAEVYRVHHPASRRAARARAVEVLDRVGIPDAARRSRSRPHEFSGGMRQRALIAMALACEPDLLVADEPTTALDVTVQAQILDLLHALREETGMGLLLVTHDVGVAAESVDEVLVMRHGRAVEHGPVGSVLGSPAEAYTRRLLKSVPRVDTPRPPAPPAGAVADDASRDGVVLEATGLRRVFGRGSKAFTAVDDVSLEVRRGEALGVVGESGSGKTTLGRMLVGLLEPSAGEVRLDGAAVTGVRPDVQMVFQDPVSSLNPRRSVGESVADPLRARGERGPAVRARVAELLERVGLDPAHYDRYPHEFSGGQRQRVGIARALAAGPRVLVCDEPVSALDVTTQAQVVELLDELRRELGLALVFIAHDLAVVRRVSDRLAVMRHGRVVEYGPADGIYESPGDPYTARLLAAVPVLDPGLAALRRAERREPAVT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00874 | ABC transporter ATP-binding protein | MLSVEGLHVAFPGRRGGADARAVDGVDLDIRRGEIVALVGESGCGKTTLARSLLGLVRPVRGRVTFDGAPLAHSARALKAYRRRAQLVLQDPSGSLNPRHTVYDIVAEGLRIHGRPGDERTAVAEALSRAGLRPPERFFLRYPHELSGGQRQRVVIAGALVLRPELLVADEPVASLDASVRGEILALLLRLRTELGLAALVVTHDLGLAWNIADRVAVMYLGRIVETGAVEQVLTAPRHPYTRALLSVLPEAPGDPVVLTGEPPDPSNIPTGCRFHARCQVLADGTAERAGVADACRSREPAVLHGGGESQVACHWALAAPREVSPAGPAPR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00879 | ABC transporter family substrate-binding protein | MSHVRVGPRAVTRSVAFLTAGVLAVPALAGCTSDEPAGKPLAAQDVAAAPRSRVADGGTLRWAVDSVPETLNAFQADADDTTNRVAQAVLPSMYRTDDTGRPARNPDYLESAEVVDTEPKQVVVYKLNQQAVWSDGREIGAADFAAQWRALSGKDSAYWTARNAGYDRIEKVERGAGDLEVKVTFSRPYADWQSLFTPLYPKDVTGTPDAFNDGARRELKVTAGPFAVQKVDTKDDEVVLAGNPRWWGEPAKLEQIVLRAVPRDKRVSELVAGKLDLAEVDPETADEVGLAAGPRDAGTGTPLMGPQGTPAAGAPGSPLAGDRGRSAAQALRSWALANGSDEEAAEEEVLAREERRETEAKAQRRQRALSGFEVRKSLEPAYTQLALNGADGPLADERVRRAVARALDRKKLAEAVLKPLGLPAEPVGSHVALAGQPAYADGSGALGDQNAKEARALLADAGWVPGGPVKKTEKGEKAAGAEGDGEKEKDGKKSEDGDDGDDGTYIVGEDGKNPGDGGDGENGEGGAKADAESGEKHSSGKNTAQGGAPGAYAPKGTAAPAAAAAPVAKDGKALTLRFVLPSGPGSEALRTVAGRVSDMLDEIGIDTAITKVPDESYFKDHIASGAYDLALYSWPATAFPATDARPVYAKPVPAADGSLNVAQNYTRVGTDQVDQLFDRAMSTLDRKEARDLLRKADSRIWAAAGSVPLYQRPQLTAARKGLANAGAFGFETPVYEDMGFLKKGAQGPRPAASPSS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00884 | ABC transporter permease | MLHYALRRCGWTLVQLAVLSLVVFLLTDLLPGDAATVDFNEQAGLDQVAQLREQMGLDRPLVERFADWAHGLLTGDLGTSLVGGGPVRDVLSSSVPVTAALAVVTLVLLVPLAVAVGLLTGLRAGSRTDRTVSAVTLTLTSVPDFVLALLLVGVFALRLGWLPSTWVGADDVWWQRPELFVLPVAVLLARTVCVLSRQIRAGTVTALHAGYTVQARRLGVPPARLVLRHVLPNAAVPGVQELARTGDQLLGGVLVVEAVFAVPGTATALVEAVQNRDVPTVQGLTLTLAAVACLLNLAADLVSHRLAPRTEVLR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00889 | ABC transporter permease | MLRYALRRSGWTLVQLAALSVIVFLLTDLLPGDAATVDFNEQAGLEQVAQLREQMGLDRPAVERFADWAHGLVTGDLGTSLVGGAPVSEVLTSSIPVTAALAAVTIMLLVPLAVGVGLLTGLRAGSRTDRVVSAVTLTLTSVPDFVLALLLVGVFALRLGWLPSTWVGADDGWWKRPELFVLPVAVLLARTVCVLSRQIRAGTVTALDAGYTVQARRLGVPPARLVLRHVLPNAAVPGVQELARTGDQLLGGVLVVEAVFAVPGTATALVEAVQNRDVPTVQALTLALAAVACLLNLAADLVSHRLAPRTEVLR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00894 | ABC transporter permease | MNLLAFAGRRLAGAAVLLVLLSAAVFAVTAVLPGDAVSAVAGVDASAAQRADVRAGLGLDRPAAERYAAWAADAVRGDLGHGFVGERPVTDILATRLPNSLLLAGLTLAVTAPLAALLGLWTGLRGGGTADRVVSTGAQVLAAIPEFVVAALLVAVLAVWAGVLPRVSVVPLGGTPLDAPRALVLPVLTLSAVGLAVATRLLRVSVADAAATPYCEAARLGGVRGIRLAVRHVLPNAAGPAVQALTLTTGALVGSAVVVENVFDYPGIGRELQLAVAARDVPMVQGIATALVAVMLLVLLLGDVCARLIGAREGHGR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00899 | ABC transporter permease | MDLGTSEAATLEQPPGPDGTNPHERPRSLWTDAWHDLRRNPVFIISALVILFLVVISLWPSLIASGSPLKCDLAKAQEGSQPGHPFGFNGQGCDVYTRTVYGARTSVAVGILATLGVALLGSVLGGLAGFFGGAGDAVLSRITDVFFAIPVVLGGLVLLSVITSNTVWPVIGFIVLLGWPQISRIARGSVITAKQNDYVQAARALGASNSRLLLRHIAPNAIAPVIVVATIALGTYISLEATLSFLGVGLKPPSVSWGIDISAAAPYVRNAPHALLWPSGALAVTVLAFIMLGDAVRDALDPKLR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00904 | ABC transporter substrate-binding protein | MSILRNRTATAAIVAVAAGALTLTACGGGDSDSSSKDNSKQKEDAKSQSKPVQIGDAQASTGPAPDVEGAKSGGVATVYQATDFSHLDPGQIYVSDGKLLSRLIFRGLTQYDEDENGNLTVVGDLATDAGKESDGGKTWTYTLKDNLKDENGNPINSADFRNTVERLYSNYITDGPTFLQQWLSGDGTTYRDAYQGPDKGKHLPDDVLETPDDKTIVFHFDTPRPDLPQMLTMPGYQLVPEETDTKEKYDSAPVSVGPYKISDFKPGKSMTLVKNTQWDPKSDSVRHQYLDGFNISMNHDDEDQTKTLLADQGEAKNAMMFTGQVATTQLQKVVGDKQAMENRTIQGYAPYVWQLNFnMDRIKDKKLRDAISLALPSDAVFKADGGAYGGEVANSLMSPTTPGYDEKFDPFNREKKPNGDVEAAKKLIKEGGFEGKSLVYAYGNTPERQKQAVLIATALEKIGLDIQKKEIDSATWYEQVGKVKNGYDLYMTGWGQDWPSASTVFPPVYDGTQIQDGASNYSHINDDHVNSEIKRIQKITDTDEATKAWAELNEYISKEVNPAAPIYYTKVFQIFGSNIGGIRYSSDSSYVDVTRVFLKK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00909 | ABC transporter substrate-binding protein | MPVTPTRRSVLAAAVATGAGLLTGCSSANSGSSSPKKGGTLSAAFPGAGVKETMDPHAQRQFVDIARHKAVFDKLVELDSTLRPVPRLARSWSSDDEARVWRFELREARFHDGHVLDADDVLYSLSRILDPDAADHLAKNSLSHVDLANCRKVGRRGVEIALTRPNAELPSQLAMTGTPVVRDGWDDPSKPVGTGPFRFASFTAGRGFTGRRFDDHWNGAPHLDEVRILSAESEARAAAVRSGEVHFAHEMTPTFARTVAHDGRVRVVATKRSGVQGFALKTDRAPFDDPDAALAVKLLVDRKRLVDVVCAGRAEIGNDLYGKGYTYYPDGLEQREQDVAEARRLLRRTGLYNKKVTFYTSTAADGFAQAAHLFTEQAGEAGLKVEVVNGPPESYFTDALSKGTVTNHRCGAMTIPTYIGERLLSDAPQNQTAWKHEDFDDDFTAARAEVDDEKRTARYRSVQTTLRDRGGLVLWGHPEWLNAVSRTAHGVKEAPPNTVDWARFDTVWLD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00914 | ABC transporter substrate-binding protein | MRYTGAIGVVTATATGLTACGGPASTGGGAGGAGGGGDTVGAGISYPLSTGFDPMITSGATPYAAnMHIFEGLVDLDPATLVARPALATGMPQKINATTYRAVLREGATFHDGSPVTANDVVFSFERVLDEGNASLMAQFVPFVDKVTAVDRSTVEFKLKYPFALFPSRISVVRIVPEKIAGADAKSFDSRPVGSGPYRFVSAVREDKIVMEAYDKYNGPHPAKAGKLVWRLISDPSARVSALKSGRVQAIEDVPYIDVAGFTGKDEVESVQSFGLLFLMFNCADPRFKDKRVRQALHYALDTEKIISTALLGNAEAATGYVPASHPDHHRAATVYGHDPARARKLLAEAGVGKLSFTLLLTDNGWVKDIAPLMKESWAAVGVDAALDIQQSPAQYAKIDQGDFDALAAPGDPSVFGNDADLLLRWFYYGFWPEKRYGWQGSKAYKQTRSLLDKAASEGDEARRKELWGRVTDLVADEAALYPVLHRKLPTAWREGTLTGFEPLPTTGLSFLDVGRA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00919 | ABC transporter substrate-binding protein | MRGATHAKWAACAAAAALAATACGGGGGGGNGGGDSGAVLSSSWGDPQNPLEPANTNEVQGGKVLDMIFRGLKRYDPESGEAQnMLAEKIETSDSQNFTVTVKDGWTFSNGEKVTAQSFVDAWNYGASLKNNQRNAYFFAYIDGYEKAHPEDGGKQSADTLSGLKVTGPRTFTIKLSQKFSTFPDTLGYPAFAPLPKAFFDDHDAWLKKPVGNGPYQVDNYTRGSQMSLRKWEQYPGDDKAQNGGVDLKVYTDNNTAYTDLMAGNLDLVDDVPAAQLKNVKNDLGDRYINTPAGIIQTLAFPYYDDAWNKSGSEKVRKGLSMAINRKQITDTIFQQTRTPATDWTSPVLGEDGGYKAGLCGEACEYNAEEAKKLVKEGGGLPGGQVKITYNADTGSHKQWVDAVCNSINNALDNDKACVGNPVGTFADFRNQITDRKMSGPFRSGWQMDYPLIQNFLQPLYYTNASSNDGEYSSQKFDDLIDKANGETDTAAAIKSFQQAEEVLRDDMGAIPLWYQNGSAGYSDRLSNVKLNPFSVPVYNEIKVG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00924 | ABC transporter substrate-binding protein | MTTQRTSGRRKQAMAAAAVVAALLTTAACGGGDSDSGGSKNGAAGFDAANNKIAQADQVKKGGELKFASTQDADSWDTTRGYYGFMWNFSRYYARQLVTNTPAPGEKGAGVSPDLAADVAKVSDDGKTYTYTLRDGVTWEDGKPITSKDVKYGIERGWAQDVLAGGPTYLKEVLDPDGKYEGPYKDKSADKLGLKSIETPDDKTIVFKLPEANSDFEEMLALTSASPVRQDKDTKSKYGLHPFSSGPYKFESYNPGKDLTLVRNTEWKQDSDPVRKAYPDKISIKFFTNANELDQRLIAGDYDIDLAQTGLSPQGRTSALKEHEGNVDNPVSGYIRYAVFPQSVKPFDNIHCRKAVLYGADHVSLQTARGGPQAGGDIGTnMLPPAVPGSEAQKYDPYEMAGANKNGNIEKAKEELKACGQPNGFKTTIAVRNNKPVEVATAESLQASLKKVGIEVGIDQYDGSQTAGIIGSPSNVKKKGYGIIIMGWGPDFPSVQGYGKPLWNSEFIQESGNNNYALIDDKEIDGLFDKYGTELEDSAKADIAKQINHKVMEGAYYLPFVFEKFINWRSSRVGNVYTSDGYSGMYDFVNIGLKSSSK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00929 | ABC transporter substrate-binding protein | MPVTPTRRSVIAAAVATGAGLLLPGCSSAGSGSSSPKKGGTLSAAFPGAGVKETMDPHAQRQFVDIARHKAVFDKLVELDSTLRPVPRLARSWSSDDEARVWRFELREARFHDGHALSADDVLYSLSRILDPSAADHLAKNSLSHIDLANCRKVGKRGVEIALDRPNAELPSQLAMTGTPIVRDGWDDPTKPVGTGPFRFVSFTAGRSFTGRRFDDHWNGAPHLDELRILSAESEARAAAVRSGEVHFAHEMTPTFARTVAHDSRVRVVATKRSGVQGFALKTDRAPFDDPDAAMAVKLLVDRKRLVEVVCSGRAETGNDLYGKGYTYYPDGLEQRERDVAEARRLLKRTGLYNKKVTFYTSTAADGFAQAAHLFTEQAGEAGLKVEVVNGPPESYFTDALAKGTVTNHRCGAMTIPTYISERLLTDAPQNQSAWKHDDFDDAFTAARAVVDDDERTARYRSVQTTLRDQGGLVLWGHPEWLNAVSSSVQGVKEAPPNTVDWARFDTVWLA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00934 | ABC transporter substrate-binding protein | MITHDQHRRGRTAPRPWRARLLAALGACALLLASGTVAPSASAENGDGDGGGGGDKVLTVAVAQSVDSLSPFLAVRLVSTSIHRLTYEYLTNYDAEDNHVIPGLATEWKSSPDKLTWTYTIRSDSRWSDGERATAEDAAWTFNTMMTDPAAATANGSFVGNFAKITAPSPTQLVIRLKKPQATMTALDVPIVPKHVWEKVDDFSEYNNDKDFPVVGNGPFVLTDYKPDSYVRLKANKDFWRGAPKFDELVFRYYKDQDAAVAALRKGEVSFVAGSPSLTPAQADSLKGEENIRVNDAPGRRFYALATNPGARAKDGTKFGNGDPSLLDRRVRNALFKAVDRKAIVDKVFQGHAVEGAGYIPPRFSSYFFEPSAGQELAYDPQQAAELLDEAGYRTGADGKRLGKDGKPLDYRVLCHATDPNDKAVGKYLQEWWGELGISVTLDCLDNVTDPWLAGEYDLAFDGWSVNPDPDFVLSIHTCDALPATPKDTGATDNFICDKEYDELYARQLAEYDAGKRAGIVKQLESRLYDTGYMNVMAYPNAVEAYRTDQIESITTMPAAAGNIYGQDGYWSWWSAVPADSGDSSGGSSSTGTVIGIAAGVVVLAGLVVLFAVRRRATADDRE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00939 | ABC transporter substrate-binding protein | MRSLRRPRLLAPFLLTPLIAGCFASGGGDSGDGGGKGGDGDRLRVALAFPPAENLSPYGADATLLSRLGVTEGLTALDANGSAAPALAESWRRDGEKTWEFTLRDATFQDGSDVTPDAVADSLGQAVRAKPAPAALAGVGLTAEAGGERVVRVTTAEPDPVLPLRLSSPSLAILSAKAYEEKGGKADPVGTATGPFRLTKVNGATSASLDRFDDYWGGRAQAAGIDARFVADGTARANALRTGELDIAEAVPVAQAASLDEGTRRDTATTRTTSLLFNASSGTFKDAGLRAAARGAVDTSVFAKDVYEGYGDPGAGIYGPAVTWAEGKRSAPVGRAGAGKPGGDDVIDLATYDNRPELPEAAQVVKQQLEKAGFTVKLTVREYSRLEADALDGKFDAFVLARNTLLDTGDPVAVLASDYTCDGGFNIAQLCDKDVDRAVADAERIADTAKRQDAAMAAEARILGSDAVVPLVHQRIITGVADSVQGVILDPYERTLVGTGTRR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00944 | ABC transporter substrate-binding protein | MRHPSRRTRRAAAALTVSLIVTAGAAACGPEDNDAKSGGADGDPQKGGTLTVLNAVPQTDFDPARLYTSGGGNVPSLVFRTLTTRNREDGAKGTEVVPDLATDTGRPNKDATVWTYTLKEGLKYEDGTKITSADVKYGIERSFAAELSGGAPYLRDWLIGGADYQGPYKDKGKGLDSIETPDERTIVFRLNKPEGEFPFLATQTQFAPVPKSADKGTKYEEHPVSSGPYKVVRNENDGERLVLERNEHWSEKTDAERKAYPDRIDVRSGLDSSVINQRLSASQGADAAAVTTDTNLGPAELAKVSGDKELAARVGTGHFGYTNYIAFNPKVKPFDDPKVRQAIAYAVDRTSVINAAGGSSLAEPATTYLPNQKSFGYTAHDHFPAGESGDPAKAKELLKEAGHADGLTVTLTHSNAKDFETSPEIATALQDALQKAGITVELEGLEDNDYRDTIHDAKSEPGFFLAHWGADWPSGGPFLAPIFDGRQIVRDGANFNTGFLDDKSVNDEIDAINKLTDLDEAAQRWGALDKKIGEKALTVPLFHPVYKRLYGKDVKNVVISDWTGVLDVSQVAVK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00949 | ABC transporter substrate-binding protein | MSRQFDRRAFLRRGAAGAAALAVGPGLLAACSTDAPGADREGAGSSPRSGGTLRAAFVGGGASETLDFFNGPSALDLVRARAWHGTLGNLDPEGPDGVRYGVLKGIDVSDDLSAYTLHVRPGVRFTDGSELTSADILHSLSVLAGRSTLPVYRLAAANFDLASAKADGDLKVVLPTLRPIADGRMILCQGNFLVVKDGTRAFRKGMPSCGPFRLTEFTAGQGSAFERYDDHYGHVPLLDGLELRSIADSTARAGALTGGEVDFAHDLSPVTARTLTDDAKVRLVPTGSPYLVGLSFQMnMAVEPFDDPRVREAFKLAVDRETMVKTVFYGNAETGNDLPAMGFPDYAGSLPRRTHDPERARKLLKEAGADGTEVRLTTGPETPGMVEMATLFVEDLKKVGVKASVRELPAGQLYADFAAYAALPLAGSYQMPIPALSTYQMSTAGGSPSAFGWKDAETDALVAKARAASDPAEAKELGTLAQRTRWEKGNQVLPVFKPNLNAQAEGVAGIREDLFEQFPGFSQASLA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00960 | Acid phosphatase | MPDRSKRPPARAAAGTRALRAAVAAVLAGALGLGALTTGGTAAAAPSAPASASGEASGGTDYTKLVDPFVSTAGDDGNDLPGAQAPHSLAKVNPMTVPDRNHSGYDYNEDHIAGFTATNLDGVGGSGGGGDLLVVPTSEQYDKRPATSTYAHPYSHDDESASPGSYRVGLGSDAGTIDAEMTATTRTALERYAFPDGARPQLVLDLANNFTSRTRSTLDATRLKDGTTAISGLVAGSFNGASYRLYYYATTNVPVTSLRSWGDDGALGGATARDGTDTGAVLGFDPADGDDVELRITLSPISAEQAATDQHNEVAGRGFEEVRAQTEAEWNSTLGTVAVEASRKADPDSTLTKQFYTHLYRMYALPVNATSTSGTYRGVDGAVHKANGFTYYDGWSTWDDFRKYSVTAYIDPAGYRDMVQSAVILFADARSTGKSLGSLTHSVPTVRWERLPVVIADALSKGYKDFDRLDEAYPALKSYAGYYTGTELRQGYVAGDPGTTVQRGYDQWALSLVADALGEDADAKKLREQATMATDNLVKPGAWTADDGTEVGLLTPRDGEGAWQGVDYEKFEEAKLYQGTLWQYHWYDAYDMGGLIEAMGGEKAGRAAIRHMFGEDSDADDGSAMLHSNANEIDLQAPYLFNYVGEPSLTQKWVRAIYTGETWNRYIATGSTGEAPSSGGEFRPPVKTKAYELAPDGFLPTMDNDAGTMSTMFVAAALGLFPVTAGSSQFQIGSPFFDSTTVHYAGGAEFTVEADGVSPDNYYVQGARLNGKRFSNTWLDYSQIVAGGTLKFDMGSAPSSWGARTEPAYSLNTDTGDGDDGSAPGRGTTVVSARPDSVDTAADGTVKGNIELRLSGKASFAAREGTSLTRSGAAGVTGLPDGVEADLRVTGRRTASLRLTGATQTDARLGLTFRDRAFAHGVPASTVTGAGVSVTDPLVVSAAVVHRGSLGALVEEASLVREGNYSDGSYGVFRTALERARTVLADADAATGTLMAAHDALKSAIDALTLDEGGYAVLQAEDPDSMEGPSLVKEAYHSDGDLGGVTEGAWEQYTNLDFGGVAPRGVSVRYANAQAPEAEPSSVDIHAGDAEGPVVATVSLPGTGGWQYYTTVRAAVTDPQALLEASTATFVFHAPSGQQWVSNFDWYQFSPAEPASSSPVTTLATLTTANATATGDGSLPLKLTNGVFENVTNGAWAEWRGTGLGDGADTVTVSYDKPRSRAASDSHIELRLGGRDGPAAVDVPLEYTGSGWGTVATTSVRLDPETFGGAQDVYAAFVSGTQTDAQPYVANVYSLTLTRETDAPVVFDATAFGASSGGGLKSEPATWDGAGSATSLGGTYDGAWLDYGDIDFGTEPKNTVTFTYVNNSARCGTGSAVEIHLDSFDADAPGTPDATVPLPVTGSSWSSGGTTSLTLPEAITGTHSVHLRLTTNADSSHPYVANLGRVAFDHVEAPAETDLSALRKAVEQYGGLAEHKDRYGTIDFGVFVRELAAARALLDAGDATQLEADLQTRGLTLAANQLVPLPRLKLENLVATASARADERYTDASWKAFTTALTAAKETVADDAASDATLTARYTSLDRAMSALRTKHRTVPAAPGAVSATASGTSVQVTWSAPEDDGGSPVTGYEVTLGGGRQVEIADPASRSTVFTRLADGTSHTARVRAVNALGDSAPSAPTRPVVTGDNRPQTPTVTGVVTDGKRVRVTWRPAGDGGFPVLGYTVALDDGTTAHVSGTTDSALLTTAGGAKAHTATVTARTLAGTSADPAPKAAATAGTGTATSTGTATGTGTAAASDPADYEPAPFPDDVLDAAYPSDEWPRTGDGGDYFTNLLSGFDDLGPGTLGANGELPEGSELGAENDEITVAVNNAATQKQVDRAEVDASNSATVTMADGLGSRLGPIYGEALKEGQLPKTSALFSRVAENLDTHDAAKNRWNYLRPYVRLGFAGDGGRIYESEDSSYDGLAKQGSYPSGHTYGGYEAGTILATLLPDLAPSILARTSEYGDNRLVLGFHYPLDVMGGRITAQATVAHRWADPAFGKLLQQAHTEIENVLLARCEEEGYGDTLTACAGDPYAGLGTAETVDLYTRRLSYGFSQVGEAGQALQAPSDAAALLITAFPDLTEEQRTQVVEQTATDSGLPLDLTGTGGPSWQRINLAAAMAADVTVGADGSVTVTNFPDATRAAVADASALTVEGVPLDGFDPGVGTYVVDWPEHGRIPAVGAVAAKSGARVKVTDGSRTVSSSRPGFTARTVTVTSADGEHSRTYTVGFQRTDHDHRPPWSGGPGGPGGHGDPWDRGGHDGPDGTGLWSPAREWEDARGR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00967 | Acyl-CoA synthetase | MTPGHGSTVDGVLRRSARRTPARVAVEYRDRTWTYGELDTAVSRAASVLLDEGLSPGDRVASYVHNSDAYLIAFLACARAGLVHVPVNQNLTGDDLAYILRQSGSGLVLTDPALAARLPGASRTLSLRDTDDSLLARLAAAPAYDGPEPAAEDLVQLLYTSGTTALPKGAMMTHRALVHEYLSAITALDLGAGDRPVHALPMYHSAQTHVFLLPYLAVGATNIVLDAPDGDRLLDLVEAGRVDCLFAPPTVWIGLANRADFATRDLTGLRKAYYGASIMPVPVLERLRARLPDLALYHCFGQSEIGPLAAVLGPDEHEGRMGSCGRPVLFVDARVVDEDGKDVPDGTPGEVVYRSPQLCDGYWDAPEETRAAFRDGWFHSGDLAVRDADGYFTIVDRVKDVINSGGVLVASRQVEDALYTHDAVAEAAVIGLPDERWIEAVTAVVVPRAEVTEDELIAHARAELAAFKAPKRVRFVDALPRNASGKILKRELRDRFTAS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00972 | Acyl-coenzyme A thioesterase THEM4 | MSGTSPGLQPPADAVKPVRHPEAPAPGELLGAHYGQCFGCGGDQPHGLHLQARAGEGVSITAEFTVRPAHQGAPGLAHGGVLASALDETLGSLNWLLRTIAVTGRLETDFRRPVPVDTTLYLEAEVTAVAGRKIYSTVTGRIGGPDGPVAVRADALFVEVKVDHFVENGRDEEIRAAMDDPDQVRRARAFEVNP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00977 | Acyltransferase papA5 | MRMTDIQRCEIRPGRLVEWTLSPRTLDIAAGLPEDARPPAYIQESHIRTARSVREGGLFVPTWLGAAFDIPGAVDLDVLQEALRSWTLRHETLRSGFRWSGESGDTMRRFTLEPDAVSLHREDVGDFPDAADLAGHLQDRFDRVADALRWPNLIYTAVVRDDGVSVYMAFDHSNVDAYSIYRIPAEVGELYAAGIAGRTVPQPRVGSYVDFCEAERADADRIDADHDIVARWREFIRRCDGRLPSFPVDLGLRPGGALPEQRLLREPLVDAADAAAFEAYCRPYGGSLVGVLAATALIVHEIGGESVYRTVVPFHTRSRSQWSESVGWYVGGAPIEVPVDRAHDFPAALRTVRAELQANRRMSRMPIDRVLRLLGTDFRPGSPDLYSIVSYVDARDVPGAGDWAEQTAYAMLRVSYGDQVCAWVTRLPEGLWFASRYPDTDIAHKNLRLYVERLRDVITGIGQKPTD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00987 | Adenosyl-hopene transferase HpnH | MAMPLRQSIKVATYLAEQKIRRRDKFPLIVELEPLFACNLACEGCGKIQHPAGVLKQRMPVAQAVGAVLESGAPMVSIAGGEPLMHPQIDEIVRQLVAKRKYVFLCTNAMLMRKKMDKFKPSPYFAFAVHIDGLRERHDESVAKEGVFDEAVEAIKEAKRRGFRVTTNSTFFNTDTPQTIVEVLNFLNDDLKVDEMMISPAYAYEKAPDQEHFLGVEQTRELFKKAFSGGNRARWRLNHSPLFLDFLEGKVDFPCTAWAIPNYSLFGWQRPCYLMSDGYVPTYRELIEKTDWDKYGRGKDPRCDNCMAHCGYEPTAVLATMGSLKESLRAMRETVSSNRE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp00996 | Allantoate amidohydrolase | MSFHSMWAELLPVGRSSASGGYRRYAWTGADSDCRTWFREQAQARGLAYETDRNGNQWAWLGDPAAGNAVVTGSHLDSVPDGGAFDGPLGVVSAFAALDELRGRGARFTRPLGIVNFGDEEGARFGLACVGSRLTSGALTAEQAHRLTDADGITLPQAMEAAGHDPDTLGPDPERLARIGAFVELHVEQGRALDLSGDRVGIASAIWPHGRWRFDFRGEANHAGTTRLTDRHDPMLPYAEAVLAARREAQLAGAVATFGKVAVEPNGVNAVPSLVRGWLDSRAADQEDLDAVVAGVEKAAREYAAAHGVDLGVECESFTPVVDFDHALRDELARILGKEADLRVPVLGTGAGHDAGILSGRVPTAMLFVRNPTGVSHSPAEHAAEDDCAAGVHALADVLEGLART | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01013 | Amidohydrolase | MSESTTPPPTVLLRRGEVHSPADPFATAMVVERGQVAWVGSEGAADAFADGVDEVVDLDGALVTPAFTDAHVHTTATGLALTGLDLSGASDREAALALVRDFAAARPGDRVLLGHGWDAARWPEGLPPTRAELDDATGGRPLYLSRIDVHSAVVSTALLDLVPDGAARADGPLTGDAHHAVRAAALGAVTPAQREEAQRAALAHAASLGIGTVHECAGPEISAEDDLTGLLRLSAGEPGPRVVGYWAERDVDKARELGAVGAAGDLFVDGSLGSHTACLHQPYADAGHTGTAHLDAADVAAHVVACTEAGLQAGFHAIGDAAVAAVVEGVRTAADKVGLARVRAARHRVEHAEMLTPETVAAFAELGLTASVQPGFDALWGGEDGMYAQRLGVERARTLNPYAALLRAGVPLAFGSDSPVTPLDPWGTVRAAAFHRTPEHRVSVRAAFTAHTRGGWRAIGRDDAGVLVPGAPADYAVWRTGELVVQAPDDRVARWSTDPRSGTPGLPDLTPGRELPVCLRTVVGGRTVHVRPGE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01018 | Amidohydrolase | MTDRAVLHVKGRVLVGPEEVRDEVWVIDGRISYDRPAGAADVRTVEGWALPGLVDAHCHVGLDRHGAVPADTAEKQALSDREAGTLLLRDAGSPSDTRWIDDRDDLPKIIRAGRHIARTRRYIRNYAWEVEPDDLVAYVAQEARRGDGWVKLVGDWIDRDLGDLSACWPRGAVEAAITEAHRLGARVTAHCFAEDSLRDLVEAGIDCVEHATGLTDDTIPLFAERGVAIVPTLVNIATFPALADGGESRFPRWSAHMRRLHERRYDTVRNAYDAGIPVFVGTDAGGALAHGLAGAEVAELVTAGIPPVEALSATTWAARRWLGRPGLEEGAPADLVVFDRDPRADVRVLTDPRRVVLNGRVVG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01023 | Amidohydrolase | MTPTPHEKPKPGAARGEPADLVVTGCTVLVHDERERIGFEQDAAVVVREGAVDSVTTAAAGAAVPAAERIDARGQVALPGLINCHTHAPMAALRGLAEDLPTEEWFNDVVWPVESNLTARDVVLGTRLACAEMIRAGVTTFADSYFHMDAVAAVVDRCGMRAQLGQAYFSSQGPAGLEASVEFALRLRDGSGGRITTALAPHAPYTVTDADLAETARLARAHGLPVHLHAAENLDQTHTSLARHGATPIGVLERTGILDTDVLIAHGTGITDADLPLLARAGGRTAVATAPRGYLKFAWPTTTPVRALRDIGIPVGLATDGAASNNSLDVWESMALTSLIQKSTEGDPRWLTSRQALHHATVQSAHAVGLGDAVGRIAPGRRADLILVDLTGPHTQPVHDLAATLVHSARSADVRTTIVDGRVLMRDRELLTVDVPGTVRELGERLPALTDRGHGRRIQEYDT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01028 | Amidohydrolase | MLTIHAAERVRRTWDSASLEGGAVAVEGGRVAAVGPLAELAERFPGARVRRWPGVLGPARVHEGPLPDAPTPREQVHAVLKLGAVAVLAEYAGSRELRAAAERNDVAVLERARPAALVDLGRADLAVLDDGGACIATVCAGRLVHRRR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01033 | Amidohydrolase | MHLDALYTNGRFTTLDASRPTAHTVGVFAGRVVGLDDEVAGCTADRVHDLRGAPAVPGFNDAHQHLSMRGRRLLQLDLHTGTVPTLDALYAAVRERAARLGPDEWLFGAGYDQNKIGAHPTAAALDEAAQGRPVWLEHVSCHMGVANTAAFARAGFTDRTGVPDVAGGHVERDTGGRAAGLLQETAQHLVTRAFRPTPVDSIVAAIAAGNDKGVTEGITSVTEPGIAAADHVGHGPADLHAFHRAVEEGVLSIRTTVMPYMTVLHDAGPAGGGDTWFGLDTGLRSGFGDDRLKIGATKIATDGSLIGRSAHMCCGYHDEPDNSGFLLFDEDRLHHMINEAHRCGWQVAAHAIGDAAIDVVLDAFEAAQAAHPRPDARHRIEHFAVASDEQVRRLVAGGVVPVPQGRFVSEIGDGMITALGPERATRCYRMRSLLDAGAVLPGSSDAPVAHGSPLLGIHDMVNRRTAGGAPLAPAEAVTAEQALYAYTVGSAYAEHAEDRKGRLAPGMLADFAVLSDDLLAVDPGRIGALSVGATVIGGRVVHDAGALD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01038 | Amidohydrolase | MNAAGNSSGLGTGRPGTPVVFRNGTVLTMDDRRTLHRGADVLVVGERIEAVGPLPAVPEGTREIDATGGIVMPGMIDTHRHMWQTAMRGYGADWTLTQYFVWYYLEHGTHFRPEDVYAGNLLAAVEALDSGVTTTVDWSHGLQTVEHADAALDALDEVPGRFVLAYGNIRAAPWEWTAAPEFRAFVDRRFGGDRTGLQLAFDVTGDPDFPEKAAFEAARELGVPVTTHAGVWGATNDDGIRLMHEHGFMGPDTVYVHAATLGADSYHRIAATGGSVSVSTESEQSCGQGYPPTWALRAHGIPVSLSTDTSVWWSGDLFSAMRATLGADRAREHLEAHAGGETVTHSHLRAEQVVDWATRGGAKALGLDDRVGSLEAGKRADVVLVKNDHSPVMFPLLNPYGHVALQAQRGDVHTVMAGGRLVKHEHRLIGVDLAKVRRTVDSTVEHLRSRLGAEAWEQGMNPDVPETKMLDNPYTYTGYRTAATHGG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01043 | Amidohydrolase family protein | MSRCRCVAMSPCRRDVAVSLCRDPGWVRACRGMAWTCRKPGPWGGRDAVVRRMPSVGSLLTGHRADSGGnMSRFAVANTRVFTGTHVADASVVVVEDGTIAEVGHEAPEGVEKIDGVGGTLLPGLIDAHTHTDEDGLRTALSFGVTTELDMMSVPDAMEPLRKKARAEFDVADVRTASWGLAHPDGHPHQLRRGLGDPVWPTATVPGEAAAFVDGRLSEGADYIKIMVEDGDVFGTSLPLVPYDVVVAVVEAAHERGVMALVHALGAAATRVAVEAGADGVTHLHHDEVISDDLVVRMREQGMFVISTLAVTASGASDGAGPRLGADLRVASRLDAEWRDNLGREFGWNAHLPTALRSAGLLHAAGVEILAGTDAAHLGAPGIAHGASLHDELRLLEAAGLSPVEALTAATRRTADRFGLTDRGRIEPGASADLVLVDGDPTSRLSSTLNTRAVWRRGHRLALGGATAERAA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01048 | Amino acid adenylation domain-containing protein | MNHTARGMMRTPALSTGLARAVHERAGLTPHAPAVSDGGRTLDYAALDAEAAGAAAALRALRVGPGDAVAVALPRSWQLVCVMLGVLRLGARVVPVDLQSPAERRDHVLADSGAVVHVHTGDAPHGLPPGVAAVPVDGLLRDGRDAVDRPSPPDTAPPVSFVFYTSGTTGRPKGVEVRDAGILRLARPGYLRLEETERFACLANPAFDALSFEVWVPLLTGGCCVVLADDDVQSPERLAEVLLRERVDTAFVTAALFNAVVATVPDCFAGLGQLLIGGEQLNARAVRSWYRHNAGSGTRLYNGYGPTECSTFALCHPIPRDLDTPVVPIGRTLPETGATLVVPGTTREAAPGEVAELLLSGAGLAAGYRNLPEESARRFVPLSRPDGPPVVHYRTGDLVRRDARGDIEYIGRADRQVKVRGFRIEPGELEQRILAHPAVRQAHVCTRRAGGDGPNELLAYLVVDSALTWAEFDRHLAAHLPAYMRPHHLYRIDAVPRTANGKADQAALLARTDPPWRPDGDAAEVTDPVQRELLEMAGRVLGLPDLRPGDTWIACGGDSLTALRLRFEIRRRWNRDLPQSLVLRGDLAALAEAVRAAPDTDAPGYPSASAAGAGSAPATSEQQRLWLIQQQSPHSRAYDVRLAFAVEGDVDVPALRRASSRLVARHPALRTAFEAAPEGLLQVVGEPYDPWVPAERPYASPGVVAGGVPDPGAPQGAFFAEPFDLSRPRMLRMGLLPAESGSGSVLLLHLHHIAVDGWSVNVLLRDLSDGYAAALAGGEDAPDRAAPAPTPLDFAVWQEQWRAEPAYDALRTGLLAHYADRTEPGRAVPQPAPHLADRPGAALLHTQLDVVRRAALDRLCGAAGLTRFQVLLAVYAWALYGVTGDARPRVAAPVAGRPVREFEDSVGMFANTVLLPLDVSPRRELRQELLRLGRDTQEVLERQDVALADVVQGQGPLRRAGSPFDFLFVLENTDFDSLELPGCETSPRWPVPAGAKCPVTLSVIERPDGLACQWEYAPEHFTPERAAALAELFRRGVDALAEEHSATGTVADLVAGHRGSLPEPGRGESRAWAWTTVAEGFALQVARTPSDPALMTAEGPVDYRTLDAWAAALAADLRATAGARDAEGPCHVALFLEPSVEHVVALLALARLNLTAVPVDPSYPPALLRQILEQTDPLCVLLPPGDQSAFDAVDPRGRLGLPRRTVTLSAAPDPALPDPPHRGERPLYTLFTSGSTGTPKGVRVYDRTLCNLLQWQAASGGLGGAAATQQFSMLSFDVSFQEIFGTLCSGGCLHLVRPGLRQDVPALLDRLEAAGIERLFLPFVALQMLAEHAVHLGRYPSRLREVVTAGEQLVCTDAVRRWFAGMPGSRLFNQYGPTETHVVSSLCLDGDPSRWPERPAIGGPVANAVLHVVDEAGLPVPPGCPGDLLLGGVIDAPCYLGDGRLNEERFTELPGQGLFYRSGDRARFDSDGLLHFLGRADDQVKLSGHRLEPGQVEAALLRHPAVVGAVVAVDGGELVACLRCGDAAPSPAELREHLAGLLPAHVRVARYRLLAELPRTPSGKLDREAALRAPSRELPGAHRAADGPSSGREAALAAAFEEATGSAIGPDQTYFEAGASSLDLMRFHLRCTTVLGLPLTVADLFEHVTVRRLARFLDTDAGAGTGGGAGAGMSTGTATSTSVGAGTGDHAGAAAGAGAGDLTGAAAGAEGIAVVGMAVRAPGAPDLAAFWELIASGAGGIEYFDAPEGIVGARSQMDGLLAFDPERFGISRQEARLMDPQQRHLLMACVEALAHAGLADTGAARVGLVAGAGENTYFQAMLREADPAHLPDGFQLALHHDKDFLATKAAYHLGLTGPVLAAQTACSSSLVAVHLAAGMLRQGDADVMLAGGVLVDTSLSQGYRYRPQHILSADGHCRPFSDDADGTVGGSGTGVLVLKPLSRARADGDTVYAVITGSAVNNDGSAKLGYSAPSLAGQRAAVRTALRRSGRPGSDVAYVEAHGTGTRLGDPVEAEALRQALGTTEPDHCALTSVKSQIGHLGAAAGAVGLIRAVLSVHHGVIPPTRGFRALNPEIGPDPTPFYVPTEALPWPARRDRVAAVSSFGIGGTNAHVVLEGGSAAGPPDAADSGAADQEVVPLVVLSAAGAVRLRSDASRIADYLERRPEAYGQVLRHLQAGRPQERLRAAAVCPTPLSAVDWLRAAAASSAEPGAGERPAAPPRDPVAAAECRSVSELADAWLAGRTVAWPEGSAQAPWDFPPPSFDLADFHFGRASAAHSAPAPSGAPAAAPSGALAAARTPERLPEAQWLHQPQWVRLRRAATVPRGDRARTLVVVAEGPADAALVDAFAAGHRRVVWVRASADRARTGADRFEADPADPAHLRYVLDAVTEDGPPGVDWVHMLPLSVDGPVHATSVDRAAWACLDTPAALLRAVSGRPYAALLRPWWVSRGARPVHGDVSRPETALLAGVTEVGPQEGAPRGHWVDLPGTGPWAAQLAALFAEPETAGLPRQLALRQGCWWEQVLLPVAAAPDHEGEPLPASEGDHLILGGTGGLGTGIAAWLLAHTPGRVLLLSRRPRLPEVLAPWAERVELVDADLAVEPTAEVAVRIASRTTGLASVVHAAGVAAGGLVARRDAEDMRKALAPKLRGALLVEQLIEEHRPALAVYCSSMSAHLGGVGQFDYAAANALLDAFARYGGPGGGTTARSALAWDVWRETGMAVRTLHSDARHRAHLGVGLTVDEGQRVFARAVGLGLPHLLVSTTDVEESRVFYEGAGHDASDVPAARLPGAPAGDRAPAPDSARELLAEQLCILLGVDRLDPDASLYDLGADSLTLLSVIEAVDRSFGVELDLGSLSHRVSLDEIVARLDEARGEADRTQDSQDHLNPEEGKDEDGDEVTLTVWQQGAGRDVVCLVHPVGGDVQAYRFLAAALDPGATVALIADPGLRGRELPRWTIAERAHHYLAALRARFPETTWRWHLAGWSFGAWVAAGMAAEAESAGRPARSLHLLDPPPPGSGSVFQEYDERQLKTVFAAELGLGGEETGPGRQADTYADRLTRCCLANVHSMAAHRLPRITVTATRLWLARDPVEGLPSLGTPGEQRARWRAHLPEPTAAEVLDTTHYGVVRPPHAAAVAHAVNEAVHEAVAEGSTGGSAAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01053 | Amino acid adenylation domain-containing protein | MRRSSLAPARGPATVFAGKRTRGPVPAGRRSPSRTNCVDVRATSGGEPAEPRFSRRCDCNSGPPSQWPGPFTPRRTAPAGRAITSTTRRTCGSRSRGRPTRAAAPAPSPPLGRTGTPSARHSGRPDSAACRAAGRSARRNRVLTASVPRRGGELASVVAFANRRAGNTRRSPLTWSSAPPNDWLRLPHPRAGVAEYARSHPWQPFQHGRRPHLTATHTPHASSPGSQDDGFPPPLSFGQERLWTLAQTAGAVAAYNEPMAFRIRGPLDRALLGRALDVVVSRHETLRTRFVDVDGEVRQVVGPPESGLPLRVEDLSGAPDAEARLADHQREECETPFDLRRGPLVRGRLITLAPSDHALLLTLHHAVSDGRSGQVLTRELGVLYGALLRGEEQPLPPLPEQFAAHCRRQRAWVNGPEAAGQAGFWREYLDGAPPLLALPTDRPRPPRQSHEGDRVHVRFDADLTAALRAAARKEKCTLFAAVLAGWHILLSRLSGQPDGVVGIPVEGRRGSAASGLIGFYVNSLAHRVDLSGNPTGAEALRDVRASLRSVLRHQDLPFAHVVEAVNPRRSLSHGPLFQTMLTWGASRKDFLELAGTRVEPLAIDFAPAKFDYTLYLHEEDGGLVGYLDYARALFDRGTVERHLRYLTRVLRQLADDPGRRVADLVLLDDREHGELLAKGHGPVAPSPAADLVELFEEQVRGRPHGPAVVAGGTRLDYAALDRRANRLAHSLLARGVRPQQVVGLHCGRTAELLVGIWGILKAGAAYLPLDPGQPAARLRTIVEEATPALVLSDLGDPPGPWLPLGQVAAEGERDDPPGVAIGPSHLAYVIYTSGSTGRPKGVAVTHGNVVNLIGNWLDQYGAIPGEPSSAWASIGFDASVHELFLPLTTGAVLHVVPEDLRGDPEALLDWMREREIVHAYLPASYITWIDEDPGGRLRGLALRQVTTGAEPLPEMALHRMREVLPGLRVCYVYGPTETTVYSITYNQPQALGRRCPIGRPVRNTLVHLLDQGRRPVPPGVTGEVYIGGAGVARGYLNRPDLTDERFLPDPFVPGGRVYRTGDLARLLPDGDYEFVGRVDDQVKLRGFRIEPGEVAAALREVPGVTEAAVLADRDEAGETRLVAGVARAGGGSPLLPHEWRAALSERLPDYMVPSLFAEFERLPLNRSGKLDRQALLAHARSALSAAQVNTHAPRDRVEMSLYRIWRQVLVHPGMGITDDFFAVGGTSLSAIKVAHLVREEFGHDLPIREVLEHPTIERLAARVREGVPAKGDDSLIEFRAGGGAGRVVCVHPAGGTAFCYLPLATALPEGIGVQGVQALGLNPGEEPLASVESMAEHYLRLVRPEPGEALVLCGLSYGGLVAHEMGRRLAEAGHDRSAVVLLDTHGTDDPAERAAFAPVGADDFRARLVRFNGMYPGIDDAQIDRYFRIYNHNRAAARDHTPRSTAAPLLLVQADAEAPSPAEAAAVEERQRRFWGERALAGLVVERVEGGHWDVLEGERVSRIAALITDELARLDGRSV | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01058 | Amino acid adenylation domain-containing protein | MTDSPSAAHRDKVAIIGIGCRLPGHAGDHRSFWRNLIEGRDCLVPTPADRYDTTTLGSRDRAKPGRLTGGRGGYIDGFDEFDPHFFGISPREAEHMDPQQRKLLEVSWEALEDGGQRPAELAGRDVGVFIGAFTLDYKILQFADLGFETLAAHTATGTMMTMVSNRISHCLDFRGPSVSIDTACSSSLVAVHLACQSLQRGESELALAGGTLLHLAPQYTIAETKGGFLSPDGRSRAFDASADGYVRAEGVGVVVLKRLSDALRDGDPVHAVVIGSGVNQDGRTNGITVPSADAQATLIERVCAEAGVTPGSLQYVEAHGTSTPVGDPIEARALGRVLAQGRAPGARCYVGSVKTNIGHTEAAAGVAGLIKTALALRHRRIPPHLNLEQPNPAIDFAALPFEIPTAPVDWPEHQGPARAGVNSFGFGGTNAHVLLEEAPPRPPEEPRATARTPSLSVLPLSARHASGPAELAAGVRRELAAGVSLADLGHTLAHRRQHFEERLAVVHSPLGPPGSLDEVLAACERGEQHPRAVRGRLREPGAPRLVWVFTGMGPQWWGMGRELLDAEPVFREAVERCDREVRRQAGWSLLDELTRPEAESRMAETWLAQPANFAVQAGLAALWEHHGVRPDAVVGHSTGEIAAFHQAGVYGLEDAVRIALARSALQHRLAGTGVMLAANLSEEEAERLVRPYRDHVSVAAVNSPASVTLSGDRDTLRELAGRLEREQVFARFLDVEVPYHSVRMDPIEAELREALTGIAPRAAGLPLYPTAREGRARGPELDAVYWWENVRRPVRFRAAVDRLVDDGYTLFLEIGPHPVLGHSIRECLEGRAVEGVTLPSIRRREDEPERFARSLAELYTLGVDVDWSVLQPVGRPVPLPGYPWQRERYWVEPAPVEQIRLGRLDHPLLGRRASALQPTWESRLDTERLPYLADHRIEDSTVFPAAGYLEMAAQAVRALTGGDTATLADVEFSRALFLPDGEATTVQLAFAPEEAGFTIASLAGSGTGTPDRTVHASGVVRTGQPRRLAQPLDTGAVRARAGRRLDREACYGELAALGYHYGPAFRAIDEVWTGPGEALSLIRPTPGMGDGAADCHVHPVLLDACFQTMLTAMTPDDGRSAGIRLPAGIAELRLDAVGDRAALWAHATVTAESDEELVGDLALYAEDGTPLGRIGGFRAAAVDRGASSVKLGTIDGWLAEVVWEEAPTEAETPTEAPEDVGTAEGSGAGPGGSPAPGLVVFADEGGLGARMAEAVVARGGRCRLVRPGSRYRSGARHVTVRPDSAADLRRLFAELGPGFGAVVHLWNLDLPPLDTVGAADLDGIGTLGGYSLVLLAQVLPEAFPQGRLHIVTRGAQAVVPGEPVEPFGAPAWGIGRVLWQQELTGHSGKLIDLDPAGGPGEPEVLLRALTTDDGEGEIALRSGRRHLSRLRPPAGLTRPLPLRLRADGAYLVTGAFGALGRLLCRTLVRRGARRLVLLGRTGVPARGAWRGLDPGGPEGRRVAFLRELEALGAEVLVAAVDVTDAAAMEGWLAGRRAAGLPPVRGVFHLAGQVRDVLLPSLDREAFDAGYGPKAHGGYLLHRLLRDEPVEHFVLFASVASLLTTAGQVNYAAGNAFLDALAHHRRALGLPALSLDWGPWATGMIEELGLVAHYRDARGMSSLAPEAGMAVLERVIGQDRAQLLVAAVVDWPVFLSWYPTPPPLVSALAAAAAREVPAGQGGSLLAAFRAADEAARTALVAERFAALAAGVLRVRPEQVDADARLGSLGLDSLLAMELRARTHTELGVSLPVVALLSNGPVSELTERLHAGLTELAAAGGPVAETAVELFTDEACYPLTHNQQALWFLRQLNPDGFAYNIGGAVEVRAELDPELLFDAFRTLIARHPSLRVNITTEDGRPVQRVRPEAVADTGLLDVSGLPWDEVRARLVAEYRRPYDLERDPLVRLRLFRRAPDRWVLMKAVHHIVSDAISTFVFIEELFEVYHGLRTGRPAELAPVRARYLDFLNRRNRFLAGPEARRMLEYWREHLPREVPALELPTDRPRPPVQTDNGASEFFQLDDELSARVQTLAREHNVTVFTVLLTAYYLLLHRWSGQDEIVVGSPVTGRTEEELASVYGYFVNPLPLHVSLAGEPSVAELLGRVRDTVLGGLDHQEYPFVLLVEELGLQHDPSRSAVFQAMFILLTHKVGVERFGYTLEYIELPEEEGQFDVTLSAYEDRSDGRFHCVLKYNTDLFDAATVRRMAAHYQNLLDGLTRAEGERPAGRLPMLGAGERERIVTGFGGVGRRIDHDVPVHELIGKIAAQFPEAVAVSVPGGRRLGYRELDQRSRRVAASLRERGVGAGTVVAVRLAKSPELVIALLAVWRAGGAYLPLDPDHPAERLAELMENAGATLVLTDGRRGGAARLPGRPVTLDELDRPGTEERPEPAVDLDQTAYVIHTSGSTGRPKAVRVSHRNLASVFVAWQQEYRLDTDVRVHLQMAGLSFDVFTGDLVRALSSGGTLVLVDRDLLFDTARLYRTMRAEGVDCGEFVPSVARGLLAHCEREGLGLEFMRLVIVGSDAWRADEHHRLVALCGPGTRVVNSYGLTEATIDSAYYEGPAEGLEPGRMVPVGRPLPNSELYVLDRHGEPVPPGVAGELWIGGAGVADRCLGDPERTAERFVTLEPGGEPVRLYRTGDLGHWDAEGVLHLLGRRDGQVKVRGHRVETGEIEARLAARPELAQVCVTVRRDETGENVLCAYCVPAPGAAADARELRRHLAEQLPTYLIPAHFTELSALPLTANGKVDLDALPKPRAEAGPERYEPPVTLYETRMAAHWRSLLGLERPGLRDDFFEAGGSSIKLIQLIHHLRTEFNASVPVGRLFKTSTLHGMARTLEDVVTGRLPGAEPYLWFNPGADPAATVFCLPPAGGHGLVYRQLAARLPEHRFAAFNYLSGPDKAARYADLAEELHPGGPYTLFGYSLGGNLAFEIAGELERRGRAVDLVLIMDSYRMAEAVALGEEHLAEFEAELTEHLRRHTGSEIVARETVEQAREYLAHCAAHPSLGVLDAPIAVISDQDKLLRFAVDEPGGWHGGTAAGCTVREGHGRHAEMLDGSFLDGNAELVRALLTGGAANGRA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01063 | Amino acid adenylation domain-containing protein | MRVDGGLLPKPCTTRGPGSDHGPHPGHRRPGRLLAARGISPRIGAAKVTVTVGEVLALVADRLVLPAEQLDPERSFVAAGADSLSLMALARAVQSEFGVRVSVRELFTGVDTPQKLAEAVAGRAMNRSAPAVPAASAAPAQVPTTALATEPVGHAPVAQPPAPTGDALESALALFTDQLQLAGKMMTRFSELTSEQLRVLRGLHPGPAVGASPALPAAQPAPETDLTDDVATAEPLPATGTTRRPPAGAPRTGTPDPAPAGTTARTSPDFSLYFFGDYPAPDSAVAYQHLLQAAEYADELGFHALWLPERHFHSFGALFPNPSVLAASLATRTSRIRLHAGSVVLPLHNPIRVAEEWAVVDNLSGGRVGLGFASGWHSTDFVLAPENYGRQRDIMYEHLETFRSLWSGRSVAMTSGDGRPTEVSLHPRPVQGDDVPLFAAVLSNPESYERAARAGLGVVTNLMTQSVEDLATNIARYRAARAAHGHDPATGRVVVLVHTYLEPDAERARQEARKPFCDYLRSSIDLFDNAANSLGIDVDLLATHQDDLDYVLDLAYERYCETRALIGNAAEVRPVLDSLTAAGADEIGCFIDFGVPPERMLGGLPELDRLRAASTEPRAEAAPVPAAAPRTAAVTALQRQLWLLDRMTPGSHTYYEPKALFIEGPLDTEALRGALRRVVARHPQLRAVFRERADRLEQVVLDAVAVDCPVTELPGHDDTAALLRLRDLEDETDFDLATGPLIRARIGRLDGERHLLYLVAHHAVLDALSTRILCRDLAAYYRAWPGEPTDLPELPPWPATVQESSTADGLAYWQRDLADASPLTLATDRPRTAGHEVRGATLVHEIDGELRGGIRSLARAEGCTPFMALLGAVSATLGRFAAQDDIVIGTAVTNRPEDAADVVGMFVETVALRLDLSGGIGFRELLHRVKARTTAAMDHRGVPFDQIVEVVNPDRSSGANPLFQAAVEYEEELGSVFEDTGLTAEFREVPRKHAPFGLTFYFSDRAAGIRCTVEYDAGLFDESTVRRIAEYIEKLLRRSVDAPDAALCELLALTARDEWSLAGFQGERTETEPATLHGLFEEQAALTPDALAVAGVGDPLTYAQLDAAANRLARRLADRGLAEGEVAAVSVSRGPGLATAVLAVLKCGAAYVPVDLALPAERRAFMLSDSGARLVVADGTLDGDTADTLPCPVQWLEDVAPSDTDEPLGRTVDDEATAYLFYTSGSSGRPKPVAVPHRGPVNLIRWQLRTLGALRTAQWASAGFDVSVQEIFSTLASGQALITVDDETRYDPAAVAAQLRHFEVERMSVPFTPLKYLARELKAVPSLRQLLISGEKLTLTPELRELAAHCPELSLYNQYGPTETSVVVTSHRVNPATETVVPIGRPVDNVTLAVVDDSGRPVPVGVPGELVIGGVAVSHGYHGNPDATARGFFRTPDSGERRYRTGDLVRWRDDGVLEYIGRIDEQVKIRGYRVEPEEAQWALGRLDGVREAVVLARPGESGDTELAAFVVLSPAHAPDGDWSAPLRAQLATVLPHYLVPQSWVRLDRIPYGATGKLARGELLTLRAEPALAATDVELSDLEPTVHKLWAVELGVDTIAPDTSFFDIGGNSLSAVRLLERVLTEFGQRIPVADFFAAPTIRGVAHRLTVLQGEER | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01068 | Amino acid adenylation domain-containing protein | MVPGAARPGHALREPPRGRSHPLRRLPVLHRPGRDRGVRGGTGRPVRRLRRRTARFRDGRRGQQVSRTARKIEDILPLAPLQEGLLFHSVYDEGELDPYVVQMSFDIDGALDTAALRTAAEKLLARHANLRVAFRQRKSGDWAQLVMREVPLPWTERDLSALPETDRAEAAAGLIAAERATRFDVTRPPLLRFTLLRLGADRHRLVLTNHHLLLDGWSLPVLMGDLFALYDAGGDDSALPRVRPYRDYLTWLEDQDRDAARDAWRDTFADLVEPTLVAPGADRAAVAGAEVRAELPREETAALTELARGRGLTLSTVVQSAWAIALSKHLGRDDIVFGTTVSGRPPEIDGVERMVGLFINTLPSRVRLRAAEPLAGLVARVQREQAALTPHQHLGLAEIQRTVGHGELFDTSMVFQNYPVNRSGTAGTGIGAAISLAPGKNREATHYPLLLIAAARDSMTFRLNHRPDLFDAATAQQILDRFVRVLRALVTDPEQPVGRLDLLTDRERDSVLREWNDTAHDVPDATVLGLFRAQADRTPQAPAVTSAGRTLTYAELDARSSRLAHLLAEHGAAPERFVAIALPRDCDTVVALLAVLKTGAAYLPVDPDYPAERIAFMLADTEPALLLTTRELAPGIPDSGAPRLLLDDPAHTGDLAARPDTAPTVPIPPGLPAYVIYTSGSTGRPKGVVIEHRSLGAYLQWARDAYPAMTGTSLLHSPISFDLTVTALYTTLVSGGLVRVADLDERAAEGPGATFLKGTPSVLALLEALPAEASPSELIMLGGELLLGEVADRWRARRPDADLLNVYGATEATVNSVQYRIPAGAPAPTGPVPVGRPFWNTQVYVLDSGLRPVPPGVPGEAYIAGTGLARGYWRRAALTSERFVANPYGPAGSRMYRTGDVLRWNHDGRLEFVGRGDGQVKLRGYRIELGEIEAVLAGHEGVTQAAVLLRQDQPGDKRLVAYAATAGASVPADALRALAADRLPDYMVPSAFVVLDAFPLTPNGKLDRRALPAPDYGPQAGGGRAPRSPREDILCTLFAEVLGVGSVTIDDDFFALGGHSLLATKLVSRIRSALGAEMAIRQLFETPTVAGLSGALDTGNGAARTPVTAVLPRPERLPLSHAQRRLWFLHRFEGPSAAYNSPVALRLSGALDRAALEHALADLTARHETLRTVLAEDAEGPHQVVLDEARPSLAVVSSDATRLAADLSEAAGHAFDLASEPPLRATLFEVGGDEHVLLLLTHHVATDAWSRAPLARDLTAAYAARMRGAAPQWAPLPVQYADYSLWQRDVLGTEDDPDSEAGRQLDYWGKTLAGLPQELSLPFDRPRPAVASHRGDVVTFELPPELHDRLARVARDSRTSLFMVLQASLATLLSRLGAGTDIPLGTPIAGRTDDALDDLVGFFVNTLVLRTDVSGDPTFAELLERVRTADLAAYAHQDMPFERLVEAVNPERSLSRHPLFQTMLNLNNAGPVEALDEIAKLPGLTVHHEPVETHRVKFDLGFSFAESHSTTGTPGGLRGALQYSTDVFDRSTAEALVQRMVKVLEWVVASGNGSRVSEVEVLEEAEREQILSGWQGASRPVRGASLPQLIAEQAERTPDAVAVECGDRALTYGELDAWAGRVAGWLQGQGVGRGTFVAVKLPRSVELVVALLAVTKAGAAYVPVDPEYPQERVAHILSDATPALVIDDTAMLEQETDGPFDTVRIDPHDPVYVIYTSGSTGRPKGVVVEHASVGAYLERAREVYPDASGTALLHSSVAFDLTVTALYTPLVSGGRVVLTDLDEHAATTGQPTFMKVTPSHLGMLEALPEEVSPSGTLITGGEALVGEALAAWRAAHPDVTVINAYGPTEATVNCTDFRIEPSDVMGSGPVPIGRPFWNTRAYVLDDHLRPVPPGVTGELYVAGIVLARGYHNRPDLTAERFTADPYGPPGTRMYRTGDTARWTHTGQLTYTGRTDDQIKLRGFRIELGEIQAVLMTHPHITQATVIVREDQPGDQRLTAYTVNTAGTDTTTDDLAAHTAAHLPAYMIPSHFITLDQLPLTPNGKLDRNALPTPQYGPQNENGRAPRTPHEQALCTLFADILGTDTVTIDDDFFHLGGHSLLATKLVSRIRTDIGAELPIRQLFETPTVAGISAALADKARAARRGVVAVDPRPARIPLSYAQQRLWFLNRFEGPSATYNAPVALRLTGALDQEALRQALADVVTRHESLRTVFAEDAEGAHQIVRGPADARPEFTIVETDEARLRDDLAWAAGHPFDLAAEIPFRASLFALSEEEHVLLLLTHHIVSDAWSRAPLARDLTAAYAARVRNAAAPEWAPLPVQYADYSLWQRDILGTEDDPTSEITRQLDYWTHTLTGLPDQLELPYDRPRPAVATYRGDRIPFDIPAELYERVGEVARRVQASPFMVLQAALAALLTRLGAGTDIPLGTPIAGRTDEALDDLVGVFLNTLVLRTDTSGNPTFAELVDRVRERNLGAYAHQDLPFERLVEAVNPERSLARHPLFQVLLTLNNTDYQGALDSLGDLPGLRAEREPIESSVAKFDLAFGYTERRDPHGRVTSLHGVLEFSTDLFDRRTAGALVDRLLRFLDHAVTTPDVKVGDIEILAGAERGRLLELWNDTAREVPERSVVELFEERVASNPLAEAVVAGEEALSYEELDARAERLARVLVERGAGAERFVAVALPRSVDLVVALLAVWKTGAAYLPLDTEYPAERLAYMLDDANPVLLLTTSDLTPVLPEEPAVPRLLLDTPETTEALSRPAGDRSLTRPALANPAYVIYTSGSTGRPKGVVVPQGALVNFLTAMRDRFELGAGDRLVAVTTVGFDIAGLELFVPLLSGASITLAERDVVRDPAALCRLVRSAGASVMQATPSLWRAMLAEDASALAGVRVLVGGEALPADLAEALVQRAMSVINLYGPTETTIWSTEWPVTAEGARRPRIGRPIANTRVYVLDGTLRPVPAGVPGELYIAGDGVVRGYHGRPGLTSERFVADPHGPSGTRMYRTGDLVRWTVDGELEYLSRVDDQVKLRGFRIELGEIEAVLAGHERVAQAAVLVREDRPGDRRLVAYLVPAAEAVETAEVRAHLAAHLPDYMVPSAFVTLDSFPLTPNGKLDRRALPAPDYDQGTSEGRAPRTPREDILCTLFAEVLGAGSVTIDDDFFALGGHSLLATKLVSRIRTVLDTEIAVRRLFEAPTVAELAAVLDNATGTRKPLRAPVSRPDRVPLSYAQRRLWFLHRFEGPSATYNLPVALRMTGTLDQEALRLALADVVDRHESLRTVFAEDAEGPYQIVQDTAEVSLTVTATDEEHLPEDVDRASRAPFELSEEPPLRAFLFELGEDEYVLLAVVHHIAGDAWSMGPLAQDLTSAYAARVRGAAPEWAPLPVQYADYSLWQRDVLGSEDDPDSEAGRQLEYWKNSLSDLPAELSLPFDRPRPATASYVGDRVTFELPEDVYGGLVRVARAGRSSLFMVLQTALATLLSRLGAGTDIPLGTPIAGRTDDALDKLVGFFVNTLVLRTDVSGDPTFAELLERVRTADLAAYAHQDLPFERLVEAVNPERSLSRHPLFQTMLTLNNTDQGAASAVASLPGLEVSSRPVGIGAAKFDLSFRLAERRPTSESESATLGGALDYSTDLFDRETAQSITERFVRVLTALAQDPDRRVSEVEVLEEAEREQILSGWQGASRPVRGASLPQLIAEQAERTPDAVAVECGDRALTYGELDAWAGRAAGWLQGQGVGRGTFVAVKLPRSVELIVALLAVTKTGAAYVPVDPEYPQERVAHILSDATPALVIDDTAMLKQKTGKPFDGVRIDPHDPVYVIYTSGSTGRPKGVVVEHASVGAYLERAREVYPDASGTALLHSSVAFDLTVTALYTPLVSGGRVILTDLDEHAATTGQPTFMKVTPSHLGLLEALPDEISPSGTLITGGEALLGEALASWRATHPDVTVINAYGPTEATVNCTDFHIQPGEPVPSGPVPIGRPFWNTRAYVLDDHLRPVPPGVTGELYVAGIVLARGYHNRPDLTAERFTADPYGPPGTRMYRTGDTARWTHTGQLTYTGRTDDQIKLRGFRIELGEIQAVLMTHPHITQAAVIVREDQPGDQRLTAYTVGTDTTTADLAAHTAAHLPAYMIPSHFITLDQLPLTPNGKLDRNALPTPDYNQHTSEGRAPRTPHEEALCTLFADVLGTDTVTIDDDFFHLGGHSLLVTKLVSRIRTSLGAELPIRQLFETPTVAALSAVLGNDTAPSRPTVTAVDPRPARIPLSYAQQRLWFLNRFEGPSATYNIPVALRLTGALDQEALRQALADVVTRHESLRTVFAEDADGAYQIVREPADARPDLHVIETGPEEVEERLRDAARRGFDLSAASGELPFRVTLFEVGDGEHVLLLLLHHIVSDAWSRAPLARDLTAAYAARVRNAAAPEWAPLPVQYADYSLWQRNILGTEDDPTSEITRQLDYWTHTLTGLPDQLELPYDRPRPAVATYRGDRIPFDIPAELYDGVAALARDTQASPFMVLQAALAALLTRLGAGEDIPIGTPVAGRTDEALDDLIGVFINTLVLRTDTSGRPSALTLIERVRNQTLEAYAHQDLPFEQLVEAVNPERSLARHPLFQVLLAFNNTDTAAVEDAVAKLPGLSVSRATADTGVGKFDLSFAFAEQAGSGTGLQGVLEYSKDVFDRETVETLGLRYLRLLRAMVDAPQKPVDEAVLLDEAESRTLLSGWNDTACEVPGRSTVELFEERAASDPAAEAVVAGTHSLSYGELNDRADRLARVLAAHGAGAERFVAVALPRSTDLVVTLLAVWKTGAAYLPLDTEYPAERLAYMLDDANPVLLVTTSDLSPLLPASTQVPRVLLDEPGLQEELAAPAGPGPLRGIHDPSASAYVIYTSGSTGRPKGVVVPHGPLVNFLTAMQRQFPLGANDRLLAVTTVGFDIAGLELFLPLLTGASAVIAERDTVRDPGALCTLIRTSGATTMQATPSLWRAVLAEDPTVLTSRHVLVGGEALPADLATALTRHAASVTNLYGPTETTIWSTHWPATSDTAHHPRIGHPIANTQIYLLDHTLQPVPTGTPGELYIAGHGVVRGYHNRPGLTAERFTANPHGPAGTRMYRTGDLARWTPDGTLEYLARVDDQVKLRGFRIELGEIETALTAHPHVAQAAVLVREDRPGDPRLVAYLTPTAHQPIPTTDLRQHLATHLPDYMLPTAYITLDAFPLTPNGKLDRRALPAPDYATHTEGGRAPRTPREELLCTLFAEVLGTDTVTIDDDFFTLGGHSLLATKLVSRIRTVLDTELAIRQLFEAPTVARLAGVLDSSAAARGRLVAAPRPARVPLSHAQQRLWFLQHLEGPSDAYNVPISLDLTGELDQEALRLALADVVDRHESLRTVVVEDGSGAAHQVVLGREQTRVPLAVERVASDAEVDARMRRAAGYVFDLASEIPLRATLFAVGEEGVTDRWALLLLTHHIASDAWSRGILIRDLVAAYAARTTTGRAPDLAPLPVQYADYSLWQRDVLGSEDDPGSEARRQLDHWKRALSGLPEELSLPFDRPRPAVASYRGDRVAFDLPQDVYERLVRVGREQGASLFMVLQAGLAALLTRLGAGTDIPLGTPIAGRTDDALDDLVGFFVNTLVLRTDTSGDPTYAELVDRVRAESLAAYAHQDLPFERLVEAVNPERSLSRHPLFQTMLSFDNAGRAATHADLAGLAVSGRTLGAPAAKFDLSFELAERPAGPDRAADLSCALDYSTDLFDRGTAQDVADRFVRVLTALADDPGRRIGETEILGRDERRRMLVEWNETAVQHADRTPVHVLFEERAAAEPEALAVVSGEERLSYGELNARANRLAHRLLGRGVGRESRVAVFQERSAELIVATLAVLKAGGVYVPIDPQQPASRSEFILRDTGAVALLTDRDPGDLPFAVDVPVLDVGPGTDLSGEADTDPGVPTDAEQLVYVMYTSGSTGTPKGVANTHHNVVHLAADRYWRGGRHERVLMHSPYAFDASTFEIWTPLLTGGTVVVAPAGRLDAADLAAAISGHGVTGLFVSAGLFRVLAEERPECFRGVREIWAGGDVVSPTAVRRVLETCPGTVVANEYGPTETTVFSAVNPLRDPAEVPEAVVPIGRPLWNTRLYALDERLRPVPVGVPGELYIAGSGVARGYLGRAALTAQRFVADPFAGAGERMYRTGDVVRWLADGRLEFLGRVDDQVKLRGFRIEPGEVEAVLAGRPEVSQAAVVLREDRPGDKRLVAYVVAGAAAEPEALRAHVAGTLPEYMVPSAVVLLDGLPLTLNGKLDRRALPAPDYGADTERRGPRTEREKVLCGLFADVLGLAEVGVDDGLFDLGGDSIMSIQLVSRARRAGLELSVRAVFEHRTVAALAEVVTETDTTVTEEPGAGIGDVPLTPIMRWFLERGGPVDGFNQSRLVQVPASLRLPDLTAALGALLEHHDALRARLTDGSERRLEIRGPGAVDAGSVVRRVDAAGLDDDTLQDLVRGETVAARERLDLGAGRVVQSVWFDRGDSRPGLLLLIVHHLVVDGVSWRILVPDLAEAHRAVVAGRPVELQPVGTSLRRWAQRLTEVAGDPARTAEADWWRSVLRPADPLLGRRPLDTARDTYASARHLTLTLPVAVTERLLTRVPAVFRAEVNDVLLAAFALAWARRGGGRGAGVLLDLEGHGREEELVGGADLSRTVGWFTSLHPVRVDAGPADLADAFAGGPAAGAVVKRVKEQLREVPEKGIGYGLVRHLNPRTAPGFAGLPTPQVAFNYLGRFTTAGVENAGSEAVPDWTVLATASGVGGTDPRVALAHPLELNARTNDGPRGPELSATWSWAGGILDEDEVRELAELWFRALEALADHAENPEAGGLTVSDVSLSLLDQSEIELLEDEWRNL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp01073 | Amino acid adenylation domain-containing protein | MPTPDRRSAPPPEHRPLLAAQEGIWAGQQLDTESPAYNTAEYLRIAGPVDTAVFDRALHRVVAETEALNATFDIDDTGRPRQATTPAGDWRTHIADLTAEPDPHAAALAWMDRDTARAVDLTRGPVFGHALLRTGPQEHLWYHRVHHIALDGFGLSLVARRVAEVYSGLMAGDPVPESGFGTLDSVREEEAAYLASARHTQDRAYWTDRYADHPPVATPADRSALPARTFHRHVTDLGPAAAHRLRTGARELSVTWSEVLLAVTAAHLHRLTGAPEIVLSLPATGRLGSVSLRVPATVRNILPLRVPVAPDDGLRDLAPRVSRELRAGLPHQRYRYERLRRDLKLVGGGRRLSGPGVNIMPFEYDLRFAGHPSTVHNVSAGPVDDLAVNVYDRGDGTGLRVAVDANPDLYTEAETAAFQEGLLALLEQALTDPGRPLGGPRAHRTVAVLDGGPLPAPARPVLSLIADHATRGGGAVAVEHAGERLTYARLLGAARDVARRVTALGVAGGDVVAVALPRGTDAVTAVLGVLMSGAAYCPLDPKAPAERTARLLADTAPALVLTTADRAADFADHTVLPLHEPDPAPAGAHTPSAKGDSAGAGSTARRRSELGPLDGNESQEPGPRHFAAPAVEDPAYVLHTSGSTGRPKGVQVSHGALAHFVAAATHRYGLRREDRVLQFAPLHFDASVEEIFLTLCAGATLVIRPDDMTESVPGFLDACARLRVTVLDLPTAYWHEVAHTVSTGAAALPRAVRTVVVGGEPALPERVERWRKAVGTSVALLNTYGPTEATVVATVADLHDPGLGTGDVPVGLPLPGTRAAVLDGELYLLGPALADGYRPEVPDSARFAPLTALPDGPRAYRTGDLVRIGEDGQLRHLGRADDEFKISGQRVQPAEVESALLFHPGVREAAVAGQVLPDGTRRLVARLVPEGPAPSAADVREHLRARLPAAMVPSAVEFVGRLPRTGSGKIDRAALAAPPARRAPTTGSPLEQTVTGVWCRILGIDAVAVDDDVFDLGAQSLQAIQAANRLGTELGRDVKVAWLFQHPTAGGLARFLAQGPQPRAAGPAGLPPALLADARLDPDIRPGTRSAPRDAPRRILLTGATGFVGAHLLAQLLSDTGAEIVCTVRAADVPEATGRVHAALARHGITLDERTSARLTALPADLAHPGLGLPPDTLAGLAASCDAVFHNAATVSIMRDYANLRAANVESTRRLVRLAAVHATPLHYVSTLSVAPPASRAPEVPEAFLPPHEGLRHGYQQSKWAAERLLQQAAERGLPVTVHRLGRVIGRAGTGGVNERDFLWSVLRAGIPEGIVPELFEDEIWTPVDFVARALVHLSLTPDTAATGPVFHHATLPRVRLADVYDWVRAYGYPVRALPLARWRERLPRSADVAATTLAFFDAAELDAAGPDSTELGFSEPDSTGPDFTGRDSHDRTTATDLRLGHVRADRVRAGLVGSGITCPPVDRALFFRHLDHCVTAGVLPAPAGRPVSRSGPAAK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01078 | Amino acid adenylation domain-containing protein | MMEPTARLVLLSPKHLTDLRRRTGDHSDAALATACAIGLSYWATGQSPAGLDLTAATLFGDVLGWADNGGAAPEGWGVAADGRTITLPEGVVPDDAQLALDDLADFPGRPLGTIGPAGPTARLENLARWNDTDADRERPTLMEMFLEQARARPGAVAVVDERRTLTYRELSDRSAQLAHRLRERGLSDEDVVGISLERSADMVVGLLGVLRAGCAFVPLDPHWPAERRAVVAADARVAVQLNASGEPAPHEPEAVPVDLADWRHGDRPTEGPDPTVRGDALAYVIFTSGSTGRPKGAMIRHEAISERLLWQVHEILDFGHDDASLFKAPLSFDISINEIFLPLVCGARLVVLRPGGERDPHHLLGVIAEQRVTFTYLVSSMLDVLLEMAGDTGRLDSLRHVWCGGEVLTPELYERFRTQLDIPLYHGYGPAETTIGVSHVVYRGAAERLSTSIGRANPNTRLYVLDDELRPVPVGVGGELYAGGLLLGRGYVNAPGLTASRFVANPFADDGSRLYRTGDLARFAPDGSLDFLGRADNQIKIRGMRLEIEDVEAGLAEHPGVRHTCVVPKKNTAGGTYLVGYVIPAAGHGSLRPDEVKAWAAEHMVEYMVPTHVVVTDAFPLTANGKLDRQALPEPTVAASAARPPGTENERAVCTAVAAVLQLDEVGTDQDFFRLGGDSILAISLLSALRDAGLYVTARQIFTHSTVGALAAVASREDTAAVDHRDTPTGTVVGPPVVQWLGETTGAIDGFVQSVVLNTPAALTADALDEILTALVRRHPMLRARLVRGDRWGFDIPDEVPAGALWQESDRPLDSCTALATEALDPAGGAMLRAVWRRSARQLVLVAHHMVIDGVSWRVLMEDLATAWRQYASGAPVELPVEGTSFRRWTGLLERAASDADGQYFRRPLPAADEPVGRRALTEDDTVARERIRTVETGAETTAAVLGTVPAAFHAGVGDVLVTALAVALARRRRDLGQDQTFAHLELEGHGREAAFVAPSAGFEPELSRTVGWFTTLFPVVVDPGTAPDLTAPEYLATALKAVKEDLSRVPDNGISYGALRYLNRVAFDAPAPQVLFNYLGRFDAGAPGDWQLAGSTGQLGEKRDPAMRLPRALEFNAVAEPGPDGEYRLVTTVSWPEGLFTDQDIDALAGHFQDALTGLAALERGGHSPADFRPLRLTQADVDDLDGPALRDILPLTPLQEGLYFHSVYDDETAGSYVEQQLLTLDGDVDADRLATAATRLLTLHPGLAARFTALADGRVVSVLESGHHAPFTTLDRPGITDEEIRDLAERDRRAGFDLATGPLMRYTLIRAGAGRHVLVQTVHHIVADGWSVPPMLRTLLAEYHRPGSAHPLGGFPEHVRRLAALDDRESDRVWREQLAGLPGPSLIAEGHTPSDRFADTATTPGIDVDAAARAAGVPLSVAVHSAWALTLGGILHSEDVVFGSTVSGRDADVPGIQnMVGLLINTVPVRARWSADTTAAELLAQVRAHQSAVLPHQHVSLARTARHTGTGPLFDTLVVFDVATDVGALREPGDTLVVTDIVNEGAPHYPLTLVVERTPDGTPRFNAVHDAALLRESQVQDILHTFTRTLTTLLTSPDTPVAAPVPHTARRAPAVAPATLGDLLDAAARRDPAATAVTQCSLDGATRSLTYGELTEAKDGLAAVLRAAGAGPGRLVAVAVPPSVEQVVALTAVTGAGGAYVPLDAAHPDERLEYILADAAPQVVLVDREQRERFTRLLERAGVPARVLVQGDEPAPADDGPASPAGWHDPAYVIYTSGSTGRPKGVVVPHSGVVTLLAHTQADMGFGPDDVWVQFHSFSFDFAVWELWGALAHGGELLVPEYALTRSPVDFHRLVREHRVTVLNQTPSAFHRFIEADRHAGEPLPALRRIVFGGEALDLGRLRDWVDRHGTATPELVnMYGITETTVHVTHRVLTDADFGPGDAPSPIGTPLPGLVVHLLDDRLRPVPPGRVGAVYVAGDQVSLGYLGRPGLTAGRFVADPFTGDGSRMYHTGDLARRTLDGELHFAGRADDQVQLKGFRVEPGEVEAALRDLDGVSDAAVTVADGGDHLVAHVVGRAPGDLTALLAARLPAHMIPGRVLSVDALPLTVNGKLDRKALAERAANAPLPDGALHRTDSGSAAPDGPAVLDTVVRVFAETLPGSTPDADTDFFAAGGDSIVAITLINRARAAGLSVTPRDVFLLKTPRALAEHLTASTPPPATPEPVRREDGPLPPTPIILRQRELGGSLARFAQARTLLAPEGTAFADVERAARAVVAAHPALRLRLRVDHGVWSLRTEADREVTVVRADGTDPTAAADEAASRLDPESGDVAAFSWLAANRTLVVTVHHLAVDAVSWLILLDDLAGALRGTPVPAPTTSYAEYAEALTHRAAHAAPGLGHWTTALQAPTPLPPPEALRETTAVLAPGISDRLTRTAPTALGLGLTELLCGALRTALTRIQPSPTDLAVDLERHGRVPALEHHDYTRTVGWFTAVAPVRLTPHTDPVAAAREVTERRPDEREHVAYGLLRYLNAQTAPLLTARPQVLFNYLGRGAESEAPRLAGGDRGSPYAVEVNAWTDAATGSLHAVFTLAEGIPDTLTAHWLAALEQLADSAATAERTAPVTPLQRGLYFQSQLTGPTGHYVAQSWFTLERRLDTDALADAMAHVIARHPVVGAGFTTDDDGNPVQVLGAGRRVPVRTVEAATDAEAEALRLADRDTGFDPAEPPLVRLTVVRLPGDRDGLLLSYHLLLWDGWSRETVLRDLFDAYEDILAGTPLDTAPATPRFEDHARALAARDPAPAERFWSEHLAPLSGPTLLAGPAPSLSDDLPHALVHTLTAAESERLRETARTHGVTLNSVLTGAFGLLLGAHTGRADAVFGVTVSGREGEGASGVVGVLLNTVPMWTRARPHDTVRAYLTAVQASRVAAMEHEHLGLGEIQRAAGHDTLFDNLFVLQNFLDLDAFAEMNARHGITSVQADDSTHYPFTWVVTPGDRLTVKLEHRDHDAGRARRLLDDYLRVLADLAASDGPLGALPGPAPAPAPGARTDIGTDTVVDRFDRAADRNPRRVALVAHGSTLTFAELRDRSRAVAGVLVRRGIGPETTVGIAVPRSLDSIVALFAVLRTGAAYVPLELDHPDERIAAIVADARPDVILTVGTVAPRLTGDLIELDRPLPEAEPYVTFAPDDPHRLRHPAYIIHTSGSTGKPKGVVTEYAGLTnMLVNHRRRIFEPVLAEHGHRTFRIAHTVSFAFDMSWEELLWLADGHEVHVCDEELRRDAPRLVEYCAEHAVDVVNVTPTYAQQLVAEGLLDDPARRPALVLLGGEAVTPALWRRLAETEGTVGYNLYGPTEYTINTLGVGTFECPDPVVGVAIDNTDVHVLDPWLRPLPDGVPGELYVSGIGIARGYLGQTAQTAHRFVACPFGAPGERMYRTGDLVTRRPDGNLTYLGRTDQQVKIRGHRVELGEVEAVFTAHPAVRFAAAVAQPDPQVDGAHRLAAYLVLDGADLATVAAEVGAGLPDFLRPTHYARVDGIPLTVNGKADTRALPEAKPLGALTTAGERPPATETETTVCEFFAEALDLDDDEVSAVSDFVSLGGHSMLAVRLTGLLRREYGPVITIRDLFTLRTPEAIARHLDDH | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01083 | Amino acid adenylation domain-containing protein | MQETAPDPVAGRQPAPAAGPEDAVAALAHACAAALASDPASVRLAARLKVASVLLGRASPAPDASWRDLVRHVGTDDGRSEAEEAWANASAAAGATAERLGRYELRALRLMRDDPDLPHTRHGLLTPEETEAVVARGAGPLRPLPGRRFHELFEERVRRHPDAVAVVHGTTTRTYRELNDDANRIAGALLREGLAPEDVVAVVTGRHPLWPAAVLAVFKAGGCYLPLEPEFPASRIARTLTRSECRWVLSDPDVASLDEALNGRDTIRRMTVGDLARGDGPTRDPGVAVAGDQLAYVYFTSGSTGEPKGAMCEHDGFLNHLYAKIEDLGVQEGDTVGQTAPQCFDISLWQLVSPFLVGGRVLLVEQEAVLDVARFVDLVNRHRVQVLQLVPTYLELVLAEAARGRAALPHLRVMAVTGEALKKELVRRWFEQFPGVPLVNCYGLTEVSDDSHHGVMHTVPDHRSVPLGDTIRNCRVYVMDEQLHLVPDGAPGEIVIAGVCVGRGYVNDPDRTAAVYHQDPLRPAERLYRSGDFGRRLPSGELEYLGRRDAQVKISGFRIEIGEIEDRLLQVPGVRDGAVVVAGTDDAPQLVAYYTGEDAPDGAGTAHALGTALPHYMVPHRLHRVRELPLSGNGKIDKKALTARARDNAHARGSAGTGAPRLDTPAERRVAAVWARLLRVPEDRIGRDSRFTDLGGTSLTAIRLAIELDRRVTVAELRDTPTVADVAALLDGKSAPARATAPAGPAPATTPARPAEGPAPLPLLDCRAADPEPDPAARATAHRAPALAALAASGAVMLRGVGARTPADVARVAAALGIEPLTEREGFAPRTALAPGVYSGSHWPAEDPMCMHHELSHAATVPGTLLFACLTAPDSGGRTTVADSQQVLAALPSGLTARFAEHGWLLRRAYHDVGLSWPEAFGSTDRASVDAYCAEAAVEPTWLADGSLLTRQRRAAVVPHPRTGAPCWFNQIAFLNGLTLEPAIREYLTDVYGPGGLPFDTAAGDGGPVTAGTVEEINAVYDRFTVGEPWQQGDVLLVDNIRTAHAREPYEGAREIAVVLGDPVRLPGHVLPLSDGGPS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01088 | Amino acid adenylation domain-containing protein | MSEARLLRRPVSAAQSGIWVAQHLHADSPLYNCGGYYEIAGPVDAEIFAEAVRRGVQETEALRSRFAQEERDTDSGPEVTLHQLVEPAEPHPLRFVDLRAASDPEAAAHRWMNARMARPFDLTRGPVSEQALLTLADDLHWYFHGYHHAVLDGFGQSVYATRVAALYSALLAGEEPSPTGFATLDRVVADEAAYAGSRRHTRDRAHWREVFTDLPEPVSLGRASGSTHSLRRHVRTLPTPLAERLPGAAARLGVQWPALALAATAAFFHRMTGGTDFTFSIPLAGRSGRTSLTTPSAMVNVLPLRVRLTSDIRFTELAAQVSRSLADVVRHQRFRGEELIHELGLSGAGQARLGPTVNIMAFAGEPLFGTTPAVTHPLSTGPVNDLKINFYGTADSRTGIRVELDGHHELYGADELAAHCDRLVRVLEWVADSDDESRVSEVEVLEEAEREQILSGWQGASRPVRGASLPQLIAEQAERTPDAVAVECGDRVLTYGELDAWSARTAGWLQGQGVGRGTFVAVKLPRSVELIVALLAVTKTGAAYVPVDPEYPAERVAHILSDATPALVIDDTAMLKQETGKPFDGVRIDPHDPVYVIYTSGSTGRPKGVVVEHASVGAYLERAREVYPDASGTALLHSSVAFDLTVTALYTPLVSGGRVILTDLDEHAATTGQPTFMKVTPSHLGLLEALPDEISPSGTLITGGEALLGEALASWRATHPDVTVINAYGPTEATVNCTDFHIQPGEPVPSGPVPIGRPFWNTRAYVLDHRLRPVPPGVTGELYVAGIVLARGYHNRPDLTAERFTADPYGPPGTRMYRTGDTARWTHTGQLTYTGRTDDQIKLRGFRIELGEIQAVLMTHPHITQAAVIVREDQPGDQRLTAYTVNTVGTDTTTDDLAAHTAAHLPAYMIPSHFITLDQLPLTPNGKLDRNALPTPEYNQHTSEGRAPRTPHEQALCTLFADVLGTDTVTIDDDFFHLGGHSLLATTLISRIRTTIGAELPIRQLFETPTVAGISATLDQQPARAAVRRPGVTAGPRPGRIPVSYAQQRLRFLSLLEDGSTAYNAPGALRLTGALDQEALRQALADVVTRHESLRTVFAEDESGFTQVILEPYEVALGLDVVAVDEERLAARLAEAARYSFDLAAEPPLRATLFEVGDDEYVLLLLLHHIAGDGSSMRPLARDLAAAYAARVRGATPEWAPLPVQYADYSLWQRDILGTEDDPTSEITRQLDYWTHTLTGLPDQLELPYDRPRSEVVTQHGGQVSLRIPAELHGQLHELARTTRSSLFMVFQAGLAALLTRLGAGTDIPLGSPIAGRTDAAVEELVGFFANTLVLRTDTSGDPTFAELVERVRARSLEAYQHQDLPFERLVEAVNPERSLTRHPLFQVCLTLHNTDPRATVAEEARLPGLAVELERLPIEDTKFDLNWELTEHVDGLGRPAGVTVDLEFSAELFDRGTARSVADRFVRLLSATARDVEVPIGEIDVLAPGERTEILDEWSDATRPPVAAALSGSSLPRTADDTRAYVLDDTLVPVPPGVVGQLYVTGSGPAGDAAEQERWLPCPYGRAGWMYRTGTSARWSADGELRLVEVPGRTPVGPADVWPARSRGPRSPREQILCTVFAELLGVASVGIDDDFFDRGGHSLSAVRLLSRIRAVLGVELSIRRLFENPTVAGVVEALDEASGARRPVTAVARPARIPLSYAQQRLWFLNHLEGPSATYNIPVALGLKGALDRAALRLALTDVVARHESLRTLFAEDSEGARQIVLPAAHATPELIEVDVAPGELPGRIRAAASHPFDLATELPVRAWLFSAHDGERVLVLVVHHIAGDGWSMGPLARDLSLAYTARARGDAPAWTPLPVQYADYTLWQREVLGSEDDPDSEISRQLAHWKTALADLPEELELPVDRPRPARQSHRGGRVPFEVSAGLHARLAAFARETGTSLFMVAQAALAALLTRLGAGTDIPIGSPVAGRTDAAVEDLVGFFVNTLVLRTDTSNDPTFAELVGRVRETNLGAYGHQDVPFERLVEVLSPVRSLARHPLFQVLLGFDNNQEALEILRLPGLTVDVHAPETGRAKFDLAFFFDERYGPHGEPEGLGGAVEYNSDLFDRSTAQEFAERLLRVLEGAVADPERPIGRLEVMSPAERDRVVDEWNRTAHDVPPLPVPTLFERQVAAEPRATAVLGEDVTLSYAELNSRANRLARLLAASGVGAEDVVAIALPRSADLVVALVAALKTGAAYLTLDVSAPEQRLRAVLTDCGPRVVVTDLATRPLLGDGIALDVVLDAPETVRELAAGADADLTDADRVRPLDLRHPAYVVYTSGSTGTPKGVVMPMSSLVNLLAWHTGTYCGGVGTLTAQFLAVSFDFAVQEILQALVVGKTLVIPEEHVRRDAYELAQWIARYSINELFAPTLVIDAVLAAAADTGERLDSLTDLFQGGEQFRLSHELREFCASGWRRMAHNIYGPAETHAATTATLPGDIDEWPTAASIGQPLWNASVYVLDAGLRPVPPGVRGELYIGGAQLARGYLGRPDRTAERFVASPFGRPGARLYRTGDVVRWNHCGELEFLGRADHQVKIGGFRVEPGEVEAVLADHPSVETAVVVTREESAGPTRLVAYVVPEGQDADPALGRTLRAHLEQQLPHYMVPSFVVPLDELPLTANGKLDRRALPAPGSDTVAAEPRTEREKVLCGLVADVLGLAEVGVDDGFFDLGGDSIMSIQLVSRARRAGLQLSVRDVFEHRTVAALAEIVTETDTTVTEEPGAGIGDVPLTPIKRWLLARTDDLDAFnMSAVLRVPADVDADALTGAVQALLDHHDALRARLTPAPQRRLEVREPGSVDAGALVRRVDASGADGADLHALVREAGAAARDRLHLGEGRVVQAVWFDRGRDSAGMLLLIIHHLVVDGVSWRILIPDLAEAYEAVSAGRKPALQPVGTSLRRWSQRLTEEAVKPAWVADAAWWQDVLRSAGPPPGRRPLDPARDRQATAGRLTVTLPTEVTEAVLTRVPAAFHAEVNDVLLTAFALAWARWRPGGPELLLDLEGHGREEHLVEGADLSRTVGWFTNLYPVRLDTGGVDLARAFAGGSAAGSAAKRIKEQLRSVPDKGMGYGLVRHLNPATAAGFDGHAAPHVAFNYLGRFTAADCDRAADWTPVTGFDAVAGDPPQLPLAHPLELNSRTEDGPEGSELVAFWTWAEEILDEDEVRELAELWFQALRALVTHSENPHAGGLTPSDVSLSSIGQDEIEAFEEELDDLFDDFDDEPHDFETEEEASK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01093 | Amino acid adenylation domain-containing protein | MPGRVVEMINAQVRRHPRAPALVAPDGSLDYAELDRRSAYLAGHLTRQGVRPGDVVLIQASRGVALGVALLAVLRSGGAFCVVDPQYPADRIQHMWRRSHARFALIESGLRAPDVPDGPAVLPLRQWATPGSAHRAPAPHRAEPGSEDPAYLVFTSGSTGGPKAVLMPHRCLDNLIEWTLASTSSEPLRTLLFAPLGFDVFVQEVFTAWCSGGCLYTPSDAERVDLQCVWELCREREIQRVFLPPVALRRLADLTVEFGILPGALREVAVAGEALHITPAIRELFGRLPAARLHNHYGPAETHVAVAHTLTGPPRSWPDLPPIGRPLPGMTAQVVPRAEGGELWLTGVGLAHGYVHDPRQTQERFRSILVEGRTVRAYRTGDLVRERTDGALEYLGRADGQLKIRGYRVEPGDIEAALLRHPAVRECAVVAWTSLGSEERRLVAHVAAVPGGAPDAAELRAHVAGLLPDYMVPHHVVLATELPLSPNGKIDRRRLPPPGDADDSAGTLPEPEPGDVRSAVADIWSTVLGVADIPPDRHFMDLGGTSLSAALVVTRLHQRFQVQVSVQEFLYDPRVDAIAALITERAAA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01098 | Amino acid adenylation domain-containing protein | MSGHRTQQTYTRIPRWTMPGSDEQGAAEHREALPAPLTRALEERAADTGAELPAVLLAAHARVLATVVAEPDLLIGLVPAAGRAESPLGLTVTDSSWADLVGLASTAPAAAPRAEGRPEVVFDLSGLTPTDTAPAGRADPDGTAVGLGEGVVLRVAVVAGSAGLSLRLVYDRAHLDESYARRLAGYHLRALELLAADTSAPHHGRSLLSEEEIDTHLYGLAGPRVDLTDRTFVDHFEDRVREVPDAVAAVHGPVRWTYRELDGRANRVAHALLDAGVRTEDVVAVVMDRTLDWIAAALGVFKAGGVYLPVRPDFPADRVAAQFSRSECAFVLTEPGSATLARKAGELTGRAPTVLSVPEIQASGVSDAAPRVPIAPGQAAYIYFTSGSTGAPKGAMCEHAGMVNHLHMKLDDMEMTNGTAEVVTQTASQCFDISLWQFAAPLMVGGSVRVVDTDALLDVAGFLDEIVTGGVTVVQIVPSYLEVLLTHLEQHPRPLGALRTVSVTGEALKYELVQRWFALYPEIKLVNAYGATEVSDDTMHEVLDRVPDRDFVTVGRSLRNVNTYVLDQDLALVPLGSPGEIAFSGVCVGRGYINDEERTREAFVPDPFRDGTRMYRTGDFGRWLPEGRIEYLGRRDEQVKIRGFRIEIGEIENKLLALTGVREAAVVIDGTDDGQRNLVAFFSGGDGGARPDAEPTTERARDFLAGLLPEYMVPTYFHRLDRLPLTENGKVDKKALIRLAGTLGHGGAAYAAPSTPAEQRLAMLWAQVLGVPLERIGRDDNFFELGGTSLAAVRLLVQLDRALSLKDLVAHPVLADLGRALDERVRGGERAAAENLLQPLANATDPHRILVCFPYAGGNAVNFRSLAAELERDGIAVLGVELPGHDFAGGDDPMADVPEIARRVRDEIAARVTTPVLLWGHCAGAAPALETARLLQEAGRPAERVFVGALLLEDVGALRAEMAEAAEADNKSLLSRLRADNAYVELDELKPERADVVGRAYRHDVLTANSHLIRIREDAGSHRIDAPVDVVVARDDASTARFAADHGDWKAVSDRVTLHELDQGGHYFIGTRAADTAALVRACCPKPTHRD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01105 | Aminoacyl-tRNA hydrolase | MDGMSGPHVIRGSVLLPEAELVWRFSRSSGPGGQHVNTTDTAVELRFDLARTGALPEVWKRQALERLAGRLTDGIVTVRASEHRSQWRNREAAAVRLAALLAEATAPPPRPRRPTRIPRGINERRLREKKQRSQTKRGRSPKDWD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01110 | Aminopeptidase N | MSCMSVLTRDEAQTRSRLLDVHHYAIALDLTRGDETFDSRTAIRFTVRGDTDATDTFVEVKPAELRSVTLDGQPLDPAALDGNRLPLRGLAPGEHELRVDAAMRYSRTGEGMHRFTDPADGETYLYTQMFLDDVQRVFAAFDQPDLKAVFDLAVTAPEGWTVLANGTTEHTGDGHWKAATTPLISTYLVAVAAGPWHSVRTEHRGLPFGIHCRRSLAPHLDTDADELFEITRACFDRYHEKFTEPYPFDSYDQAFVPEFNAGAMENPGLVTFRDEFVFRSAVTDTQRQTRAMVIAHEMAHMWFGDLVTLRWWDDIWLNESFAEYMGYQTTAEATRFADTWTDFGVSRKAWGYDADQRPSTHPVAPEHVEDTASALLNFDGISYAKGASALRQLVHWLGEKDFLAGINIHFERHKYANASLADFIDSLAAATDRDVHAWADAWLRTTGVDTLTPRVTGDNGGRALEVGRKGERPHRVAVGLYDRDLNDEGRLTLRERLDLDLPQDDPRPIGKLPALVVLNDGDLSYAKVRFDAESFRTIREGLSGLPDPLTRAVVWNALRDAVRDGELPARAYLDIARAHLPRETDLALVDGVLAFAAGQVADRYVAPEQRPAALTTLAELCRDLIRRTEDGDHPGLRLIAVRHRIATAAHPDTIAAWLADGTVPGGPELDPELRWRILTRLAVLGATDEAAIAAELERDPSATGQEGAARCRAALPDAEAKSRAWEAMFATDDLSNYLFTAMAQGFWQPEQADLVREYVPRYYAEAVAVAARRGPAIADAAGRWAFPGHAVDADTLRLGEQCLADAEPLPALRRKLTDQLDDLARALRVREAGAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01115 | Aminopeptidase N | MPGTNLTREEARQRATLLTVDSYEIDLDLTGAQEGGTYRSVTTVRFEVAETGGESFIDLVAPAVHEVTLNGDALDPGEVFQDSRIALAELLPGRNILRVVADCAYTNTGEGLHRFVDPVDDQAYLYTQFEVPDARRVFASFEQPDLKATFQFTVKAPEGWTVISNSPTPEPRENVWVFEPTPRISSYVTALIVGPYHSVHSVYEKNGQSVPLGIYCRPSLAEHLDSDAIFAVTRQGFDWFQEKFDYAYPFKKYDQLFVPEFNAGAMENAGAVTIRDQYVFRSKVTDAAYEVRAATILHELAHMWFGDLVTMEWWNDLWLNESFATYAEAACQAAAPGSKWPHSWTTFANQMKTWAYRQDQLPSTHPIMADISDLDDVLVNFDGITYAKGASVLKQLVAYVGEDAFFQGVQAYFKRHAFGNTRLSDLLGALEETSGRDLKTWSKAWLETAGINVLRPEIETDADGVITSFAIRQEAPALPAGAKGEPTLRPHRIAIGGYDLDADGKLVRGDRVELDVDGELTAVPQLVGKVRPAVLLLNDDDLSYAKVRLDEQSLAVVTEHLGDFAESLPRALCWASAWDMTRDAELATRDYLSLVLSGIGKESDIGVVQSLHRQVKLAVDQYAAPTSREALLTRWTEATLAHLRAAEAGSDHQLAWARAFAATARTPEQLDLLDALLDGTQTIEGLAVDTELRWTFVQRLAAVGRFGGSEIAAEYERDRTAAGERHAATARAARPTEAAKAEAWESVVDSDKLPNAVQEAVIAGFVQTDQRELLAGYTERYFEALKGVWESRSHEMAQQIAVGLYPALQVSRETLDRTDAWLASAGPTAALRRLVSESRAGIERALQAQAADEAAGA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01120 | Aminopeptidase N | MRTPRLLASAAALTALAACGGDGAVGGGPGGPGAGDPYFPEAGNGGYDVGHYDLKLDYDPGTGRLAGLATITARATRDLSAFNLDLKGLNVEKVAVGGRDARSHRAGQELTVRPADALDAGETFRVTVRYSGRPVTVTDPDASEEGWLRTADGAVGLGQPTGSMAWFPGSHHPSDKAAYDLAVTVPEGLGAVSVGELRGERTRAGRTTFTWHAAEPVSSHVVTVAVGRWETDRSRTGDGLPVYTAVDPQQADASREVLARIPEIMDWARKNFGPYPFSSTGAIVDRAGDAGYALETQNRPYFPGAPDTVLLVHELTHQWFGNSVSPKTWRDMWLNEGFATYAEWLWQEDHGGDSAQQTFDALYDGTYYPDEAANDAVWSFPPADPPDAAHISASPVYQRGAMVLHQIRRAVGDDAFRALLRGWAAAHRHGNADTADFTAYVEKSAPDEDFTEIWRTWLHGEGRPRRS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01125 | Aminopeptidase N | MLHTPHLPAPRPRAHSRRRLRAAALLASAVSVCLVAASAPPTPLGVGDRLYPHLGNPGYDVAAYDLAFTYSGSNSEPLEAVTTIDARATADLDRINLDFAHGKVDSVEVDGEPADFAPAGADLVVTPQDALDEGERMRITVRHSSDPVYAEDRPGGWVRTTDGLAMANQADVAHLVFPCNDHPSDKARFTFHVTAPDGLTAVANGLPTGVERAGGSTTWTYRTQHPMATELAQVSIGRSTVLHRTGPHGLPVRDVVPTEHRAALEPWLEKTPEQIAWMEKKAGRYPFETYGLLMADATTGFELETQTLTLFERELFTEPAYPKWYVESIMVHELAHQWFGNSVTPATWSDLWLNEGHATWYEALYAEETADRPMAERMKAAYGASDRWREAGGPPAAPKPPKSGSKTGIFRANVYDGSALVLYALRQEIGRTAFEGLERAWTATHRDGTATTADFVRLASETAGRDLGGFFQAWLYGEKTPPMPGHPDWKPVAEKEPVKASRKPQGE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01130 | Aminopeptidase N | MPLRLGAFVHRRFIVPGALGAATLMLAIPASAAAHSPGAPGIGDPYYPAYGNGGYDVSHYDLRLKYQPDTDRLEGTATILARTTEDLSRFDLDFLLDVGEVRVNGAKASFTTSGEQELEITPAKPLDKDTPLTVVVRYSGVPSSKQAFGFTSWHRTPDGGIAANEPEAAAWWFPSNDHPLDKATYDVSVQVPDGTQAISNGTLQSTSSRLGWTRWNWRSAQPQATYLATLAIGRFDLTTGTTEGGIPVVNAYSEDLGPNGGAARASVERTGEVADWLSGYFGPYPYDALGGYVPNTDTGFALETQTRPFYSPRQFANGSNVSVVVHELAHQWYGDLVSLRGWKDIWINEGFARYAQWLWSEHEGEGTAQELADYTYASYPADDPFWTVKPGDPGPENQFDTAVYDRGALAVQALRNEIGDDAFFTVLKGWPAKYAHGNASVADFQRYAEEVSGKPLAALFDTWLFQPSKPDAAAARAQSLAKPAGTPAQPRSWRKIAATNDVHDHDHGHRH | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01135 | Aminopeptidase N | MSRDEARERAALLSVDGYEVSLDVRSALGEARGEAPDEAQGGGPRTFRSVTTIRFRCNEPGASSFADLIAPSVTAVSLNGRDLDPSEVFDGSRIALEDLAAENELIVDAQCAYSRTGEGLHRFVDPEDGEVYLYTQYEPADSRRVFANFEQPDLKAPFRFEVRAPEEWTVWSNGAGERADGVWRFAETKPISTYITCVVAGPYHYVTDTYERTFEDGTRLEIPLGALCRKGLAPHFDAGDVFLITKQGLDFFHDRFDYPYPFGKYDQAFVPEYNLGAMENPGLVTFREEYIFRGKVTRASYEGRANTILHEMAHMWFGDLVTMEWWDDLWLKESFADFMGAFANVGATRFKDAWITFANRRKAWAYRADQLPSTHPITADIRDLEDAKLNFDGITYAKGASVLKQLVAYAGQDAFLEGARRYFKRHAYGNTRLGDLLSVLEETSGRDMTAWARSWLQTAGVNSLTPQVLLSTAGTVDELAVVQEAVESHPELRPHRVAVGLYRRTAEGALERYARAEVDVEGPRTVVAELAGAEAPELVLVNDDDLTYCKTRFDATSLATLREHLGALTDPLARALCWSALWnMTRDALLPARDFAALVLRFAGRESDIGVLQMLHAWAGSALVHYAAPDWRETGGRLLGEGAVRELRDAAPGGEQQLAWARFLASVASGEEELSLLRGLLDGTEKIDGLAVDQELRWAFLAPLAAHGAADEGVLAAELARDDTASGKRHQVRCLASRPSAEVKARAWAQVVESDALSNALVEATIAGFAQASQRELLAPYAERYFAVIERVWAERSIQIGMDVVRGLFPSLRDSPETLDATDAWLSAHEDAAPALRRLVLEARDDLARALRGQACDAAAAAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01140 | AMP-ligase | MADLHARLEQLASDRPHDTALVLGRRDGSGRAITFARLVAGCREAADAFERAGVRRGHKAVTMTGDPYHLFTTVHGLLAVGAVPVLVDPGLPRADLRQCLDEVAPEVFVGQPLAHLGRTALGWARGHVRTAVVTGAAVPGLRRRLPVPGARRGWAPAGPPPVRDPLPPTPDDGLALIAFTSGSTGVPKGAEYHHSTLLGQAETLARLVGTDGTLFAGFLPVVLLGPVLGHTTVAPAVNHRAPARTPSARLVRPLLENRTEVVVGSPAVLGLLAEHCARRRLVLSCVDRVISFGAPLRAGLADALHAVLRPDAEVLSAYGATECLPVSAVSTTDACAPGAGTCVGRPLGGVAARILDAGPDGVGEIAVTGANVSPAYHARPEITAATKTATDRGVQHRTGDMGLIDGEGRIWFHGRRSHRVIGTDYVLTTEDVEAAADTLPGVRRTALVGVGAPGRQRAVLCVELTARGPGRGAAVTAVRELLDRRPEGRHVAAVLVHPGFPTDIRHNSKINRDRLADWATRRLRRPR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01161 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | NCIeH838 | Human Lung adenocarcinoma | IC50 : 0.83 - 2.0 μM |
| dbacp01204 | ATP-binding cassette domain-containing protein | MPESATTATPGPAAEGPREDTPLLEVRGVTKAFGSGRRRLTALDGVDIEVGRGTTLGLVGESGCGKSTLARVLLGLERPDAGTVRFDGTDPFALRGKELLAWRRRVQMVFQDPFASLNARMSAADLIGEPWRTHRDVVPGAGAREKRIRELLDLVGLRAGDAHRYPNEFSGGQRQRIGIARALALDPDLVVCDEPVSALDLSVQAQVLNVLSDLRTRLGVTYVFISHDLSVVRHISDRVTVMYLGKVVEHGATDEVFETPRHPYTAALMSAAPALHPGGGSRREEIQLRGEVPSPFDIPSGCRFRTRCPRAEERCASEAPPVAARGTADGGEPHTALCHFPLAAGSSWA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp01209 | ATP-binding cassette domain-containing protein | MVPVLAADGAAVELADTTLLAPTTFEVGPGERWCVTGGNGTGKTTLLRAFAGTRSLTAGSVSVRGEPVAMTDPRHRRLMASLVEPVPVARDMTLREQVALVAASWYGNSTAAAEGTGRVVERLGLSALGERFPHQVSSGQSQLFSLALTLVRPADVVLLDEPERHLDRHRVDLVAGLLAERAEAGTAFLVATHDPALVAACDGRVELG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp01223 | ATP-binding protein | MGVVVLAMLGSLAVLAVAGPLWWGHAADRPDPSAVLQGPTGRHPLGTDHLGRDLLARLLASTWPSLLPAVAATLLGAAAGITLGALTAVVGGRVRRLLGAFVNLLLAFPALLIAMFFAALFGAGARGAVFALAVACAPGFARLTQTLAAGVAGTDFMAAARVLGLRRHRLLLRHVLPHVAEPLLLNVTVAVGSALVALSGLSFLGLGAQSPSYDWGLLLSQGLERVYTEPLPAVAPGIAIVYAGVAFQLLGEVLAKTATRHAVPRHAEEPAPPPAPAGRRPASPDHVLEVEDLRVALPAGDRTIRPVRGVSLALRRGEMVGLVGESGSGKSLTALALADLLPDGARATWNAHWFLGADVGSLTRGERHRQLATGMAMVFQNPASAFNPALRIETQLTEAVRAHHGTPRDQAVEQALVQLRRVALPGERRLLRSRPFQLSGGQRQRVAIAAASMLRPDLVIADEPTTALDVTVQRQIMDLLRRLRRDDATAILFISHDIALVADTCDRVLVMYGGTIVESLPARRLADGARHPYTRMLVASVLDLTADRDGTPPTVEGPPPDAAGTDPGCPFLDRCPQRLDRCAVEGPVPTLLAPGHEVACWRPLPLAAPPGQPETEEAET | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01231 | ATP-grasp ribosomal peptide maturase | MTVLILTSEEDVTADMVVVHLNASSVPVVRLDPADLTESVALSGEFVHGSFRGHLSAGERLVSIGGLRSVWLRRPGGPAARAAEPSAWLTEESGQALYGMLRGSGARWMNQPDAAHRARYKPWQLRLAQQCGLPVPATLITTFPRAAREFAERYPDLVVKPVSGAHPQDPPLAVPTSRVPPEADFSAVAHGPTLLQRRVAKRADIRLTAVGDELLAARKATAHPDPDEVDVRFAASAEPWRPVEVPPRVAESVRSYLRAAELAYGALDFAEDGDGTWWFLECNQSGQFGFVEVDTGQPIARTIAEWLARPGPGDPMPSGPPGATAVG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01236 | ATP-grasp ribosomal peptide maturase | MDDPTTDLVIDELHGRGVPVVRFDSGDFPATLSIAATLTSNGIGGTLTTPTRTADLSRVRSLYYRRPSGFAFPHLDDQTARFAVTQARYGIGGVLASLPGCRYVNHPHRIGDAEFKPSGLAVAAACGFRLPPTVITSDPDTARAFVKAHGPVLYKPLSTPLYRIDGVSCTVEVREATADEIDDSVTGTVHLFQQRIDKTGDVRVTVMGDHVFCVRIDSDLLDWRTDYARLRYGVVQPPPGVLESLHAYLDHFRLVFGAFDFAVDRRGRWWFLECNPSGQWAWLEPETGLPMVAAMADLLERKTT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp01253 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01262 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01272 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01282 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01293 | Aurein-1.3 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | HOP-62 | Lung cancer | IC50 : 5 μM |
| dbacp01312 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Not specified | Not specified | Not found | Lung cancer | Not found |
| dbacp01321 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Not specified | Not specified | Not found | Lung cancer | Not found |
| dbacp01330 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Cell membrane disintegration | One-dose and five-dose assay | HOP-92 | Lung cancer | IC50 : 5 μM |
| dbacp01339 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Lung cancer | LC50 : 10-5 - 10-4 M |
| dbacp01348 | Aurein-2.7 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | EKVX | Lung cancer | IC50 : 5 μM |
| dbacp01359 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | GLFDIVKKIAGHIAGSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | NCI-H23 | Lung cancer | IC50 : 5 μM |
| dbacp01367 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKIAGHIAGSIGKKR | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Lung cancer | LC50 : 10-5 - 10-4 M |
| dbacp01372 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | NCI-H226 | Lung cancer | IC50 : 5 μM |
| dbacp01384 | Aurein-3.3 [Cleaved into: Aurein-3.3.1] | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | A549/ATCC | Lung cancer | IC50 : 5 μM |
| dbacp01407 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01416 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01425 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01433 | B1AW | FLPLLAGLAANFLPQIICKIARKC | Wuyi torrent frog | Cell membrane penetration | MTT assay | H838 | Non-small lung cancer | IC50 : 32.15 μM |
| dbacp01531 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01536 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01541 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01546 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01551 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01556 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01561 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01566 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01571 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01576 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01581 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01586 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01941 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | H157 | Lung cancer | IC50 : 3.37 to 5.87 µM |
| dbacp01945 | Brevinin-1OS | FPLIASLAGNVVPKIFCKITKRC | Schmacker's frog | Not specified | Not specified | H838 | Lung | MIC : 10 μM |
| dbacp01977 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | A549 | Lung carcinoma | LD50 : 10 – 15 μg/ml |
| dbacp01978 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | A549 | Lung carcinoma | LD50 : 20 – 25 μg/ml |
| dbacp01979 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | A549 | Lung carcinoma | LD50 : 30 – 40 μg/ml |
| dbacp02003 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 11.7 µg/ml |
| dbacp02004 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | EKVX | Lung cancer | IC50 : 12.1 µg/ml |
| dbacp02005 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HOP-62 | Lung cancer | IC50 : 12.6 µg/ml |
| dbacp02006 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HOP-92 | Lung cancer | IC50 : 7.2 µg/ml |
| dbacp02007 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H226 | Lung cancer | IC50 : 13.3 µg/ml |
| dbacp02008 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H23 | Lung cancer | IC50 : 10.8 µg/ml |
| dbacp02009 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H322M | Lung cancer | IC50 : 10.7 µg/ml |
| dbacp02010 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H460 | Lung cancer | IC50 : 12.1 µg/ml |
| dbacp02011 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H522 | Lung cancer | IC50 : 11.2 µg/ml |
| dbacp02108 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | H157 | Non-small cell Lung cancer | IC50 : 7.02 μM |
| dbacp02225 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Calu-6 | Lung cancer | Activity : ~90% survival rate at 10 µM |
| dbacp02226 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Calu-6 | Lung cancer | Activity : <20% survival rate at 100 µM |
| dbacp02232 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 60 µM |
| dbacp02235 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 15.8 µM |
| dbacp02236 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 16.1 µM |
| dbacp02237 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 15.8 µM |
| dbacp02242 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 100 µM |
| dbacp02246 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25 µM |
| dbacp02250 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µM |
| dbacp02253 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 32.2 µM |
| dbacp02254 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 28.6 µM |
| dbacp02255 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 28.6 µM |
| dbacp02256 | Caerin 1.1 | GLLSVLGSVAKHVLPHVVPVIAEHL | Australian green tree frog | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp02257 | Caerin 1.1 | GLLSVLGSVAKHVLPHVVPVIAEHL | Australian green tree frog | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp02258 | Caerin 1.10 | GLLSVLGSVAKHVLPHVVPVIAEKL | Magnificent treefrog, Australia | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp02259 | Caerin 1.10 | GLLSVLGSVAKHVLPHVVPVIAEKL | Magnificent treefrog, Australia | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp02302 | Carrier domain-containing protein | MTRPGPAVRDGRPAPDAAGPATAPATYAQERAWLASRLAHDPPTYCAVDEFPLHAAVTANDLVHALYVLMDRHEPLRTVLRTVDGRLRQEVHPRPEPRIELTDLRAHDHAAQAEERRSLRARLARTPFDPHRAPQWRAAVLNLGEGAWSVVFAAHHTVYDTASGFNVHAELTELCAAAEEGREARLPRLPLGYGAYARRERERARTGGADAAAAHWRTRLRGLPPVHTVPLDRPRPPARTFRGAEVRAALPVGVTAALTGAARHHGTRPVMLFLAAWTALLHHHSGAADLAVGLPVAGRDDPATRAMVGTFVnMRVLRADLSGDPDGTELVRRTTAAVRAGEKFDIPFQSLVELLAAPRLPGVPPLYQLAFNHTPADGLGPPVSSCEEDLLLDVAGSGLRLVYDAALFDRSTADLLLADYLRLLAALLDAPGTRLSALLTGPAPRGTPRPAPTAPRARTAPRDAAEERVAAVWRTLLGTDGGTVDVHEDFFTAGGHSLQALRLLARLAPARGSGPTLRTFFADPTVAGLATALKSTPDGRTAWR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02309 | Catfish PACAP38 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK | Sharptooth catfish, North Africa | Cell membrane penetration | In vitro cell proliferation assay | H460 | Lung cancer | IC50 :13.17 μM |
| dbacp02446 | Chaperone protein DnaJ | MATDYYAVLGVRRDASQDEIKKAFRRLARELHPDVNPDPKTQERFKEINAAYEVLSDPQKKQVYDLGGDPLSQAAGGGAGGFGAGGFGNFSDIMDAFFGTASQRGPRSRTRRGQDAMIRIEVELDEAAFGTTKDIQVDTAVVCNTCNGEGAAPGTSAQTCDMCRGRGEVSQVTRSFLGQVMTSRPCPQCQGFGTVVPTPCPECAGDGRIRSRRTLTVKIPAGVDNGTRIQLAGEGEVGPGGGPAGDLYVEIHELPHSTFQRRGDDLHCTVTIPMTAAALGTKVPLETLDGLEEVDIRPGTQSGQSIPKPGRGITHLRGGGRGDLIVHVEVTTPTKLDPEQERLLRELAQQRGEERPTGQFQPGQQGLFSRLKDAFNGR | Beras-beras | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02451 | Chaperone protein DnaJ | MSTKDFIEKDYYKVLGVPKDATEAEIKKAYRKLARENHPDANKGNARAEERFKEISEANDILGDPKKRKEYDEARSLFGNGGFRPGPGAGGGGGTFNFDLGDLFGGGPQGGGGQGGAGGFGGGLGDVFGGLFNRTGGPGTGTGPRTQPRRGQDIESEVTLSFTEAIEGATVPLRMSSQAPCKACSGTGDKNGTPRVCPTCVGTGQVARGSGGGFSLTDPCPDCKGRGLIAEDPCDVCKGSGRAKSSRTMQVRIPAGVSDGQRIRLRGKGTPGERGGPAGDLYVVVHVKDHPVFGRRGDNLTVTVPVTYTEAALGGEIRVPTLGGPPVTLKLPAGTPNGRTLRARGKGAVRKDGTRGDLLVTVEVSVPKDLTGKARDALEAYREATADEDPRAELFQAAKGA | Beras-beras | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02456 | Chaperone protein DnaK | MARAVGIDLGTTNSVVSVLEGGEPTVITNAEGARTTPSVVAFAKNGEVLVGEVAKRQAVTNVDRTIRSVKRHMGTDWSVNLDGKDFNPQQISAFVLQKLKRDAESYLGEKVADAVITVPAYFNDAERQATKEAGEIAGLNVLRIVNEPTAAALAYGLDKDEQVILVFDLGGGTFDVSLLEIGDGVVEVKATNGDNNLGGDDWDQRVVDYLVKQFQSGHGVDLGKDKMALQRLREAAEKAKIELSSSTETNINLPYITASAEGPLHLDEKLTRAQFQQLTADLLERCKTPFHNVIKDAGIQLSEIDHVVLVGGSTRMPAVAELVKDLTGGKDANKGVNPDEVVAIGAALQAGVLKGEVKDVLLLDVTPLSLGIETKGGIMTKLIERNTTIPTKRSEIFTTAEDNQPSVQIQVYQGEREIAAYNKKLGMFELTGLPPAPRGVPQIEVAFDIDANGIMHVTAKDLGTGKEQKMTVTGGSSLPKDEVDRMRQEAEKYAEEDHARREAAESRNQGEQLVYQTEKFLKDNEDKVPGEIKTEVEESVAELKEKLKGEDTAEIRTATEKVAAVSQKLGQAMYADAQAAGGEAPGAGAGAGAAAGDKADDDVVDAEIVDDERKDGAA | Beras-beras | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02465 | Chaxapeptin | GFGSKPLDSFGLNFF | Spore-forming, Gram-positive bacteria,"gifted" actinomycete strain C58; extremophile | Cell membrane disintegration | Cell invasion assay | A549 | Lung cancer | MIC : 50 μM |
| dbacp02489 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp02500 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp02539 | CoA ligase | MEPAPQAPTQPVIDARRPEAGPRWETIGELIKDAALLHGDKEFLRCGDKTLSFSETDTRTDRLAQALIAQGVKPGDRVAVMMDNVADWPLSWFAAIKAGAITVPVNTRFGATDLAHVLKDSQAVLVLASPGCVPLARDVSGSIGNPCAVRTLRELEAGFGDRPVDGPGLSAHADDTVNFQYTSGTTGFPKACMLSHDYWLRTAWMIAVHSGLRPDDVVLTAQAFSYMDPQWKAVMCLMGGVPLVVLPRFSASGFWHSVRQHRATLTYVLGSMPMLLYKQPPHSGDRDHAMRLVLCSGIPRDLHHAFEDRWGAAWREVYGSTESGLDLIMPPGEEATVGSGAMGYPPSGKEVLVADERQRPVQPGQIGEILVRGRPMMKGYWNNPDSTERAFRGGWYHTGDLGRAEAAGSVVHAGRLKDMIRRGGENIAAAEVESVLEAHPAVLAAALAGIPDELFGELPKAFLQLRPGYRPTTATARSVLAHTRRHLAKFKVPAYVEFVDSFPMTPSARIQKRQLLRPGDDQRTGAFDAAADAWA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp02541 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H1299 | Non-small cell Lung cancer | Not found |
| dbacp02542 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H1437 | Non-small cell Lung cancer | Not found |
| dbacp02543 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H1975 | Non-small cell Lung cancer | Not found |
| dbacp02544 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H661 | Non-small cell Lung cancer | Not found |
| dbacp02570 | Creatininase family protein | MKTKGRAGMDASLVPADTSADVRERGSGVSRQVAVLPVGSYEQHGDHLPLATDTLVACAVAREIAAGYPVHLLPPVTIGCSHEHADWPGTVSISAVTLHAVVRDIAESLRRSGVGALVVVNGHGGNYVLGNVVQEASARGERMALFPAGEDWEAARQRAGVRTSLLTDMHAGEIETSILLHAHPASVRPGYETADFVADDRRHLLSLGMSAYTDSGVIGRPSLASAEKGKELLASLADSFGTYFSFLTAADGAEGTSAQGARGRS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02605 | Cysteine hydrolase | MGKTALIVIDMINTYDHEDADSLIPSVESVLPRATGLLERARRRGVPVIYVNDNFGEWRSHHGEILDKALSGPHSRLVEPLRPDDSSLFVVKARHSVFFETPLTYLLHQQGIDRLVLCGQVTEQCVLYSALDAHIRHLQVIVPRDAVAHIHADLADAALRMMERnMGARVCDSGELWT | Not found | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02616 | D-aminoacylase | MEELVIRDADVVDGSGADSYRADVVVDGGRIVSIVKEAAAAGCQRPKARRELDAEGLVLAPGFIDMHAHSDLALLRDPDHSAKAAQGVTLEVVGQDGLSYAPVDDRTLGEVRRAIAGWNGPGDDVDFDWRSVGEYLDRLDRGIAVNAAYLIPQGTVRALAVGWDDREATPAELERMRRLVAEGMEQGAVGMSSGLTYTPGMYAKDAELTELCRVVAEYGGYYCPHHRSYGAGALEAYEEMVELTREAGCPLHLAHATMNFGVNRGRAPELLTLLDEALDGGADITLDTYPYTPGCTTLAALLPSWASEGGPEQILKRLADDDTAERIRHHMEELGSDGSHGVPMEWETIEISGTGDPALGEYVGRTVQESARLRGESPWTVVRQLLLADRLAPTILQHVGHEENVRAIMRHRVHTGGSDGILQGAKPHPRAYGTFPHYLGHYVRELGVLPLEECVAHLTSRPAARLRLPDRGLVREGYRADLVLFDRATVAAGSTYEEPRRLPTGIPYVLVDGRFVMEEGRRTDVLAGRSVRRGSR | Not found | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02621 | D-K6L9 | LKlLKKLlkKLLkLL | Not found | Necrosis; Membrane disruption | Enzyme Immunoassay (EIA) | CL-1 | Lung cancer | LC50 : 3 µMol/L |
| dbacp02627 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | IC50 : 3.2 ± 0.6 µM |
| dbacp02651 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MDA-MB-435S | Lung cancer | MIC : 10−9 to 10−4 M |
| dbacp02655 | Dermaseptin-B2 | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV | Giant leaf frog | Immunomodulatory properties | Cytotoxicity assays, Cell Titer-Glo Luminescent Cell viability assay | A549 | Lung adenocarcinoma | LC50 : < 12 μM |
| dbacp02666 | Dermaseptin-PD-1 | GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ | Skin Secretion, Mexican leaf frog, Mexico, North America | Destroy plasma membrane | MTT assay | H157 | Human non-small cell Lung cancer | IC50 : 10-4 and 10-9 M |
| dbacp02669 | Dermaseptin-PD-2 | GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI | Skin Secretion, Mexican leaf frog, Mexico, North America | Destroy plasma membrane | MTT assay | H157 | Human non-small cell lung cancer | IC50 : 6.43 μM |
| dbacp02683 | Dermaseptin-PH | ALWKEVLKNAGKAALNEINNLV | Orange-legged leaf frog, Northern orange-legged leaf frog, South America | Cell membrane permeabilization | MTT cell proliferation assay | MCF-7 | Lung cancer | IC50 : 0.69 μM |
| dbacp02691 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02696 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Lung cancer | IC50 : 7.44 μM |
| dbacp02701 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Lung cancer | IC50 : 49.51 μM |
| dbacp02706 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Lung cancer | IC50 : 25.51 μM |
| dbacp02711 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 21.78 μM |
| dbacp02716 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 28.95 μM |
| dbacp02721 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Lung cancer | IC50 : 51.04 μM |
| dbacp02725 | Dermaseptin-PS3 | ALWKDILKNAGKAALNEINQIVQ | Skin, the waxy monkey tree frog, South America | Membrane rupture | MTT assay | H157 | Lung cancer | IC50 : 15.67 μM |
| dbacp02727 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MDA-MB-435S | Lung cancer | MIC : 10−9 to 10−4 M |
| dbacp02734 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02739 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02741 | Dermaseptin-SS1 | ALWKSILKNAGKAALNEINQIV | Skin Secretion, Brown-belly leaf frog, South America | Cell membrane penetration | Anti-proliferative activity assay | Not found | Lung cancer | Not found |
| dbacp02743 | Dermaseptins B2 | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV-NH3 | Giant leaf frog | Interact with the lipids of the plasma membrane | In vitro proliferation assay, Lactate dehydrogenase (LDH)-release assay | U87MG | Human lung cancer | GI50 : >10 μM |
| dbacp02748 | Di-PST13-RK-C | KKKFPWWWPFKKKCKKKFPWWWPFKKKC | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 17 µg/ml |
| dbacp02750 | Di-PST13-RK-K | KKKFPWWWPFKKKKKKFPWWWPFKKKK | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15 µg/ml |
| dbacp02755 | Diacylglycerol O-acyltransferase | MHAPHLGTDGGPPTPVPMGTADLAYHLAMRGEPLPAGFLFAFSGPVPTLASVRARVAERAHRIPALRYRIDREGRAFSRVEGIDVERHVHEAWLPGDDDGSGAGRLMLSHPPGGDDRPPWDVWLVHGPGGEHSLCYRTDHTLQDGIGAAHTARALLDDDPVGGPPGYHGGRPTARGLASAAGALAASFRHSDKPAFDVPLSGRTGLCQTVVPVARLRAVGRAHGATVNDVFLAALAHAVGTWHRKNTGAAHPPLPVAVPMSVRAPGEECVPGNRIVVARVLLPCDAPSPRHALSRVVARSDGMRTGRLRESLRLMQTAGPRGIGARVGTRVVNGRAVAGPVSSVNFGTALVHRGNAAHRSVVWSGLGAGIRCLVTLTSQHDTACLAVIHDEALTTADELPDLWLASLLDLEQP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02764 | Dipeptide ABC transporter ATP-binding protein | MSDNTKTTTAVADTFPQQRDGDTAPLLKVSGLSKYFPIKGGFPIKRTVGHVKAVDGVDFEVFPGESLGLVGESGCGKSTTGRLLTRLYEPTQGTIEYRGKDITRANRRELAPIRSEIQMIFQDPYASLNPRQTVGTIISGPMEINGINPPGGREKRVRELLEIVGLNPEHYNRFPHEFSGGQRQRIGVARAVALQPKLIVADEPVSALDVSIQAQVVNLLQEVQREMGIAFVFIAHDLAIVRHFSQRVAVMYLGKVVEIADRDSLYNRPRHPYTHALLSAVPEADLDAEKRERIRLEGDVPSPISPPSGCRFRTRCWKAQDKCATEEPPLVQISGNREGHLTACHFPEEGTTEARAEDVVMDPGLKALEANTDA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02769 | Dipeptide ABC transporter ATP-binding protein | MPETTEPLLEVRGLVKHYPLTSGILFKKQVGAVKAVDGVDFELARGETLGIVGESGCGKSTVAKMLVNLERPTAGEIRYRGEDITRLSGRALKSVRRNIQMVFQDPYTSLNPRMTVGDIIGEAYDIHPEVAPKGDRRGRVQDLLDVVGLNPEYINRYPHQFSGGQRQRIGIARGLALRPEIIVADEPVSALDVSVQAQVINLLARLQSEFDLSYIFIAHDLSIVRHISDRVGVMYLGRIVETGRDAEIYDHPTHPYTQALLSAVPVPDPQAREHRERIILAGDVPSPTNIPSGCRFRTRCWKARERCALEVPALAVPAEFRSVSGPAAHDSACHFAEEKQVVPPEEPGEGPHRPSGDRFGK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02774 | Dipeptide ABC transporter ATP-binding protein | MASGIPAQSDGTQEKSGGTATLTKDAAPGETLLKVTGLQKHFPIKKGLLQRQVGAVRAVDGIDFEVRSGETLGVVGESGCGKSTMGRLITRLLEPTAGTVEFQGKDITHLGVGGMRPMRRDVQMIFQDPYSSLNPRHTIGTIVSAPFKLQGVEPEGGVKKEVQRLLSVVGLNPEHYNRYPHEFSGGQRQRIGIARALALSPKLVVADEPVSALDVSIQAQVVNLLDDLQQELGLTYVIIAHDLSVVRHVSDRIAVMYLGKIMELADRDLLYKSPMHPYTKALMSAVPIPDPARRGAKSERILLKGDVPSPIAPPSGCRFHTRCWKATQVCTTTEPPLKELRPGQQVACHHPENFEDQAPQDVVLLSAAKEAAELVSEDALAQSAATSAAVAAEVAETDADADSGAGADADSGAGADVDSGAGTEEPPAQEK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02781 | Distinctin-Like-Peptide-PH | NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN | Skin Secretion, Northern orange-legged leaf frog, South America | Membrane lysis via pore formation | MTT Cell viability assay, LDH assay | PC3 | Lung cancer | MIC : ≥ 4.197 μM |
| dbacp02782 | Distinctin-Like-Peptide-PH | NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN | Skin Secretion, Northern orange-legged leaf frog, South America | Membrane lysis via pore formation | MTT Cell viability assay, LDH assay | PC3 | Lung cancer | IC50 : 32.25 μg/mL |
| dbacp02814 | Drosophila Antennapedia homodomain PFV | CALNNPFVYLI | Fruit fly homodomain PFV | Cell membrane disintegration | SPR assay | A549 | Human lung adenocarcinoma | Not found |
| dbacp02819 | Dual-functional peptide LPLTPLP | LPLTPLP | Not found | Inducing apoptosis | CCK-8 assay | A549 | Lung cancer | IC50 : 0.00022 M |
| dbacp02820 | Dual-functional peptide LPLTPLP | LPLTPLP | Not found | Inducing apoptosis | CCK-8 assay | WI-38 | Lung cancer | IC50 : 0.035 M |
| dbacp02830 | Elastin derived peptide | VGVAPG | Elastin derived | Apoptosis inducing | Cell viability assay | A549 | Lung cancer | Not found |
| dbacp02834 | Elongation factor P | MASTNDLKNGLVLKLEGGQLWSVVEFQHVKPGKGPAFVRTKLKNVLSGKTVDKTFNAGVKVETATVDKRDMQFSYMDGDYFVFMDMQTYDQLHIERKVVGDAAHFLIEGFEATVAQHEGEVLFVELPAAVELTIKETEPGVQGDRSTGGTKPAILETGHQISVPLFITTGEKIKVDTRTSDYLGRVNS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp02919 | Esculentin-2CHa | GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC | Chiricahua leopard frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent cell viability assay | A549 cells | Lung adenocarcinoma | LC50 : 10μM |
| dbacp02955 | Figainin 2BN | FLGVALKLGKVLGKALLPLASSLLHSQ | Norepinephrine-stimulated skin secretion, the Giant Gladiator Treefrog, the Rusty Treefrog, Trinidad, South America | Cell membrane penetration | Not specified | A549 | Lung carcinoma | LC50 : 7-14 µM |
| dbacp02966 | Folate-binding protein | MKSPLLSLPGAVPAEGVDEGVAAHYGDLFREQRALADGTGFVDLSHRGVVAVTGDDRLSWLHLLLTQHVSDLPAGEATEALVLSANGHIEHALYLVDDGTTVWAHVEPGTQEELIAYLESMKFFYRVEVADRTADTAVVHLPAGSITGVPEGVAVRETPYGRDVFLPREELEAFAAGAGPAAGLLAHEALRVEQHRPRLGFETDHRTIPHELGWIGTAVHLQKGCYRGQETVARVHNLGKPPRRLVFLHLDGSEVHLPPNGAEIRLADDGPDGRKIGFVTTSVRHHELGPVALALVKRNVPVDARLMAEDTAAAQETVVEP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp02969 | Frenatin 2.1S | GLVGTLLGHIGKAILG | Skin secretions, the Orinoco lime frog, north central Guyana, South America | Immunomodulatory activity | Cytotoxicity assay, Cell Titer-Glo Luminescent Cell Viability assay | A549 | Lung adenocarcinoma | LC50 : 80 ± 6 μM |
| dbacp02970 | Frenatin 2.1S (F2.3S) | MAFLKKSLFLVLFLGLVSLSMGEREKREEEEEEEEENKEEEANEEGKGESEEKRGLVGTLLGHIGKAILGG | Orinoco lime treefrog | Not specified | Cytotoxicity assay, Cell Titer-Glo Luminescent Cell Viability assay | A549 | Lung adenocarcinoma | LC50 : 80 ± 6 µM |
| dbacp02971 | Frenatin 2.2S | GLVGTLLGHIGKAILS | Skin secretions, the Orinoco lime frog, north central Guyana, South America | Immunomodulatory activity | Cytotoxicity assay, Cell Titer-Glo Luminescent Cell Viability assay | A549 | Lung adenocarcinoma | LC50 : 75 ± 5 μM |
| dbacp02973 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02980 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02987 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp02994 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp03001 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03008 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03015 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03022 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03031 | Gageostatin A | ELLVDLL | Bacillus subtilis | Perturbation of the cell membrane | Sulforhodamine B (SBR) assay | NCI-H23 | Lung cancer | GI50 : 4.6–19.6 μg/mL |
| dbacp03049 | Gamma-glutamyl-hercynylcysteine sulfoxide hydrolase | MCRHLAYVGPAEPLGGLLVAPPHALYRQSWAPRHQRHGTVNADGFGVGWYAEGDPVPARYRRAGPIWADQSFADLARVVRAGALLAAVRDATLAGADAEAAAAPFAAGAWLFSHNGAVGGWPGSLAPVAAALPPEELLSLEARNDSALVWALVLSRLRAGDDEGRALAETVLEVAAAAPASRLNLLLSNGTTVTATTWGDTLWYLTRPGAGGTVVASEPYDDDPGWQQVPDRTLLTATRTDVLLTPLKDPGEPAPADAVATEKEPRT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03057 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 6.49 µg/ml |
| dbacp03065 | GlcNAc-PI de-N-acetylase | MTDRPLTLMAVHAHPDDEATSTGGVLARYAAEGIRTVLVTCTDGGCGDGPGGVKPGDPGHDPAAVTAMRRQELEASCGALKISDLEMLDYADSGMMGWPSNEAPGAFWQTPVADAAARLAELMRHYRPDVVVTYDENGFYGHPDHIQAHRVTMAALELTDLSPKVYWTTMPHSGVRRFGEIMSEFQEGAPEPDPAEAAATAELGLPDDEVTTWVDATGFSGQKFDALAAHASQGENIFFLKMGREAFGELMGTETFLRVRDTTGAPLPENDLFAGLR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03071 | Glutathione hydrolase proenzyme | MRRPVARNLTVLAVSAAVVVSLGAAAPPTHPSGPAGPDRPAAPKAPVAVGYGGAVSSVDQDASAAGIEVLRKGGNAVDAAVATAAALGVTEPYSAGVGGGGYFVYYDARSRTVRTIDGRETAPLTAGEDLFTEDGEPLAFADAVSSGLAVGTPGTPATWQRALDRWGSRRLSSVLEPAERLARHGFTVDETFRSQTADNEERFRYFPDTAELFLPGGELPAVGSTFKNPDLARTYRELAREGVGALYHGALGKDIVDTVNAPPVDPDSGWNARPGDLSAKDLAAYEAKVQAPTRTSYRGLNVYSIAPSSSGGTTVGEALNILERTDLSEASKARYLHRFIEASRIAFADRGRWVGDPAFEDVPADELLSQRYADSRECLISDDAALTGPLAPGDPRHPAACAAGGTAAPTTYEGENTTHLTVADKWGNVVAYTLTIEQTGGSGITVPGRGFLLNNELTDFSFAPANPAVHDPNLPGPGKRPRSSIAPTIVLDRHHKPVVAVGSPGGATIITTVLQTLTGFVDRGLPLVDAIAAPRASQRNAAQTELEPGLYDSALRAELEALGHSFKENPEIGAATGVQRLPGGKWLAAAEKERRGGGSAMVVEPVRQR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03088 | Glycoside hydrolase family 92 protein | MQYRVRHRWGPAVVMTTAFALAVGSQGAAVALPNAPAKTDREFTSSFEDGDPAPDWVSTVDTGADGGKRSSGVDGGFSTGIPGNVTEHVTRVRASAENTNGGEVKENLADNEPGTKWLTFAPTGWVEFDLDAPTKIVKYALTSANDHSERDPRDWTLKGSADGESWQTLDTRSGETFGEPFTTKTYDLAEAAEFQHFRLEFTKNNGAGDALQLGDVQFSTGDAETPAPEDMLAFVDEGPTSSPTAKANAGFTGTHALRYAGRHTADGRAYSYNKVFDVDVKVDRRTELSYKIFPAMADRDLDYDATNVSVDLAFTDGTYLSDLEATDQHGFPLTPRGQGDAKILYVNQWNSVESGIGSVAAGKTVDRILVAYDSPKGPAKFRGWLDDVEIKRAEPERPEAHLSDYALTTRGTNSSGSFSRGNNFPATAVPHGFNFWTPVTNAGTTSWLYDYASGNNDDNLPTLQAFGASHEPSPWMGDRQTFQVMPSAASGTPDTSRDARELAFRHENETARPYYYGVRFENGLKAEMAPTDHAAMMRFTYPGDDASVIFDNVEDKGGLTLDKENGTFSGYSDVKSGGSAGATRLFVYGEFDSKVTGGEDTGGVKGHLRFDAGRDRAVTMRIATSLLGVDQAKDNLRQELPKRASFEKVKRDAQKQWDTILGKVEVEGATRDQLTTLYSSLYRLYLYPNSGHEKVDGKYKYASPFSKAVKENTPTETGAKVVDGKVYVNNGFWDTYRTTWPAYSFLTPSKAGELVDGFVQHYKDGGWTSRWSSPGYADLMTGTSSDVAFADAYVKGVDFDAKAAYDAALKNATVVPPSSGVGRKGMETSPFLGYTGTETHEGLSWALEGYLNDYGIAKMGEKLYKETGEKRYKDESAYFLNRAQDYVNLFDSKAGFFQGKDTKGNWRVDSEKYDPRVWGYDYTETNGWGYAFTAPQDSRGLANLYGGRDGLGDKLDEYLSTPETASPDLKGSYGGVIHEMTEARDVRMGMYGHSNQVAHHALYMYDAAGQPYKTQKNIREVLQRLYTGSEIGQGYHGDEDNGEQSAWFLFSSLGFYPLVMGSGEYAVGSPLFTKATVHLENGRKLVVKAPKNSTKNVYVQGLKVNGKRWTSTSLPHSLISKGGVLEFDMGAKPSSWGTGENAAPPSITKDDEVPTPRADAITGEGALFDNTSATDATVTSVDLPVADKGAKALQYTLTSSADHTGAPAGWKLQGSADGKTWRTLDRRSGESFAWDRQTRAFSVKSPGTYAKYRLVLDGEHTLSEVELLS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03093 | Glycoside hydrolase family 92 protein | MRAPRRLRLCVAGVVAASALLTAPAAQAVPTTDQHLTDLVNPFIGTENEGNTYPGAAVPFGMVQFSPDTGHSTGYDHSDTHIRGFSLVHLSGVGCGLGGDLPVLPTTGDVTETDYTKYAAPFSHDDEEASPGYYRVGLGSGVDAELTATERTGVQRYTFPSTDKANVLLNAGQSLHKNVSTKVEVLDSRTVRTAITGSGFCQDTKPYTVYTVTRFDRPFASYGTWDDGTVTAGAKSGGDGAYVRFDTTEDRTVEATTALSYVDARGAARNLRAEGGHSFDSVRRGAERTWEKRLDDVKVRGGDDTLRRTFYSSLYRSFLAPNVGSDVDGRYTGWDRKVHRAKGFTYYQNWSLWDTYRTQSQLLALLAPREARDMAVSVIKIDEESGWLPKWGYGTVETNIMTGDPVTPFLTNAYQQGLLHGWEERAYRALKKNADGVPPTDSPAVGREANREYLADGFAPYVKGRPHAKPGDSDYDHGASATLEYALSDAMLSRMARDLGHDRDAKRYAERAQSYRNVFDASTGFFRARDAEGAFTGPADPAQSEGFHEGTSWQYQWMVPQDLPGMIDLIGGTDAANERLDSFFAYDQLLADPAKTAREVWVNGPYDYYNADKYNPQNEPDLIAPYTYLSTGQPWKTTDVVHAALTLFTDTPTGMTGNDDLGTMSAWNVLSSIGIFPIQPGYDTWGLSTPVFDRVDLALDRRYYPRGALTITAPGTSDTDRYVQSARTDGAEYARTWLTTDALRSVRSLAFTVGPQPSGWGTSAEAVPPPLT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03098 | Glycosyltransferase | MASRTRRHGAARSARGGFRRRLPLRLLLPLLVLVALAAMLMLRGYVHSEILADHRVQPPAATDKVPEKILEGGPVIDVRGGRTEGLSVPDHRLVLTFDDGPDPTWTPRVLDVLKKHDAHAVFFVTGTMASRYPDLVKRMVDEGHEVGLHTFNHPDLSFQSTKRIDWELSQNQLAITGAAGVRTSLFRPPYSSFADAMDNKSWPVTEYIGSRGYITVVNNTDSEDWKKPGVREIIRRATPHGGKGAIVLMHDSGGDRHQTVQALDEFLPGLKEKGYEFDNLTEALEMPSAMSPVTGAELWKGKAWVFLVQASEKITDVLVVGLAVIGTLVIGRFGLMLLLSGVHARRVRRKRFSWGRTVTEPVTVLVPAYNEAKCIENTVRSLVASDHPVEVIVIDDGSTDGTARIVEGLGLPGVRVIRQLNAGKPAALNRGLANARHDIIVMMDGDTVFEPSTVRELVQPFGDPKVGAVAGNAKVGNKDSLIGAWQHIEYVMGFNLDRRMYDVLGCMPTIPGAVGAFRRSALEPIGGMSDDTLAEDTDVTMALHRAGWRVVYAENARAWTEAPETVQQLWSQRYRWSYGTMQAIWKHRRAVIEKGHSGRFGRVGLPFVSLFMVLAPLLAPLIDVFLLYGIVFGPTEKTVVAWLGVLAIQAVCAAYAFRLDRERMTHLISLPLQQILYRQLMYVVLLQSWITALTGGRLRWQKLRRTGVVEAPGGSVPRQRSRSSDDRRPVA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03103 | Glycosyltransferase | MTTPTTPTAPPSPPARGRRRGPSRIGRAASRAAALQRPRVLLALLLLLALTCVMLLDGYLRAEVGGDERVRTGASASDVPDDVLDGGPILTFPGGQATTVSVPDKTIVLTFDDGPDPTWTPQVLDILDEYDVPGTFFLVGSMISRHPGIVRDLVEQGNEVGVHTFTHVDLSYQSEARVTREIEQTQLALAGAAGITTTLFRAPYSSETNAIDDYSWPVYQNLGEDGYTSVFIDTDSDDWKRPGVSKIVEWATPEDDEGASVLFHDAGGERSQTIAALPKYIEKMKAKGYTFTTVSGAMADQQSPQQEADQQSQQQQQESQQPGGGRQPEQSGGGLQAAHHKATGATLYEGKALVAAVAVAEWTVPALSVGLVIVGVAVMGRFAMMLVLARRHHRQRNRRRFSWGPPVTGPVSVVVPAYNEKECIEATLRSLARSTHPVEIIVVDDGSTDGTAEIAESLGLPGVRVVRQANAGKPAALNNGVRHARYDIVVMMDGDTVFEPDTVRHLVQPFADPAVGAVAGNAKVGNRRTLIGAWQHIEYVMGFNLDRRMYDLLRCMPTIPGAIGAFRREAVLQAGGMSDDTLAEDTDITIALHRAGWRVVYEEHARAWTEAPGSLGQLWSQRYRWSYGTMQALWKHRRSLTDKGPSGRFGRVGMPLVVLFQVVTPVFAPLIDVFTVYSMVFVDFRAALLAWLAVLGVQLVCAAYAFRLDREKYRYLLMMPLQQLAYRQMMYLVLIHSCVTALTGGRLRWQKLKRTGEVGTPAGNG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03109 | GNAT family N-acetyltransferase | MVDVVLKLSVRDLVHADLASCGWAGSDHHLDGVAEQLVRARIGEVDYLAVCAATNIPVAKGGVDYQVKEGVGTLWQLAVHPALQSCGIGTFLVEAAELRIRRRGLRQAELGVEENNPRARALYERLGYVAYDRQPDAWDEQAPDGSLRRYETMCTLMRKELA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03114 | GNAT family N-acetyltransferase | MALADCERVSRIRVRGWQSAYAGLVPQPYLDAMDTAEDAERRRATFARAAEGVVNLVAEDDDGRVVGWAAHGPYRDGELRTADAELYALYVDTGRFGAGVGRALLGEAVRRCGAAGHPRMLLWVLRGNARARRFYERSGFLADGAEESFEVRGVAVPEVRYARPLPG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03119 | GNAT family N-acetyltransferase | MPGDLLLRSAGPADLDAVLAFWKAAAEGTSISDDREGVERLVARDPEALLLAEAGGDLVGTVIAGFDGWRCHLYRLAVHPDHRRRGIGSALLAAAEERFVRLGGRRGDAMVLRRNERAQHAWRAAGYAPEEQWRRWVKPLAE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03157 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp03162 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp03167 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp03290 | HECI | TVLRGCWTFSFPPKPCI | Hylarana erythraea | Cell membrane disintegration | MTT anti-proliferation assay | H157 | Lung cancer | MIC : 1µM |
| dbacp03329 | Human A-defensin-1 (HNP1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Not found | Inducing apoptosis | MTT assay | A549 | Lung cancer | Not found |
| dbacp03330 | Human A-defensin-1 (HNP1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Not found | Inducing apoptosis | MTT assay | COS-7 | Lung cancer | Not found |
| dbacp03347 | Hydrolase | MPDSQPQPPHSPSPSGPADPGSLLLCGARLTDGRTVDVRLCRGRIEAVGTAGSLSPPRAPGPGTRVDLAGYLLLPAPAEPHVHGDTALTADAPGPASYEPQDVEGRATEAALLQLGHGATALRAHVRVGDVAGLGALTAVLRARRTLRGLVEVTAVAMPRVLTGVAGADGLAVLRDAVKMGADVVGGCPDLDPDPAGYVEAVLEVAAEHGCPVDLHTDAGDPARLARLAAMAGGLRPGVALGPCDGLARLPAEMASRAAEQLSAAGVTVVCLPQGACGAVDHHDGMAPVRLLRAAGVRVAAGSGALRDVSNPVGRGDPLEAAYLLASRHGLRPEDAYAAVSSAARAALGLPEVRVEAGFPAELLAVRGDGLAGALSLAYSRVVVHRGRVVARTNAVREYGDATAGADLGLPRQGRGKRGRE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp03352 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | A549 | Lung cancer | LC50 : 2.5 ± 0.2 μM |
| dbacp03356 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH2 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | NCI-H1299 | Lung cancer | MIC : 0 - 50 μM |
| dbacp03357 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH3 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | A549 | Lung cancer | MIC : 0 - 50 μM |
| dbacp03358 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH4 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | H460 | Lung cancer | MIC : 0 - 50 μM |
| dbacp03366 | IbACP | AASTPVGGGRRLDRGQ | Sweet potato leaves | Apoptosis | MTT/MTS assay | H1299 | Lung cancer | MIC : 5 mg/ml |
| dbacp03378 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | H-322 | Lung cancer | IC50 : 3.6 µMol/L |
| dbacp03473 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9 | Human lung cancer | MIC : 25 μM |
| dbacp03475 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | A549 | Human lung cancer | MIC : 25 μM |
| dbacp03477 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | OECM-1 | Human lung cancer | MIC : 25 μM |
| dbacp03479 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9 | Human lung cancer | MIC : 3.1 μM |
| dbacp03481 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | A549 | Human lung cancer | MIC : 3.1 μM |
| dbacp03483 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | OECM-1 | Human lung cancer | MIC : 3.1 μM |
| dbacp03488 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Lung cancer | IC50 : 8.64μM |
| dbacp03493 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Lung cancer | IC50 : 18.51μM |
| dbacp03498 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Lung cancer | IC50 : 9.88μM |
| dbacp03503 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 9.97μM |
| dbacp03508 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 11.17μM |
| dbacp03513 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Lung cancer | IC50 : 48.80μM |
| dbacp03516 | Kassiniatuerin-3 | FIQHLIPLIPHAIQGIKDIF | Senegal running frog, Africa | Membranolytic mechanism | MTT assay | NCI-H23 | Non-small cell Lung cancer | IC50 : 4.52 µM |
| dbacp03517 | Kassiniatuerin-3 | FIQHLIPLIPHAIQGIKDIF | Senegal running frog, Africa | Membranolytic mechanism | MTT assay | NCI-H157 | Non-small cell Lung cancer | IC50 : 21.54 µM |
| dbacp03518 | Kassiniatuerin-3 | FIQHLIPLIPHAIQGIKDIF | Senegal running frog, Africa | Membranolytic mechanism | MTT assay | NCI-H460 | Non-small cell Lung cancer | IC50 : 1.67 µM |
| dbacp03519 | Kassiniatuerin-3 | FIQHLIPLIPHAIQGIKDIF | Senegal running frog, Africa | Membranolytic mechanism | MTT assay | NCI-H838 | Non-small cell Lung cancer | IC50 : 10.03 µM |
| dbacp03520 | Kassiniatuerin-3 | FIQHLIPLIPHAIQGIKDIF | Senegal running frog, Africa | Membranolytic mechanism | MTT assay | LNCaP | Non-small cell Lung cancer | IC50 : 3.79 µM |
| dbacp03570 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03575 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 16.4 µMo/L |
| dbacp03578 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03583 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 37.7 µMo/L |
| dbacp03589 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 71 µMo/L |
| dbacp03594 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 15.6 µMo/L |
| dbacp03601 | l3,10,13K7,8K4R2L9 | KLlRLLkkLlRLlLK | Diastereomeric peptide | Plasma membrane perturbation; Necrosis | XTT assay | D-122 | Lung cancer | LC50 : 4.5 µM |
| dbacp03603 | l3,4,8,10K5L7 | KLllKLKlKlLK | Diastereomeric peptide | Plasma membrane perturbation; Necrosis | XTT assay | D-122 | Lung cancer | LC50 : >50 µM |
| dbacp03613 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 53 µMo/L |
| dbacp03618 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 14 µMo/L |
| dbacp03621 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03626 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03661 | Lanthionine synthetase C family protein | MTAPEATHVAVGEVEDVAADGLRWLLGAARETPGGGLAWPAGPSDDALHPMLYSGTAGTVPVLLEAWRHFGDDSYADAALRAARELAARVDDLDDDSLYFGRTGLALVLRTLQEELGDTAAGAAADRALALVRSRFDGTRWGSLFELMGGNAGIGLGALLTGDPELAVLALEPYLRTAERTANGVHWAHRPDTDARMHHLSHGTLGIAVALARVGAATGRTDLLDLGLTAVRDVVARDEAGPEGFLVRHSTPQFRPDVIDPVSYGWCHGPAGDAQVFRALRYVTSDPAWTALADRCWHTVTHSGLPRRLRPGFWDNNGRCCGTAGVLALACDRIAEQGDDQDTRDFAGVLVTDLVARAVRDADGARWSNFDHRSTPGDLEPQTGWAMGGAGIVRELLRFVRVARGGSPRYAFTWPDQPPVPA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp03673 | Large ribosomal subunit protein uL2 | MGIRKYKPTTPGRRGSSVADFVEVTRSTPEKSLVRPLHSKGGRNNAGRVTVRHQGGGHKRAYRVIDFRRHDKDGVPAKVAHIEYDPNRTARIALLHYADGEKRYILAPRNLQQGDRVENGPGADIKPGNNLALRNIPVGTTIHAIELRPGGGAKFARSAGASVQLLAKEGSMAHLRMPSGEIRLVDQRCRATVGEVGNAEQSNINWGKAGRKRWLGVRPTVRGVVMNPVDHPHGGGEGRTSGGRHPVSPWGQKEGRTRSPKKASNKYIVRRRKTNKKR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp03693 | Lasso peptide biosynthesis B2 protein | MRLESADPPPWPLRPPAVLAAAVARVLTRLPPARLRRVLTFASRGAGPASAAQALRARNAVVHVSLACAGPRCLQRSVAAALLCRLGGTWPQWCTGVVTEPFGAHAWVAVDGEPVGEADAHARAFHVIMSVPPRR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03698 | Lasso peptide biosynthesis PqqD family chaperone | MSFALKPGVSLADTEHGTVLLDERSGRYWMLNRTGAVVLRSLLDGESPQEAARTLLRRYPDAADGAGGHVESLLDALRTAKVIVP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03703 | Lasso RiPP family leader peptide-containing protein | MAKEDVYEVPALIEVGDFAELTQLTSQGYWIDSPWGAWWL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp03724 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog | Cell Apoptosis | MTT assay | HCT116 | Lung cancer | IC50 : 2.02 μM |
| dbacp03728 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog, China, Asia | Cell Apoptosis | MTT assay | HCT116 | Lung cancer | IC50 : 2.02 μM |
| dbacp04110 | Lipid II isoglutaminyl synthase | MSDNQLRIVWIYPDLLSTYGDQGNALVVERRARQRGLDVARLDVRSDQPIPTSGDIYLIGGGEDRPQRLAAERLRRDGGLNRAVENGAIVFSVCAGYQILGHEFINDLGQREPGLGLLDVVSTRGEGDRCVGDVLGDIDPRLGLPPLTGFENHQGVTHVGPHARALAQVRFGNGNGTGDGTEGAYNDTVFGTYMHGPVLARNPQIADLLLKLALDVNALPPTDDRWYEALRSERIAAAQQPA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04115 | Lipid II isoglutaminyl synthase | MAGNSDPLTPRAKIAVTAGKAVARASRAAGRGSGSVIGGRVALKLDPDLLARLAGHLDVTLVSATNGKTTTTRLIAEALKAAGPVVSNALGAnMPAGITSALASGAEARYGVIEVDEKYLVGVAQATDPKCIALLNLSRDQLDRAAETRMLAENWREGLAGSKAVIVANADDPLVVWAASSSPNVIWVAAGQMWKDDAWSCPSCGGVMQRPGDDWFCGECGFRRPTPSWALSGDHVLDPHGSAWPIHLQLPGRANKANAASSAAVTAVFGVPPQVALERMYQVQAVAGRYDVVQFQGRDLRLLLAKNPAGWLETFSLIDPPPAPVILSVNARGADGTDTSWLWDVDYTRLTGHPICVVGDRKLDLAVRLEVANQQFQVCEDLDQAVQLCPPGRIEVIANYTAFQDLRRRVGN | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04120 | Lipoprotein | MHRRRRSALLLTAAIATAAPLLTACGNDAHPGAAAVVGDQRITVSQLENRVDEVREAQRAAVPDDGQYQQVVARSGALTRDTLHGMVLDRVLHSAAAEAHVSVSRKEVQAMRGDLEDQAGGAEQLETVWLQQYGVAPGRLDDNLRVQLEAQKLAESLGTDTSRPEFWQALSKASDKLDIDLNPRYGAWDVQKAGRVDSETPWVREVAEAEPSQQTA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04126 | Lipoprotein signal peptidase | MAEAERIIGTPDTPDAAGDGQELPDAEQEQAPERPRGRRRVAVLFVVAVFAYLLDLVSKMIVVAKLEHHEPIEIIGDWLRFAAIRNAGAAFGFGEAFTIIFTVIAAAVIVVIARLARKLYSVPWAIALGLLLGGALGNLTDRIFRAPGVFEGAVVDFIAPKHFAVFNLADSAIVCGGILIVLLSFRGLDPDGTVHKD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04260 | Lon protease | MAAESAAFTPLTLPVLPLDDEVVLPGMVVPLDLSDAEVRAAVEAAQAAARSEPGKPRVLLVPRIDGNHAATGVLGTVEQVGRLADGDPGALIRGRGRVRIGAGTTGPGAALWVEGTRVDETLPEPLPGQVSELVTEYKALATAWLRKRGAWQVVDRVQAIDDVSALADNSGYSPFLTTEQKVELLETTDPVARLKLATQQLRDHLAEQDVAETIAKDVQEGVDKQQREFLLRRQLEAVRKELREINGEQEGEESDDYRARVEAADLPEKVREAALKEVDKLERSSDQSPEGSWIRTWLDTVLEMPWSERTEDAYDIQGAQGVLDAEHAGLQDVKERITEYLAVRKRRGDRGLGVVGGRRGGAVLALVGPPGVGKTSLGESVAHAMGRKFVRVALGGVRDEAEIRGHRRTYVGALPGRIVRAIKEAGSMNPVVLLDEIDKVGSDFRGDPAAALLEVLDPAQNHTFRDHYLEVELDLSDVVFLATANVLEAIPEALLDRMELVRLDGYTEDEKVVIARDHLLPRQLERAGLDAGEVTVDESALRKLAGEYTREAGVRTLERSIARLLRKVAAQHELGERELPFTVTDADLRALIGRPHHVPESAQDPAERRTSVPGVATGLAVTGAGGDVLYVEASLADPETGAAGLTLTGQLGDVMKESAQIALSFLRSHGAELELPVGDLKDRGAHIHFPAGAVPKDGPSAGVTMTTALASLLSGRLVRTDVAMTGEVSLTGRVLPIGGVKQKLLAAHRAGITTVIIPKRNEPDLDDVPAEVLDRLDVHAVNDVRQVLELALAPATSGAQPEVPVAA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04265 | Long-chain fatty acid--CoA ligase | MTGPRYADKPWLDLLTDAQKAPLHPDDSLVHALRRAAAEAPDRALIAYFDGRLTYREVDRLSDSVAGHLTARGLERGDRVAVLLQNSPHFVLAVLGAWKAGAVVVPVNPMYKSGEVGHVLRDGEVAALVCSDRAWESYLRETAARSPVRIVLTACELDFQTRRDTRVLAFERLPRAAGTDDLAEVARAGHRAPEGRDPGPDDTALISYTSGTSGTPKGATNTHRNIMYNAERQRTGLLLPDAPVYFALAPLFHITGMVCEFGACLNSAGTLVLAYRFEAGVVLDAFAEHRPHYTVGPSTAFMALAAHPSVTREHFASFANISSGGAPLPPALVEKFRAGLGPYVRNGYGLTECTAPCASVPPHLEAPVDPASGTLAVGVPGPETVVRIVDDQGAEVPFGEQGEIVVSGPQVVPGYWRRPDATAETFPGGELRTGDIGFMDTQGWLYVVDRKKDMINASGFKVWPREVEDVLYTHPAVREAAVVGVPDGYRGETVKAYISLRPGADTDPDALAAYCGERLAAYKYPRQVEILPDLPKTASGKILRRELRSRTHQDTAVNGQ | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04270 | Long-chain fatty acid--CoA ligase | MATLSVAAVLAENARRRPDKEALVEGDLRLTFGEVWRRARAQAGALVGLGVRPGDRVALMAPNTADFPQAYYAIAAAGAVVVPVHLLLSAAEVEHVLRDSGATLLLCHPAQARTGAAAAREAGVRTLTLGEEFGGLAADAEPLTSYVTRDADDPAVVFYTSGTTGVPKGAVLSHFNLVMNATVNAFDANDIRPDDVALGALPLFHAFGQTVSLNSTWRAGATLVLLPRFDAGRAIELMVREKVNTFHGVPTMFVALAAAAADAGALPGLRVCVSGGASLPVAVLERFEEAFGARIYEGYGLSETSPAAAVNQPAFGARPGTIGHPLWGVDVEIARSETEDAVELLPPGELGEVVVRGHNVFSGYLGRPEATAEALVDGWFRTGDLGTKDGDGFLRIVDRKKDVIIRGGYNVYPREVEEVLARHPGIAQVAVIGLPDDLHGEEVCAVVVPAQGSAPDAREVTEWSKEHLGRHKYPRRVEFADALPLGPSMKVLKRELRARYADRPVTVTG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04275 | Long-chain fatty acid--CoA ligase | MTVALHDLLPATLRRTWAVEGTCPDLDLYSLYRARQIADPHRTAVLDGKGKLCYTALDRKARCLAAGLSGLGIHAGDVVGVQLPNGRDAVVADLALAALGAVALPFPVGRGGREAASLLRRSEAVAVIATAEHRGNHHAADLLALTGELPALRTVVAAGPAGAAPQGAVPLSALTRTDPKTFAPARPDPDTAARILVSSGSESEPKMVAYSHNALAGGRGNFLGSLIPDGRPPRCLFLVPLASAFGSNGTPVTLARHGGTLVLLDHFTPEAALEALAEHEPTHVLGVPTMIRMMLDRIAEGGHRTFTPPTAMVVGGSPLDEATATEARLAFGCPVVNLYGSADGVNCHTGLTHGSPDGDGRPGIAAGQPDPRVADIRIAVPGTRELREVSGGTVGEIVARGPMTPLCYVAAPELDTRYRTEDGWVRTGDLGLIDDDGTLRVVGRLKDVVIRGGANISPAEVEVELAAHPAVRDVVCVGVPDPLMGERLAACVVPRDEATPTLEELCAHLDTRGLERRKHPERLLVLSELPLTPAGKPDRAVLRERCTPQAERQQQPLASAG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04280 | Long-chain-fatty-acid--CoA ligase | MKTSTALRPQSARVHHPEPGTLVHTARFHAARQPEATAVICEGRTVTYADLHRESNRMAHALRAAGLGEGDRVAYLGKESEHYYEALFACAKTGTVLVPVNWRLTAPEVSHILQDSGTRLLFLEDEFAPIVEGMPTEPPETVVPVNSIHSWRAQHPDDETEFEATPDTPVAQLYTSGTTGLPKGVVLAHRSFFAIRDGLASEGLDWIDWRAGDLALIGIPGFHVGGLWWATQNFNAGTTVVAMRAFAARQAVDLIRDLGITTACVVPAMLRMMLNEPGVSAQDFSTLRKTVYGGSPISEALLEESLTVLDCEFAQIYGLTETGNTAVCLPPAAHVPGGPLMQAAGRPYPGVRAKVIDHRGRELPPGAVGEVCLHTPARMVEYWGLPEKTAETLVDGWVHTGDAGYVDREGYVFIRDRIKDAILVAGENVYPAEIENVLEHHPGVGEAVVVGVPDARWGEKVHAFVVPAAGERPSPRDLHTFLVPRLAAFKLPASYEFTDRIPRNPSGKILRRELRDRFWNDSARKVN | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04337 | LVTX-8 | IWLTALKFLGKNLGKHLAKQQLSKL-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | A549 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04338 | LVTX-8 | IWLTALKFLGKNLGKHLAKQQLSKL-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | H461 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04339 | LVTX-9 | ASIGALIQKAIALIKAKAA-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | A549 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04340 | LVTX-9 | ASIGALIQKAIALIKAKAA-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | H460 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04352 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | H-322 | Lung cancer | IC50 : 27.1 µMol/L |
| dbacp04369 | M1 family peptidase | MTNRPDRPLRPSRRRTRRGRAALGAGLALAGTAYGMGTALGQPVPGPATAPADDGVRAYDVAGYDVRVTYDPEASRLEGDAEVAVRATADLARFDLDLALTARSVDIDGKPARSFSRSGDGSVTVVPEEAIEEGRTFTVRVRYDGDPGRSNPSWARGEDGGVITVLAPVGTWFPGNGDPDDTADFRLAATVPDGWTVVSGGRDRPVRRHGGRSTFDWRSTKPLPAKDALFGVGKWDVERTRLADGTPLTTVYAAGRKAEFEKYADQQRGIMSFLSSEFGPYPNDTLVSYFLDSVSEEVPNLAVQGGVIFPNAENEAYFDATVVAHELTHQWYGSLVREKEQRNLCLSECFASYAQWMWPEFSAGEDLDAKYRQEIEEHRTDDGFWQQRLSEGRGVYDKGPVMLHALRRQIGEAAFAEVLREWPARYGGTAPEWAELEKLVQEVSGQNLKGFFDAWVRGDRAPDDAYLRSRS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04374 | M28 family peptidase | MPRSPLSGRALTAGAVAVATLMAGGSAAGAASAAEWPAAVADAPDIPVANVKAHLTQLQSIATANGGNRAHGRPGYQASLDYVRAELDAAGFTTSLQEFTASGSTGYNLIADWPGGDADQVVMSGAHLDSVTSGPGINDNGSGSSAVLETALAVARSGYQPTKHLRFAWWGAEELGLVGSSHYVDSLGSADREKISGYLNFDMIGSPNPGYFVYDDDPTIEKTFKDYFAGLGITTEIETEGDGRSDHAPFKNAGVPVGGLFSGADYRKTSAQAAEWGGTVGEPFDPCYHSSCDTTANVDDTALDRNSDAIAYAVWELSQ | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04445 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of cancer membrane integrity | Not specified | Not specified | Lung cancer | MIC : 1 – 100 µg/ml |
| dbacp04455 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Lung cancer | MIC : 1 – 100 µg/ml |
| dbacp04464 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Lung cancer | IC50 : 10−5 - 10−6 M |
| dbacp04486 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | A-549 | Lung cancer | IC50 : 110 µM |
| dbacp04499 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H182 | Lung cancer | IC50 : 7.28 µM |
| dbacp04500 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H526 | Lung cancer | IC50 : 11.7 µM |
| dbacp04501 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H678 | Lung cancer | IC50 : 6.23 µM |
| dbacp04502 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H735 | Lung cancer | IC50 : 10.4 µM |
| dbacp04503 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H841 | Lung cancer | IC50 : 9.7 µM |
| dbacp04504 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H889 | Lung cancer | IC50 : 6.56 µM |
| dbacp04508 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Lung cancer | IC50 : 30 µg/ml |
| dbacp04525 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H182 | Lung cancer | IC50 : 12.5 µM |
| dbacp04526 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H526 | Lung cancer | IC50 : 10.5 µM |
| dbacp04527 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H678 | Lung cancer | IC50 : 4.44 µM |
| dbacp04528 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H735 | Lung cancer | IC50 : 7.23 µM |
| dbacp04529 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H841 | Lung cancer | IC50 : 11.7 µM |
| dbacp04530 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H889 | Lung cancer | IC50 : 6.57 µM |
| dbacp04569 | Mastoparan | INLKALAALAKKIL-NH2 | Eusocial wasp | Induction of apoptosis; Alteration of mitochondrial permeability | MTS assay | A549 | Lung cancer | IC50 : 34.3 ± 1.6 µg/mL |
| dbacp04573 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | H157 | Non-small cell Lung cancer | IC50 : 13.57 μM |
| dbacp04578 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung cancer | MIC : 6.26 - 36.65 μM |
| dbacp04584 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung cancer | IC50 : < 4 μM |
| dbacp04642 | MEL-dKLA | GIGAVLKVLTTGLPALISWIKRKRQQGGGGSKLAKLAKKLAKLAK | Venom base | Inducing apoptosis | MTS assay | RAW264.7 | Lung cancer | IC50 : 0.85 μM |
| dbacp04669 | MFS transporter | MASSLTKDSVSPGTPGSEKTFFGHPRGLATLFMTEMWERFSYYGMRALLPLYLVAPGGLGLSAGTATAIYSVYLSLVYLLTMPGGWFGDRVWGPRKTVAVAGGVIMLGHLTLALPYAGTFYAGLGLVAIGSGLLKANISTMVGQLYDGPDDPRRDGGFTVFYMGINLGAFFAPLTIGTIGESVNWHLGFALAALGMGLGVVQFLLGSRHLAPHSSTVPKPLSAEEKTSTLRKAAFWAALAVVFYAIVGFSGHYTLNWILVPLTLLGVIIPVLVLTSIKRDKSLDRAEQSKMSAYIWFFVAAAVFWMIYDQGGSTLSLFADSSAKNSVFGWGFPVSWYQSVNPVLIMALAPVFATLWLALARRGREPSTIVKFAFGLVLVGASFFLFLAPLGIAEGGHKAAALWLVAIYFVQTCGELLLSPVGLSVTTKMAPVKYASQMMGVWFLAVTAGDATTGLLSLAGVDLNKTGIVAAEATLAVVAGLAIWMYRRRVKELMGDVR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04674 | MFS transporter | MKNAQPDGPPPSGDDAAFFGQPRGLLTLSGLEVWERFSFLGMQAILVLYFADTVANGGLGMAAGTAASVSAAYGTLVYLVSVAGGWLADRILGSYRAVLWGGILIACGHYAMAVPAGATTWIGLGLISAGTGLLKPNAATMVGKLYRTDDERRDAGFAVYYMAINIGAFAGPLVTGWLSDHQGWHWGFSAAAVGMTLGLAQYVLGRRHLAGRRHAAEFALAPDAMRRAVRLIASGVVAAAVVATVLALAGWLTMSRFVDLLTLISVLAPVAYFAVMFASPRVTSQERGRLKPYVVIFLASTVFNYILFQAYSTMMLLASTDAETTLLGFDFPASWYASALGAFEVALAPVVAALWVRMGRRQPHASNKIAIGVVLGGLSFLLMVLPTSGDSGGHLMSAWWIVGSYLLLGLGDIVLETSGMSATTKLAPTAFSSQTMSLWFLSLALANGIQAQTVKLYDHVSQPAYFGVNGAIAVAAGLAVMAAAPYLRRTMHPVH | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04698 | MP06 | LAVISWKCQEWNSLWKKRKRKT | Green algae | Apoptosis inducing | CCK-8 assay | MRC5 | Lung cancer | IC50 : 10 μM |
| dbacp04711 | MSI-136 | GIGKFLKKAKKFAKAFVKIINN | African clawed frog | Not specified | MTT/MTS assay | A-549 | Lung cancer | IC50 : 10 µM |
| dbacp04712 | MSI-238 | gigkflkkakkfakafvkiinn | African clawed frog | Not specified | MTT/MTS assay | A-549 | Lung cancer | IC50 : 6 µM |
| dbacp04723 | Mycothiol acetyltransferase | MTSDDTVHPGRPRSIETLAELAPEQTEAVLALLAEAARNDGQYAVSEQGRLQLRGPAREGVAHLLLTADGGELVGYAQLEGVDPIEPPAAELVVHPSHRGRGHGRALGSALLAASGKRLRVWAHGGHSAARHLAQVLGLTLFRELRQMRRPLAGLDLPEPRLPEGVTVRAFAPGQDDAAWLAVNAAAFAHHPEQGSLTQRDLDDRKAEGWFDPAGFFLAERDGRLIGFHWTKVHAEEGLGEVYVLGIRPDAQGGGLGKALTTIGLRHLAGQGLPTAMLYVDADNEAAVAVYERLGFTVHETDLMYRTET | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04728 | Mycothiol S-conjugate amidase | MTDQLRLMAVHAHPDDESSKGAATMAKYVSEGVDVLVVTCTGGERGSILNPKLQGDPYIEEHIHEVRKKEMDEAREILGVRQEWLGFVDSGLPEGDPLPPLPEGCFALEDVDKAAGELVRKIRSFRPQVITTYDENGGYPHPDHIMTHKITMVAFEGAADTEKYPEAEYGAAYQPSKVYYNQGFNRPRTEALHHALLDRGLESPYADWLKRWAEFERKERTLTTHVPCADFFEIRDKALIAHATQIDPDGGWFRVPLELQKEVWPTEEYELAKSLVETSLPEDDLFAGVRDNA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04757 | N-acetyltransferase | MLSLALRDGVRLRALEVWHAQEFAAHLDRAREHIRPWVGAAFVTDDVAGARATLRRYGESGAADGARLYGIWRDGVLVGGVMYVHFSEALGSCEIGCWLEPSAEGQGLVTAACGALLDWAFTARGLHRAEWHCRADNARSSAVAERLGMSLEGVRREAWPYEGRRYDKQLWAVLAPEYAHPGG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04762 | N-acetyltransferase | MLHAGQFEQALTVTQVTERRMTSTFPNISINTERLVLRPLDEDDVPALAAMMNDEQVAAWTHVPQPFTEKDAGVWIGDHAPAERTAGRGLDLAVTEFLTQRLVGVVRLTRTDWHVRSTELSYIVAPWARGEGYASEAALATAQWLFGDQKFERVELRTAADNTASQQVAQKIGCISEGVLRGACIARARTDDGVWTDVRTDFIVWSLLPEDLEGTTGQPVGSDGFTAFTDWN | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04767 | N-acetyltransferase | MPSMPYLTRPVIAEGTLSRTPQPALPTGDGLLLRPWRADDAPAVHAAFQDPAMHQWHARAADSEDEVRGWITEWQRAWEGERGVQWAVADASDDRLLGRVALREVVLGDGVAEVAYWTTAAARGRGVAARATRALAHWALDGIGFQRLELLHAVANEASCRVAHKSGFALEGTKRSALLHPDGWHDMHLHARVRGD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04772 | N-acetyltransferase | MAPTPAHRTHATGVPDPSRAEPRGHGLHLRSWDADSDSDAEAWLRGFLDPEFQRWNTPLNLWTDVAGARESLRARARDAADGRSVSFRVTDGGSGTTLGHIGVNEISRQMKVARVGYWVLPAARGRGVAGRALLLASRWAFAELGLHRLELGHAMGHEASCRIAERCGYRAEGTLREAMFESGRHDAFRDVHLHARLATDTEPAPPDTR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04777 | N-acetyltransferase | MEPVTLTTDRLVLRTVGSQDTEAVYAAAQDPDIQRWTTIPSPYLLEHARNFAEQAVPDGWANDSMFTFGLFLPDGDLAGMLGVTMISLGVGEIGFWGTKEHRGHGYVTEAAVAVSRWAFTERAVDRLEWRAEVGNTASRAVARRAGYTMEGTLRSAINNNGVRRDCWIASLLPSDLTLPSTSPYLPAP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04782 | N-acetyltransferase | MNSPSWPAELRDGGIVLRPIRLRDQRAWREVNRRNRDWLRPWEATIPPPGPGGPITSRPTYRQMVRHLRSEAHAGRMLPFVIEYQGRLVGQLTVAGITWGSMCSGHVGYWVDEAVAGRGVMPTSVALAVDHCFRTVGLHRVEVCIRPENAPSRRVVEKLGFREEGLRPRYLHIDGAWRDHLVFALTADEVPEGLLRRWHRSRNRSTPNAGN | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04787 | N-acetyltransferase | MGGVTGGELGAEQVQAAVAGSVALLATAADRDWEAARAGRLEWSCRYTAEHVAGDLITYAGQLAGRATTAYVPFEITLDEGTGNGGVLRVIETTGALLAATLRTTPREVRAFHPYPYRSANREGFAAMGVAEVLLHTHDIAEGLGLSYEPPAGLCADVLTRLFPHVRPGGDAWRTLLWATGRGELPGRAPVTEWRWRNNLVVPAERLTLQGVTPAAATDLAAGGDGGFAWVDGGPLEGTRFSAGMVLKAYEAGTHRPEWGVFVLVRRADGRAVGGIGFHGAPDEDGRVEIGYDLAEAARGNGYATEGLRALSAWALDRDEVTSVFATTEPHNAASQAVIARAGFRRAAVVEEHGGESGQYAYELRR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04820 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | PC9 | Human Lung cancer | MIC : 25 μM |
| dbacp04822 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | A549 | Human Lung cancer | MIC : 25 μM |
| dbacp04824 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | OECM-1 | Human Lung cancer | MIC : 25 μM |
| dbacp04835 | Nickel ABC transporter permease | MSAPRSRAGRLARPDARLRRLPVTSRIALGVLLVVVLGAVFAPLLTQDPLATGIPARAPGADHWFGTDRAGRDVFARVVHGARYSLVIGLGATLAALVLGSALGALAATSRRLADESVMRTLDVVMSFPPIALAAVLVAVFGPSVPVIIFTIAFVYSPSLARVVRANVLEQYGEDYVAAERVVGARRGHIVVRHVAINCAAPVLVFATVMVADSIIFEASLSFIGAGVQDPDPSWGSVLAYGRQILLSGGWWATLFPGLCVLVTVLALNVLSEGMTDAAASPDTSRTGGTDSDATAATAPAAERADGAEVDAALAELASRLRATEPAVPPLAADAADLLVVRDLSIRFPDRYGDTRVVDGISFTVREGETLGLVGESGCGKSVTSLAVMGLLARNAEAAGEIRYRGRDLLKLTPKERRALMGPEIAMVYQDAMSSLNPSVLIGTQLKWLTSRGGTRTPAELLELVGLSPERTLRGYPHELSGGQRQRVLIAMALSRGPRLLIADEPTTALDVTVQAQVVELLVRLRDELGFAMVLVSHDLALVGDLAHRVAVMYAGQVAETGETRALLTDPAHHYSRGLLGSVVSLESGAERLHQIRGVVPAPKAFGAGCRFASRCAAATELCATTPPPATDREAGLDHLFACHHPASALRPPSADRPAAGKTPASGDGPASGGPSATSLERAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp04840 | Nickel-type superoxide dismutase maturation protease | MMPEQLSQETERARGALPFGPAEVTGPSMVPTLHHGDVLLVHWGARVRPGDVVVLRHPFQQDLLVVKRAAERRRGGWWVLGDNAFAGGDSTDYGVVPEELVLGKVRLRYRPRAGQRSPFTVVRWALSALRPVLADRSASRRLRAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp04845 | Nicotinamidase | MRRALIVVDVQNDFCEGGSLAVSGGADVAAAITELIGQAPAGYRHVVATRDHHVAPGGHFADTPDYVHSWPAHCVAGTEGVGFHPNFAPAVASGAIDAVFDKGAYSAAYSGFEGADENGTPLAEWLRSREIDEVDVVGIATDHCVRATALDAAREGFRTQVLLDLTAGVAPETTERALEQLREAGVELSGKPVVQ | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50µM |
| dbacp04892 | Non-ribosomal peptide synthetase | MPVSAAPQHHHYCPHRAATRSVDGPRGHDRRPSPHGGVHVIPASYAQRRLWLVDRLEGPSALYTVPLVLHLTGRPDVTALRAALHDVVARHEALRTRFPQVDGEPVQEIVPVGELDDLLTEDEVRADELEHEIGRTARHVFDLAAGIPFHARLLTVDDRTSALVVALHHIAADGWSAAPLWRDLSAAYAARLTGAEPDLAPLPVQYADYTLWQRELLGDADDPGSLLAEQLAHWRAALAGAPEELALPTDRPRPAASAHDGGVVRLDVPAGLHARLADLARDENATMFMVWHAALAVLLSKLGAGEDIPVGSPFAGRDEADLEDLVGFFVNTLVLRTDVSGDPAFTEVVRRVRGTAVDAMNHQDVPFERLVEDLAPARSLTRHPLFQVNLTLHNTPRLPVDLPGLTAVAEFAAPPLAKYDLDVQVQEHADAQGRPAGQRVELHYSADLFDRTTAEAIAGRLLRVLSQVAHTPELPLHAVDVLSPAEHQALTAAAGSAAAPPPGDTVPDLFAARAAAHPDAAAVTHGATTLTYAELDAESNRLARHLVARGAGPETRVAVSLERTPGLVTALLAVMKAGAAYLPADPAHPAARTGALLADAAPVLLLTTADTAAHAAAAPELRRVLLDDPQTRTAVAARDAGPLTQDERRTPLRPGHPAYVIHTSGSTGAPKGVVVGHAQVTALLRSAADRYGFGTDDVWTWFHSYAFDFSVWELWGALLTGGRLVVVDHDTSRSPDDFHDLLVREGVTVLSQTPSAFQQLDQADARRDAAALGARLRLLVFGGEALDPARLTDWHDRHGTDGPRPVnMYGITETTVHVTHLDLDPGTAAAPGTHGGSPVGRPLDHTRVHVLDDALRPVPPGVPGEMYVTGSGVARGYLNRPATTAARFVACPFEPGTRMYRTGDRARRAADGTLTYLGRTDDQVKLRGFRIEPGEVEAALLDHAPIGRAAVVLRTDTPGDRRLVGYVVPRDPAAATGEAGAELARRAREHAAALLPAHMVPSVCVPLARLPLTANGKLDRAALPAPDREGAAGGRGPATAREEILCTAFAEVLDLPSVGADDDFFALGGHSMLAVRLLDHLRTRGVRVDMRTLFTAPTPARLAAAAGPEPVRVPEGTVPPGATRLTPEMVPLAGLTEDELRTVTDALPDGAAGVADVYPLGPLQEGLFFHHRLNAGTGTAGGSGDGDPYVVRYVLGFDTPRLLDSFLAALAQVIDRHDVLRTSLAWTGLPHPVQVVHRHAELPVTETDLGDGPDPVARLLAHGDEPLDLRRAPLMDARTATEPGTGRRLLAVRMHHITQDHTTLDLVLREATAVLAGRGGTLPAPRPYREFVGRALLTTPAEEHLAHFGRLLGDVTEPTAPFGVWEVRGGGTDVTERRTVLGEPVAARLRAQARRTGVSAATVLHVVWSRVLAAVSGRDDVVFGTLLLGRMQAGDGAGDVPGMFINTLPVRARTAGTDVAQAVHAMHHQLAELMVHEHASLAVAQRAGGVRPPAPLFTAVLNYRHNPEGGPGTVLPPGTELLAFRERTNYPLLVSVDDDGGALAFDVQAATPIDPDLVTRLLHATTERVVDALEQAPDTPLADVDVLPAAERHRVLTEWNDTGRPDTARTLADVLADRATATPHAPALTHDHDGVPEQLDYAELFARANRLARHLIGQGVGPEDRVVLLMDRSPDLVVALLAVVGAGAAYVPVDPDQPAVRVAHLCVDAAPAAVLTGRAHAASVPRSAPAPIVVDDPEVRSAVAAHAPDPIGQDERTCPLRPSHPAYVIYTSGSTGIPKGVVVPHSGAVNLLAFRWPGLTADSSLLQFASIGFDVATWEIMTAFAAGARLVVAPAARLLPGAGLEDVVERHAVTHLQLPPTVLGMVADDHRLASVRTLLVAGEALGQALVDRWGAGRWFGNAYGPTEITVIAAADGPLRPGDAPTIGRPLPGVRLYVLDARLRPVPDGVDGDLYVAGAGLARGYLDRPGLSAERFVADPHGAAGTRMYRTGDTVRRTADGRLLYTGRADDQVKIRGFRVEPGEIETRLTEHEGVAHAAVVARDDVPGAPGDTRLVAYVVPSGPGVPAALRDHLAALLPAHLVPSAFVALDRLPLSVNGKLDRAALPVPDPATGTGAARPAGTYDELLCAAMAQVLGVPRVGADDDFFALGGHSLLAVRLVGRIRAVLDVEIPVHAVFEAPTAARLAARLDEWTGAQVRPSVVAGERPGRLPLSYAQRRLWFVDRLEGASALYNIPLVVRLSGRVDVGALGAALGDVVGRHEALRTRFPQVEGEPYQEVVPVAEARVELPVVPVAAGELEARIEEVSGHVFDLAGELPVHAALLTSGEESSVLVLVVHHIAGDGWSLAPLWRDLSAAYGARRAGGTPRFAPLPVQYADYTLWQRDLLGDAADPGSVLAEQVAHWRTALEGVPEELSLPADRPRPSAKTHRGAAVPVRVPAGLHARLAELARSEGVTMFMVWQAAVAVLFSRLGAGEDIPLGGPVAGRTDESLEDLVGCFVNTLVLRTDLSGDPAFTDVLARVRRDTLSALHRQEVPFERLVEELAPPRSMGRHPFFQTVLEVQSTPLLAPELDGVNVAVLPHAVRDAKFDLDLQIAESFDAEGRPTGMAGELVYAADLFDHATAETLTARLLRVLDAVADAPGRPVHTVDVLDDAERRRLVGEWSRRQPAIAGPDVRVFVLDDHLMPVPPGVTGLLYTTCDASADSTVACPFTEEESVMRPTGAQARWDDEGRVHVVPADDAAAPEADTQPSGAPVPRGSGTELREELLRTVFAQVLGVPEVGADDDFFALGGHSLQAVRLVSRIRAVLGVELLVRDLFETPTVAGLAARLDDTAGAQVRPSVVAGERPGRLPLSYAQRRLWFVDRLEGASALYNIPLVVRLSGRVDVGALGAALGDVVGRHEALRTRFPQVEGEPFQEVVPVAEARVELPVVPVAAGELEARIEEVSGHVFDLAGELPVHAALLTSGEESSVLVLVVHHIAGDGWSLAPLWRDVSTAYAARRSGKTPDFPPLPVQYADYALWQQRLFGDEDAAGSRLAAQVEHWRATLDGVPHELALPFDRPRPARPGRGGGWADIEVPAELHARMAELARSEGVTMFMVWQAAVAVLLSRLGAGEDIPLGSPVAGRTDESLEDLVGFFLNTLVLRTDLSGDPAFTDVLARVRSTALDALDHQDVPFDRLVEKLAPARYTDRVPFFQVLVAVQnMPQAQVALPGLDVDAGPGKPTTAKVDLDVQVVELHDADGAPSGMAGGLTYATDLFDHSTAESLVARLLRVLDAVTADPARRVSRIDVFDPAERRRLLTESNGARSDTLALTVPELFAVRASRAPKAVALDTGAEPVTYGQLDARSNRLAHHLIDLGVGPETVVAVVMDRSPDVVTTLLAVLKAGGAYLTLDPAQPDSRTAEMIALAGAEVCLADQRYAEAARGRFATVVVADAGDAEWADRPAGTVAGRSLPDQLAYLMFTSGSTGEPKGIGTTHRDIVDLAGDRCWQFPGTARGMFAAPHTFDGSTVEVWVRLLTGGTLIVTPPGRTDAARLRSLVADHGLTHAHLTAGLFRVIAEEDPAAFTGVHDVLTGADVVPREAVRRVLEAVPGIVVRSSYGPTEATVIATQIPLTEPDALGDVVSIGRAMDNTGVYVLDDSLQPVPAGVAGEAYIAGAGLARGYVARPGLTAERFVACPFDVPGARMYRTGDIVRRRADGALEFVSRADDQVKIRGFRVEPGEVEKILAGHPAVAQAVVTVREDTPGDKRLVAHLTAAPGEALPDVREFVAGRLPEYLVPDAVVVLDRLPLTANGKVDRAALPAPEAASTGAARRPPSLREDLLCSVFAQVLGVPRVGVDDDFFALGGHSLLAVRLVSRIRSVLGAEIPVQAVFETSTVAGLAPTVEAAGSTGVLRPALAAGPRPPRLPLSYAQRRLWFVDRLEAAGPLYNVPLALRLTGALDTGALRAAWTDLLTRHESLRTRFLHADGDPYQDIVSLDDFPPYFAVESVGRGELEARIDEAAGHVFDLTAGPPVRATLLDVDGPDTDEAVLVLVTHHIVADGWSMVPLLRDLSTAYTARRAGRAPGWEPLPVQYADHTLWQRGLLGDGDDPDSVLAGQVAHWREALDGSPEELALPTDRPRPAVASREGGWVPMSAPADLHARLTELAVAQGATAFMVWQAALAVLLSRLGAGQDIPIGSPVAGRTDEAADDLIGFFVNTLVLRTDLSGDPTFTEVLGRVRRSALGALGHQDVPFERLVEELAPTRSRARHPLFQILLAVQNVPAATVDLPGLRVEALPTELGRAKFDLDLHVAEAFDDEGRPAGIDGGITYAADLFDRTTVEALLDRLLLVLHAVAADPSRRVHDIALLDSDDRHRVLTEWNRTERAAPAATVPDHFRAQAARTPDAAALVTDGARTTYAELDAASDRLARYLTRHGAGPGRLVAVVMERSPETITALLAVLKTGGAYLPVDVGYPAARIELMLRDAAPALLLTTTDLADRLPGSAGGPDRIVLDDPSVRDAVAAEDATPTATPPHLDSAAYTIYTSGSTGTPKGVVATHRAVDRLVRPADYADLRAGDVVSHLGSVSFDSTTFDIWATLLNGATLAVGPAGSPSVADIRDYLARHRVTVALLPTGLLHQVIDLDVEALRGVRSVLTGGEALSVEHCRTLLDTLPGTRLMNGYGPTESVTYTHTHPVTRADVDSGRAIPLGRPLARTRAYVLDSALRPVPVGVPGELYIAGDGLARGYANRPGLSAERFTACPFEDGGARMYRTGDLVRWRADGVLEFVGRVDDQAKIGGFRVEPGEVEATVSAHPDVAQAVVVVREDTPGDKRLAAYAAPADPAVSGRELADRIRHFVADRLPDHLVPPFVTVLDRLPLTPNGKVDRAGLPVPDPMAAVSVARGPASPYEELLGVVFADVLRLPRVGVDDDFFALGGHSLLAVRLVSRIRAVLGAETSVATVFENPTVSGLARQLTRAGGRARPALVPMPRPPVLPLSYGQSRLWFVDRIEGPNHLYNICLVLRLTGDLDPELLRLALADVVARHESLRTTFPLVDDEPSQHVLAVEEAAVDLPVTAVTEEELAGRLDALAAHPFDLARELPLKTELFSLRPGEWVLSATVHHIAGDGWSMGPLWRDLSQAYLARAAGRAPEWEPLPVQYADHTLWQRDFLGDVDDPDSVLATQVAHWKERLRDAPQELALPVDRPRPAVSDHRAGLVPLNIPAPLHARLAELALGQGVTMFMLLHAAVAVLLSKSGAGRDIVLGSPVAGRTDQALDDLVGYFAGTLVLRTDLSGDPDFLELLDRVRTAGLDAFEHQDVPFERLVEELAPARSMARNPLFQVMLAVQNNQRGTLSLPGVQVREEPAGALTARFDLDFEVRESFDESGAPAGLDGEVVYAAELFDRSTVQTLTARLLRVLETVAADPTLPVTRVDLLDDAERRRVTEEWNDTAGPLPDGTLAGLFDRQAARTPDAVALVHDGAEITYAELDERSGRLARHLIGLGAAPETLVGVALDRSVEQIVALLAVVRTGAAYLPVDPGQPRRRTDLVLTDASPVLVLSTAETTARLGGTEAGTPARWIDLDGPLADGLRDTPAPAAVTDADRGTPLRPHHPAYVMYTSGSTGTPKGVVVPHSGVVNQLAWMQEEYRLEPADRMLQRASFGFDASVWEIFWPLLNGAAVVLSGPGSHADPEYLADLVDRERVTVAQFVPSVLRTFLDGGAAGRCTSLRTVLCLGEALPAAVRDRFRQTLDAELHNLYGPTEASVAVTAWPCDAAQDGASVPIGRPLRNIRAYVLDDGLLPVPPGTAGELYVAGTGLARGYLGRPVLTSERFVACPYGPAGERMYRTGDIVRWTAGGHLEFLDRADDQVKIRGFRVEPGEVEATLATHPEVAQAAVVTREGPGGDPALVGYLVPAAAGDDGADLVARVREYLAERLPEHLVPPVLTPLDTLPLTPNGKLDRAALPAPDYTALATGGRAPATLREQLLCSVFEQVLGVSPVGVDASFFDLGGHSLLAVRLVNRIRVVVGADVPVRAVFEAPTVAGLLAWIAREGRQGTADVLVPMRSTGERPPLFCAHTVLGLGWEYGWLTDAAPGDQPLYALRPRGMDTGTAELPDSLPRMAADYVEQIRTVQPTGPYHLLGWSFGGNVVQEMAAQLQDAGEEVAALVLLDSSPVDGPATAEQRAGFAEQEETVAGALTGEEHEAYLRIVRNNTRILLAHRTRKTTGTLLLVSADSETKAALWRPFVSGEVREHVLDCAHRDMLLNPDVVRRIWDIAADELEPTDTDDTDNDPDRA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04897 | Non-ribosomal peptide synthetase | MTKQSGLQDILPLAPLQEGLLFHSVFDEKAPDVYLVQQAIDLEGDLDTAALAAACRTLLRRHANLRAAFRYQGLKRPVQLIPHQVELPWEETDLSRLPEPERSAAADRLLEEDRLRRFDLGRPPLMRFTLMRLGDGRYRFVLTNHHILLDGWSRPMLVRELLALYRTRGDDSALPRVRPFRDYLQWLAGQDRDSAVAAWREVLAGLDGPTLVAPQAGERTPVVPGRLETELADADHAALTRLAREHSLTLNSLVQGAWAVVLSGLTGRDDVVFGTTVSGRPPEVAGIETMVGMFINTLPVRVRLRPDEPFLDAVRRTQDEQTRLQSHQQLGLAEVQRLAGEGELFDTTMVFENYPVDIGAERDEPGGIGGVTVTGTRNRDATHYPLALVAVGRDGLRLRLDHQPDLVPPAAARAVLERLVRVLRGAASEPHRTVGRFELLSAEERGAVLSLGRGTDTGPADTTLPAAFRAQAERTPHADAVRCGTTVLDYAELDVRSDRLARALVAHGVRTETPVGLLMDRSEHLVVALLAVLKAGGAYVPLRQGDPLDRLRQVTALAGVRHVLTDAEHAARAGELGVTAVRADAADAPAGGAELPSGPGHADRLAYVMHTSGSTGMPKGVAVTHRDVVELARDRSFACGAHARVLVHSPHAFDASTYEVWVPLLSGGTAVVAPPGDLDADTLGKVLTEHEVTGLWLTAGLFQLVADEAPHHLAGVREVWTGGDVVQAAAVRRVREACPGTVVVDGYGPTETTTFAVRHRIPANAPVPDTVPIGTPLDNTRLLVLDTALRPVARGVAGELYLAGAGLARGYWRRPDLTAERFVADPHGPAGTRMYRTGDLVRWTPDGTLEYLGRADEQVKIRGFRIELGEIEAVLGLHFEVAQAVVTVHEPRPGDKRLVAHLVAEEGSDPTPASLRDHLAAELPDYMVPSAYVSLDALPLTGNGKIDRRALPVPDLTAADATVESRAPRTPREEILCGLFAELLGMPRVGVDDDFFALGGHSLLATRLVGRIRAVLDAELTVRQLFDAPTVAALSRALDTAGAARPALRPAEPRPERVPASPAQRRLWFLHRFEGPSPTYNIPFALRLSGDLNRSALRAALADLTDRHESLRTVFAEDAEGPRQIVRPAAEARPELTVVPSAPSDGLEAEVARAASYSFDLAAEIPLRAWLFETGEREQVLLLLVHHIAGDGWSVPLLARDLTTAYTARLGQRAPQWRPLPVQYPDYTLWQREALGSEDDPDSPAARQLAYWRDALAGLPEELALPADRPRPATAGGRGGRVLYEVPEELHARIVTVARTCQASPFMVVQAAVAALLTRLGAGEDIPLGTPVAGRTDDALDGLVGFFVNTLVLRADTSGNPAFRDLVARVRETDLAAYAHQDVPFERLVEVLNPKRSPARHPVFQTMLTFNNTDRRPGDGLRLPGLDAESLSADTGTAKFDLLFSFAERHDAEGRPAGLGAGLEFSTDLFDPDTAEALVARLLRLLDAVTAAPDRAIGAVPLLGDEERARALSASLGPARVPVGGSLPERFAVSVARAPHAVAVETAEGVLTYAELNARANRLARLLVERGAGPESLVAVAMHRSAELVTACLAALKAGAGYLPVDPEYPADRIAYMLDDARPASVLTTRDLAGALPTGPAGTPLVVDAPATVARLGSLPDSDLTDTERTSPVGPAHPAYVIYTSGSTGRPKGVTMPVRALANLLDWHERTLPGGPGTRVAQFTAVSFDVSVQEILSALLAGKTLVVCPEDVRRDPERLAGWLGERQVQELYAPNLVIDAVCEAAVAARLDLPHLTDLVQAGEALTPHGAMRAFCAARPGRRLHNHYGPAETHVVTAHRLPADPAGWGPSAPPIGRPVDNTAVRLLDPWLNPVPPGVPGELYIGGDALARGYLGRADRTAERFVADPYGADGARMYRTGDLARLTPDGLLVYLGRADSQVKIRGFRIEPGEIEAALTAHASVAQAAVVVREDRPGDRRLVGYVVAAHQEAPDSARLREHLSGRLPAHMVPAAFVVLEALPLTPNGKLDRTALPVPEYAAGGGSRAPRTPAEHRVCTLFAEVLGVERAGVEDDFFELGGHSFLAARLVARLREEFGQDLPVRTVFDSPTPEGVAAVLTGTADGGPGRSSESLLALRARGTAAPLFCLHPGGGFSWCYAGLVRHLGPDVPVYGIQARGLDGSGPLPSSMAEMTAEYLALIRSVQPSGPYRLAGWSFGGLVAHALATALRAEGEEVSLLALLDAYPPGENADTSEPVEHEVVAHNLRAMGFEFDMAELIADQEGVLRRFREFLQSGDQALAQLEARDILALKDVYVNNVRLMRKFTPEFFDGDVLFVSAERKSADDREGRLNVSLWQPFTGGSVEVCAIDSTHGNLMTDARHMARIGQFLADRL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp04902 | Non-ribosomal peptide synthetase | MTEQSAVGLPLTPAQESLWFAHQSRPLDAGFLIAEYVDIEGELDLTTLRRAVASVARETEALRTTITDAPDGGTAGQRVHDGMALDVPLVDLSASANGEADAHRAMLQDLATPVDVTRGPVTALVLYRLSTSRHLLYLRTHHLVLDGYGAAAALGRIATTYGLLATGEEVTAEPLPLEPLVADARQYARSAEYAEDGAYWRESLAGAPHAERLTDRTGPPGTEVLRRSVALDPARWRRLREGARQGRVAWPALFVAGTAAYTHRMRGAHDLLLGMPVTGRRSRIARRTPGMTSQIVPLRLRLDPAVPVRDLLRQVTTAMRGALRHQRFPVEELRRELGLGRGDSLVGPAVNVLAFDENLRFGPATGTLHNLSLGPVEDLTLAVHPAPGGAGARVDVLANAALYDGTSAAGHLERILRLTEEFAADPDRPLSALELTGPEERDRVLALGTGPRERSRIPAPRTDAPVDGGVDGRPGPATAPTEHAGSTEHADVPEPTLPEVLARLARETPDAPAVDDGTRGLTFAELDRAVDAAASALRADGAGPGTTVAVALPRSVDTVVAPLAVLRSGAVYLPVDVTYPAERIAHLLADAAPVVLLCAPGGPVAGMAPAGTAVRSLSRSGTTAPGAPFDGPRAEDAAYLFYTSGSTGRPKGVLVEHRSISNLLAHHRRESHASAESAGGRRLRVALTASTSFDASWDPLLWMLGGHHLHIADDTTRRDPEALVAFLRAERIDVIETTPSFLGQLLAAGLTAETPTADGADGAPVHRPTVIALGGEPVGDELWQRLSSQPGLLAYNFYGPTETTVDAVTARVRGTDPVIGRPVRGARAYVLDTALRLLPYGATGELYLAGEGVARGYTGRPGPTADRFLADPFGEPGSRMYRTGDLARWHENGSLEFAGRSDTQIKIRGQRVETGEIEAALAALPGIAQAAVALHADGPAGETLAAYLVPTPDEAGDGVRRDRRRVRDALAASLPAYMVPAAYAATDRLPLTPNGKLDTAALPRATAVSTGPKSPPRTATERAVCAAVADLLGLADVGRDDDFFSLGGHSLLATGLLADLAGRTGVRLPVRALFEAPTVAGLAARVDAGRRSAGPEDPPGGRAVAERPARLPLSAAQHRLWLLEHMGEGGDRYHIPVAVRLDGDLDVPALRAAFSDLLARHESLRTVYPQDAEGPHQVVLPAGGCGVELRTAPVLPDARPEDVPAPRFELAERPPVHAVLVPTAEPAGDGPGSHLLLLTLHHIVTDGWSMGPLVHDLCAAYRARTGGHAPRWQPLPAQYADYALRQRARLGDREDPGSLAARQLAASRAALEGLPPELPLPHDRPRPERATARGGRVPVRLDAADHRALGALAREAGVSPFMVLHGVLATLLHRLGGGDDIVVGTPVAGRDEEEFHDVVGFFVNTLVLRVGVGGDPTFRELLDRVRETDLSAYGRQDLPFEQLVEALAPPRSLSRHPLFQVMLALNNTPAPRLDLPGVHAEPLRSGRTTAKFDLTWDFTETHDAHGRPDGLTGEVEYSAELFDESTVRRFAGHFVRLLRSVLRSPDARLGALGMLTEDQRLAALDTGARDDSAERGDELVHSVCDVLETQAAVTPDRTAVAEGRRTVSFGELATGLRDTARLLAAAGVRPGDRVAVALPRSARQIAAVFGVLRAGAVYVPLDPAHPAARNARILESARPALLLTERERAAALPASRTPTLYLDEAPDAAPAAEALPADGPRGADPAYVLYTSGSTGRPKGVVVEHRALANLLRHHGRHLIEPAERANNGRPLRVALTAAATFDASWDPLLWMVAGHELHLVDDASRHDPEALVRILHERRIDVLETTPSFLEQLRVCGLFAPGRPWPRVVALGGEPVHEKLWRELAELSGVSVWNLYGPTETTVDSVIAPVTAGTGPAIGHAVTGMRARVLDSRLGPTPPGVTGELYLAGAGVARGYDGATGLTADRFLADPYGPAGSRMYRTGDLVRRRPDHSLVFVGRTDSQVKVRGFRVETGEVEAALTAHPAVRRAVVTVRQAEGGGRLVAWAVPETGARPTPAGLRAFLGDRLPAYMTPSHLALVPEIPLTAHGKTDFGRLPDPAPALAEQGERPRTPQEEILCALFAECLGTDSVGRDADFFALGGHSLLATRVVNRVRSAFGAEIPVRALFEDPTPAGLARHLDGAARGRPSLHARADRPAELPLSFAQRRLWFLNRMRPDDASYNLPMAVSLCGRLDVAALHGALGDVVARHESLRTVFREAADRSGTPVQRVLSPGAARPALTVTPSTPDQVAGLLREAARAGFDLGGDLPLRAELLRTGADEHVLLLTVHHIAADGWSMGPLAQDLAAAYAARVAGRAPDWTPLPVQYADYALWQRDLLGGHDDPDSVYARQLAYWRGALADAPTETALPADRPRPDAGSGLGGSVPLPLSGSDGRRLAELARREGASTFMALHAVLAALLDRYGAGDDVVVGSPVAGRTDEALAGLVGFFVNTLALRVRTDGDPDFRALLERARETDLAAYAHQDLPFESLVEHLAPPRSPARHPLFQVMLSLNNAGRPALDLPGLHAEVRGVDTDAAKFDLSFSFSEQSGDGELTGQLEFARDLFDTATAQDLADSFVALLRLVVADPDSPLSRHDPLDASRLAGPLGHGDGPQAAPRHPTVVAGFAATAAAARSSDIAVRCGAQALSFAELARDGARLAHLLRGRGVDADRTVAVLLPRSTGSLTALLGVLAAGGAYAPLDDALPPARVAAVLSDARPAVVLATAATADRIPDGPWQTVLLDSPGTWAELAALPAEFPDGAAPGPRDPAYVVHTSGSTGRPKGVVVEHRSLAQLAEHHRRTLFDPARAATGRHRLRVALTASLSFDAAWDPVLWMLDGHELLVVDNDTRRDPAALVRAVREERVDVLETTPSHAAALLDAGLCAEGSPGHRPAVLALGGEDVPPGLWRRLREVPGLTVWNLYGPTEATVDTLYARLDRGDRPELGEPVAGTSCYVLDRLLRPAAPNTTGELYLSGASLARGYLGRPAETAARFVPDPFGPPGGRMYRTGDLVRRTADGRLEFRGRADGQVKVRGFRVEPGEIVTALEAQPGVRRAAVALRPVGSGAAHGTEQLVAYVVPGDGPGASGGPAAPDRDALRAALAAELPGYMVPAAFVVLDALPLTASGKLDAGALPAPRGEHLAHAAGRAPSGPREDLLCALFAETLDVERCWSDDDFFTLGGHSLLAARLLARVREATGVELGIRELFEAPTPAGLATALTAREAEAGTGTGPGADLACLLPLRSGGSLPPLFCVHPAGGLAWPYAGLLQHVADRPVYGLQTPNLDGTEHFPDSIEAMAAYYVDQLRTVQPHGPYRLLGWSFGGNVVQEIAVRLQEAGEEVALLSIMDAFPVPPADGLEDAGHDVVFRALLTALGVDLSAWDADAPLDAAVVRDALRESGSPLGALEPAAIETMVGNFADQARLMRRHVPRTFRGDVLFFRATEEDPASGLVPSLWDPYVDGALVVHDVPCGHAQMLRPDARAVVGPVLDAALRAT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05021 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 33 µMo/L |
| dbacp05026 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.7 µMo/L |
| dbacp05032 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 :3.4 µM |
| dbacp05033 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 :3.5 µM |
| dbacp05034 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 :4.5 µM |
| dbacp05052 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 36.2 µM |
| dbacp05053 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 37.9 µM |
| dbacp05054 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 47.7 µM |
| dbacp05058 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 9.3 µM |
| dbacp05059 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 9.3 µM |
| dbacp05060 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 10.9 µM |
| dbacp05072 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 1.9 µM |
| dbacp05073 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 1.3 µM |
| dbacp05074 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 2.8 µM |
| dbacp05075 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 2.9 µM |
| dbacp05076 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.9 µM |
| dbacp05077 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 3.2 µM |
| dbacp05086 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 1.7 µM |
| dbacp05087 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2 µM |
| dbacp05088 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 3.1 µM |
| dbacp05095 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 3.1 µM |
| dbacp05096 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.4 µM |
| dbacp05097 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 2.4 µM |
| dbacp05099 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 2.6 µM |
| dbacp05100 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.3 µM |
| dbacp05101 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 1.8 µM |
| dbacp05229 | Penicillin acylase family protein | MPPNNTASTGQQPGTSGRKKGRKGRLLVVVLVLAVVGGLVFGGYWSVSTVRASFPQTKGSITLDGLSGPVDVKRDGYGIPQVYASSEEDLFMAQGYVQAQDRFYEMDVRRHMTAGRLSEMFGKDQVGNDEFLRTLGWHRVAKKEYDEKLSDSAKKYLQAYAKGVNAYLKGKDGADLSLEYAALGFTNDYKPQEWTPVDSVAWLKAMAWDLRGnMQDEVDRALMTSRLGPKQIADLYPAYPYDRNKAIVQEGQYDELTQTFDGSGSSGGDSGTGTGAGTGAGSGTGAGAGTGAGSALEGQLAGLQNVLDDVPTAVGVNGNGIGSNSWVVSGEHTITGKPLLANDPHLSPSLPSVWYQMGLHCRTVSDKCRYDVAGYTFAGMPGVVVGHNQEIAWGLTNSGADVTDLYLEKITGEGYQYDGKVVPFETREETIKVAGGDSKKIVVRETNNGPLLSDRDDELVKTGKKATVETAAPDRGDGYGVALRWTALDAGTTMDAVFAIDRAQNWSEFREAATLFDVPSQNLVYADSEHIGYTLPGKLPVRAEGHDGSVPAPGWDPKFRWTGEYIDQDELPHEYDPERGYIVTANQAVVDEDSYPYTLTTDWGYGTRSQRITSLIEQKIKDGGKISTDDMRQMQLDNSSEMAKLLVPQLLKIDVADKDVREAQKLLEGWDYTQDADSAAAAYFNAVWRNVLKLAFGNKLPKELRVKGQCLWVDPVNTTGPADATNKVYECGQRDADQAQPDGGDRWFEVVRTLLDDPKSDWWSTPKYGTRKGADKNRDDLFKRAMVDARWELTAKLGKDIDSWNWGRLHRLFLKNQTLGTEGPGFLKYALNRGPWKLSGGEAAVNASGWNAAGGYGVIWVPSMRMVVNLGDLDKSRWINLTGASGHAYSAHYTDQTDKWAKGELLPWSFSEKAVDESTSDTLVLKP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05234 | Penicillin acylase family protein | MSAETYRDAWGIPHLRADSPEELARAQGRVTARDRAWQLEAERHRAQGTSAAFLGPEALSWDRLARRARLADTARRCFIALEEKDPETAAWVRAYVHGVNEGLALHRGGDGPGDREGPGDREGSHPLDGSPRRDDPRRPPAPEFARAALAPGRWEPWTPLAVWLATHILFAGFPAKLWREHITARLGPDAVALFAADGPGTTGSNGWLLSGERTTTGHALIAGDPHRWIEDPGVYQQVHLSCPEFDVVGLAVPGVPGVAHFGHTGTVAWAITNAMSDYQDLYHERLRRTGAGVEALGPDGTWRRAARHTETIRVAGEGTVEVEVIETDRGPVVAGGPEGLDDGTPAALSLRYPPRVTSDLGFGALLPLLRARTVADVDRALDAWAEPVNVVQAADTGGGLLHRVAGRVPVRAEANGLRPVPAWEPGHEWTGWHTPPRAGLADGAAVMANQRGLATPLGVEFAAPHRADRIAALLAGRRRWSAADLSAIHTDTHLGSAGPLLAHLTALTGLGPEATDLRDRVLAWDRRMDARSTGAAAYAAVRAAVVRRLAAHPVLAPASVAPAYPEVLQPWLALVPRVAYALEHLLRADDLYGIDRAAVVRAALEEVAARPPAGPWGDTHRLTPWRALPDPAAPADAPALSGDHDCVLCTSSVPGLTDRAARGPAARYVWDLADRGNSRWVVPHGASGTPGSSHHRDQQPLWLAGELVPVITDFDRLTLICTHTHTHTSTEETDA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05239 | Penicillin acylase family protein | MAAGTSPSAGTTAAEPAEAAANDHCGGQCSDILPPGQNGNATLAQILLNQAFGTQPEHAEDQLGPYANLATGYTGLTNDKINTFFNDASFGVPDGQAASTLRPAGRDDVTIVRDKKTGVPHITGTTRYGTEFGAGYAAAQDRLWLMDLFRHVGRGQLTPFAGGAPANQGLEQQFWRSAPYTEADLEAQIESAAAKAGERGDLALADVDAYLAGVNAYIDASDRGRYFPGEYVLTGHKDAITNAGTIERFQRADLIALASVIGSLFGAGGGGEVDNALSLLAAQEKYGVAEGTEVWESFRQRNDPEAVLTQQDGSFPYLPTPDDPQGRALPDAGSAEAEPLVYDRTGSAAGASATGASTTAAQSATASARRGMSNALVVSGEHTASGHPVAVFGPQTGYFAPQLLMLQELQGPGISARGASFAGLSMYVELGRGQDYAWSATTSGQDIIDTYAVELCQDDYHYLHRGTCTPMEKVERHNAWKPTVADSTAAGSYTMRVWRTAYGPVEYRATVGGKKVAYTTLRSSYLHEADSIIGFQMLNDPDYLDGPERFKGAVQHINYTFNWFYADSEHTAYYNSGDNPVRADGVDAEFPVWARQAYEWRDWDPAANTARYTGASAHPQSADQDYYISWNNKQAEDYPAASWGNGSVHRGNLLDDRVKKLVADGGVTRTALVGAMAEAALADLRAEDVVPGLLKVVESAPVTDPAAKTAVDGLKAWLSAGGLRTETSAGSGKYAHADAIRTLDAWWPLLVKAEFEPGLGTGLYTAFTRNLPVDESPSAAHGPTGAHAGSAFQYGWWSYVDKDIRAVLGQNVKGPLAHPYCGDGDLAACRDTLVTTLKEAAGRTAGQVYPGDENCSAGDQWCADSVIHRTLGGIKHGGIGWQNRPTYQQVVEFTSHR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05334 | Peptide ABC transporter permease | MPGRITPRRPGPHRRSGRPRATALGAALATVLVPALSACGGDAASASGDATLKWTSTYFPAHWDPVVGGSGAQFRELSLVYASLTRTDESGKAVPDLAESWEYNDEGDRITFHLRPGLKFSDGEPVDGAAVKAAVERAQKQKNSALFGDLTSIESVDAKGLDATVNLNQVDYQIPQLLGQRVLQIASPKAAAAPEKLDQNPVGAGPFTVTQIVPGTKAVLKKNPEYWDADNIHIDNVELTSAPDASTVVSGLQTGVYNFADIAPSQADAAKKAGLDVFVQPGFNASNISLNVNKAPFDNDKVVDAVRHAVNRQEFVDKLTFGYGEATNQPFPKGYVAYDPESEDAYPYDPAKSKKLLAEAGYRSGDIKLDLVIPEEDPQAEIVQSQLAAVGITVDIRIDKNWSTPFFAKDLTFSLYGTTGRDSAAQTLTAHFGPDGPLNLSTPYEPEGFESAIAKVRQTPLDAPEYPQVLQEATRAGLDSKALVFTYSQPNLIAKSKSVSGLPKNPAHLDWTGVTIGGKGAAS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05339 | Peptide ABC transporter substrate-binding protein | MKSSVSSTRRAAPGRPRAVGAMLLAGLVFVSSGCAVAGSAGGDAGRADGRTLRVVLTQEPPTLEPCEASLTGTGVVVRSNITEPLVERDPASGELDPLLATGWKQTAPRTWTFDIRSGVTFHNGAPLTAEDAAFSIDRAVNSDLACNVEGYVFGNDDLDVEAVDDHRLTVTTEEPDPILPLRISFVEIVPRTTDTEAKVRVPVGTGPYAVGSWKAGAAISLDRYDGYWGEAPDFARARYVWRSDASVRAAMIDKGEAEIAVALDPTEAGKDTTAAYPNNETTALRLDGREAPLDDLRVRRAVDLAVDREGIVDALLGGLAEPAGQLVPPGVVGHNDEISPTRQNVTEARALVERAAADGVPTGRQITLVARNGMFSGVSETAEALQYQMQQIGLNVKVRMADTATHLQYQLRPLPEDVGPIALLIMHGNQAGDAGFTTSQYLLGDGPQSTFGTEALDRRITEAGALSGEKRQRAFAGLLAEQNEDVVQYAHIAHMSGLLGLSRSIRYEPNSATGDELRLSEVHPAKGAKD | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05344 | Peptide ABC transporter substrate-binding protein | MSPARTAARRRRALAVGACAAVGVLLSGCAGGVSAPSGSKNEINYALPANFTPNWIVPIGTPGHLNTNNASISQSLWEPLIAYDGSTGEIGWNKDNSLATEAEFAADNKSVTVTLGDRHWSDGEPVTARDVEFWFNLVRENKKSWASYSPGKAPDVWTSFRTLDDRHFTLDFDRAYNRQWMLANELSMIRVMPQHAWDRTSDSGDVSDLDRTPDGAKKVWTYLIDAGKKISRYASDPLWKTVSGPYRLKSFSTSGRVELVENEKYDGGGAAHVKQVNLLSFTTVAAEENALRAGTVDYGYIRASDLGIKKSFTDLGYHVERWSGWAVTYMPYNFNNPEMGAVFRQPYARQAVQMSVDQKTLAKVLYNGTAVPTYGPVPQGQASAFLSGEQKAEPYPFSNSRARALLTDHGWSERDGTMVCTSPGEGAGHCGEGVEEGTEFRMRVLYQSGSTETDnMMSALQSSFEETGIDFDIKTAPVNSVLSQTGQCEEDDPACDWQLSFFGSAGSWYFPAYPSGDALFASGGGSNFGNYSNPEVDELIDRTTTSSSPDAMLDYSKALAEDLPVIWLPEPDYQVSVIRDGLGGFAQDSLANFHPAMWAWTE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05349 | Peptide ABC transporter substrate-binding protein | MKILISADMEGATGVTWPADVLPGTPQWERCRSMFTSDVNAAVQGFLDGGADEVLVNEAHWSMRNLLLERLDERTQMLTGRHKALSMVEGVQHGDVDGIAFVGYHAGAGMEGVLAHTYLANQLTGVWLNDVRASEGLLNAHVVAEYGVPVVLVTGDDVACEDALGYAPEARKVAVKDHVSRYAAVCRTPARTAADIRAAAKEATPLAVRHEPVTGGPFTVAMEFDAEHLAAASTVVPGVAQVGERKVAYTHDTMFEAIRTFKAVTTIASAAVEEQYG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05354 | Peptide chain release factor 1 | MFEAVEELVAEHADLEKKLADPSVFADQANARRLNKRYAELTPIVATFRSWKQTGDDIGTARELAADDPDFAAEVKELDKQRDELTEKLRMLLVPRDPSDDKDVILEIKAGAGGDESALFAGDLLRMYLRYAERVGWKTEIIDSTESELGGYKDVQVAVKTKGGQGATEPGHGVWARLKYEGGVHRVQRVPATESQGRIHTSAAGVLVTPEAEEIDVEINPNDLRIDVYRSSGPGGQSVNTTDSAVRITHIPTGVVASCQNEKSQLQNKEQAMRILRSRLLAAAQEEAEKEAADARRSQVRTVDRSEKIRTYNFPENRISDHRVGFKAYNLDQVLDGDLDSVIQACVDADSAAKLAAA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05359 | Peptide chain release factor 1 | MDLAFLHPLYEHQGPWASVYLDLSRHTEDTPHERELTAAAVARELAEQGADDATCEAVREAVDGLRHASDPHGRALFARAGEVVLDPRLARPPYGGTTADWAPLPHVAPLLDLAGEDPVCVVAYVDRKGADFELRSALGSSDAGGVTGRQWPVHRTSSADWSERHFQLRVENTWEHNAAEIADALAVCQEETGADLLILVGDDRERRSVHERLPKRLQGRVAEASRGAGSRLLDDEVERLRADHVRSRAREDLDRFLAARSPDDEGRAGAAEGVPALVEAAREHRIDELLVIPDAPDTHREVWIGEDADQLAVRRTELKTLGEQNSWSARADDALLRSAVMTGAPAISVTPVLPPETAGKAPVGGLGALLRWK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05364 | Peptide chain release factor 2 | MAVVDVSEELKSLSSTMESIEAVLDLERMRADIAVLEEQAAAPSLWDDPEAAQKITSKLSHLQAEVRKAEALRGRIDDLGVLFEMAEEEDDPDTRAEAESELAAVRKALDEMEVRTLLSGEYDAREALVNIRAEAGGVDAADFAEKLQRMYLRWAEQRGYKTEIYETSYAEEAGIKSTTFAVQSPYAYGTLSVEQGTHRLVRISPFDNQGRRQTSFAGVEVLPVVEQTDHIEIDESELRVDVYRSSGPGGQGVNTTDSAVRLTHIPTGIVVSCQNERSQIQNKATAMNVLQAKLLERRRQEEQAKMDALKGDGGNSWGNQMRSYVLHPYQMVKDLRTEHEVGNPESVFNGEIDGFLEAGIRWRKQREK | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05369 | peptide chain release factor N(5)-glutamine methyltransferase (EC 2.1.1.297) | MPSSPPGPATPAGTPSGDVLARAVATLRGAGCVFAEEEARLLLDAAPAPADLERLVGRRVDGEPLEVVLGWAEFCGLRVRVEAGVFVPRQRTRFLVDAAAELAGRPGAVVVDLCCGTGAIGAAVAARVPGIELSCADVDPAAVRCARLNVGPDARVYEGDLYDALPDALRGRVDVLVVNAPYVPTDEIAMMPPEARDHEPRHALDGGGDGVEVHRRVAAGAPAWLAPGGTLLIETSEEQAPLTARAMKDHGLVPRVSTNDEMYSTIVAGTRAVR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05380 | Peptide deformylase | MRHGSIPGAHGRVRPLALLGDPVLHAPCAEVTDFGPELAALVEDLFATMYASRGVGLAANQVGEGVRVFVYDCPDDEDERHLGHVVNPRPVEAGGVVVRGPEGCLSLPGLEAGVERYDEAVVTGVTVTGEPVTVRGTGFFARCLQHECDHLAGRVYPERLSGLRHRRLMRKAARAPWSR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05385 | Peptide deformylase | MPSVFVQGRPTASYPPFAPEARRGSVRRVTEVGEEVLHRPCRDVTEFGPDLAALIDDMFRTMYVAEGAGLAANQVGLGLRLFVYDCPDDEGVRHVGHIVNPVLDALAPAARRLLDEGEGCLSVPGAVMAVPRPDRAVVRGLDKDGAPLLVEGTGYFARCLAHETDHVNGHVYLDRLSARERKTALRQSADRREEVFARRSANAAAFA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05390 | Peptide deformylase | MAQQDTDQQHTGVLPVDDEGFVVDTEECEQREADWRGRGTSRPITVVGNPVLHKECEDVTDFGEEFQQLVADMFASQRTAEGVGLAANQIGVSKKVFVYDCPDDDGVRHVGVVCNPRLVELPADRRRLDDSNEGCLSVPTAYAALARPDFAEVTGQDEKGNAVRVRGTGYFARCLQHETDHLYGYLYIDRLSKRERKDALRQMAENEPRYPVVAND | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05395 | Peptide deformylase | MGTPSDRAPLAERVEELLALGGPLPIVAAGEPVLRRAAEPFDGQLAPALLARFVEALRLTMHAAPGVGLAAPQVGVGLRIAVIEDPAPVPEEVRAARGRVPQPFRVLVNPSYEPVGAARAAFFEGCLSVPGWQAVVARHAEVRLRARDEHGRAVDEVFTGWPARIVQHETDHLDGTLYLDRAELRSLASNASMADLWSQPTPERAASALGFELPGRPGPSGSPGLPGSAS | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05425 | Peptide methionine sulfoxide reductase MsrA | MAAQTQRAVLAGGCFWGMEELIRRLPGVTATRVGYTGGDVPNATYRNHGTHAEAIEILYDPEVTDYRAILEFFFQIHDPSTENRQGNDIGLSYRSAIYYVDDEQKRIAEDTIADVDASGLWPGKVVTEVEPAGPFWEAEPEHQDYLQRYPNGYTCHFPRPGWRLPVRTEG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05431 | Peptide transporter permease SapC | MKLTTAVLAAGAAVSLTTAVVGATRLRQNARHQAERNEAFLTRNQLDWLAQMSTNPDLAKLWAPEDMDVEEYMQLLAANRLICILSVRDRLGFVRTGHLPWHAAKLMENDACRRYWQRFGDLRAEEAEGDEQGEHFTRVLDQAAKQHPRAQAAAT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05435 | Peptide-1 | IELLQARGGC-Pem | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | NCI-H358 | Lung cancer | IC50 : 4.63 mM |
| dbacp05437 | Peptide-2 | IELLQARGGC-Pem-GGRRRRRRRR | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | NCI-H358 | Lung cancer | IC50 : 2.19 µM |
| dbacp05446 | Peptide-3 | RRRRRRRRGGC-Pem | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | NCI-H358 | Lung cancer | IC50 : 8.41 µM |
| dbacp05450 | Peptide-binding protein | MAWSEGGFGRLGAAVWSADPWYGGSRSAHVFNRKRRLRRVVAIVSLSSLATGCGLLSPDDPEDDGPIVVGTTSAPSTLDPAASWDGSWELFRNVYQTLLSYPDGATAPEPDAAEQCAFTDSANQVYRCELREGLTFSNGHSLDALAVKHSIDRIKEIDVNGGPAGLLGSLERVQAPSAREVVFHLDKPDATFPFVLATPAMSIVDPSGYPADALREDGEAVGSGPYTLRSYEDGVRAELVRNDRYQGFAERRNNAVTVRYFKDSAGMVEALRDDDIQVTYRGLAADDVIGLQAKDAGDEALRLVEGSGTEISYLVFNPEDPWAGRREVRRAVAQIVDRATLAHEVYQDTVDPLYSMVPKGLTGHTTGFFDDYGDPSVPKARKLLTEAGITERVPLTLWYTSDRYGSETATGFKEIKRQLDASGLFEITLESRPWKTYVTGYQKGEYPVFGRGWSPDFPDAENFIAPFVGEQNALGTPYPAPEITGELLPRSRRESDRADVEREFERAQQIIVDDARLLPLWQGKQYVAVSTEISGVEQAMDPSTIMMVWQLSRKTGW | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05455 | Peptide-binding protein | MNRKTLVLPAVVGLLAPVLAACGGSDGGSGGGDAIAVGTTDRFTITKDVPAPFDPAYAYDIGAWNIMRHTAQTLMTQPRGDGEPVPEAAQQCGFTDTGNERYACTLRDGLKFSNGDDLTAEDVKYSIDRAVSLEADTEVGKVLLSTVDTVETKGDREVVFHLKTADATFPYKLSTPVASILNKEQYAKDKFRDGFDLDGSGPYEMKSESKNGVLSKIVFTKNPTYKGSVKVNNDKVELVSFEDAESMGNALDKGDIDVMTRAMAPEQVKKLSDSSQGAVKLVEVSGLEIRYLGFNVDAASVEDKAVRQAMAQVINRAELVSRVYGSQAEPLYSMVPAGITGHSNSFFNKYGDPSVAKAKQTLKSAGIDSPIELTLHYTTDHYGAATKLEFEELQRQLNASGLFDIKLDGKPWDIFRPAERRLEYDVFGMGWFPDFPDADSFIAPFLDEDNTLKSPYLNQKIIKDLIPESRSEADRLSAADSLTEIQDITAADVPLIPLWQGKQYVAARDDVTGAAYLLNSSSTLQLWELGRGVSG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05460 | Peptide-methionine (R)-S-oxide reductase | MSYDVEKPDEQWRKELAPAEYAVLREAATEPAFTGEYTDTKTEGVYSCRACGAELFTSTTKFESHCGWPSFFDPKDTDAVELIEDRSHGMVRTEVRCARCGSHLGHVFKGEGYPTPTDQRYCINSISLRLEPERG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05477 | Peptidyl-prolyl | MAEQLYATLKTNHGDIEVRLLPNHAPKTVRNFVELARGEREWTNPETGEKTTDRLYDGTVFHRVISGFMIQGGDPLGNGTGGPGYQFEDEFHPDLSFNKPYLLAMANAGPGTNGSQFFVTVSPTTWLNRKHTIFGEVAGEAGQKVVDAIAALPTNPRTDRPVNDVVIESVTVETRQG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05482 | Peptidyl-prolyl cis-trans isomerase (PPIase) (EC 5.2.1.8) | MSNSKVYFDIDIDGQDAGRIVFELFEDVTPRTAKNFIELSTGEHGFGYAGSSFHRVIPQFMLQGGDFTAGNGTGGKSIYGAKFEDENFKLKHTEPYLLSMANAGPNTNGSQFFITTVVTSWLDGKHVVFGKVVEGTEVVDKIEGYGSSPQGTTSAKITVRASGKL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05495 | Phenyloxazoline synthase Mycobactin synthetase protein B | MNIPELLARYADEGVVLWAQDGQLRFRAPQGRLTDTHRAELRTHKQDILRHLEAGRPALRPDPDSRHEPFPLTDIQAAYLIGRTDAYAYGGVGCHAYVELDHPELDVERVTAVWRELVERHDMLRAVVHHDGYQQVLADVPDLHVACDDLTGLPAADAEAELARTRARLSARETPTDQWPLFDVHVSRTAGRAVLHLSFDMLVVDHASLRILLAEFRHRYGGGVLSAAPRITFRDYVLARRAQTGIDGHARDRAYWTERLDTLPPAPELPLAEPWEAAVSASTGTRGAPTDAVTFRRLEVPLSAADRERLTERAARRGLTVSTALLTAYAETVGRWSRTSRFTLNVPTVDRPDLHEDIGRLVGDFTSLELLAVDLDTPAAFAERTGALGQQLLEDLAHPLFTGSEVLAELSRRAGAPVLMPVVFTSALGTGGTAEGVPPEVAHAATRTPQVWLDCQVMHRGDALILSWDVREGALAHGVAEDMFGAWTSLVRLLSAEGEEGDAAWDAPVDIPLPAAQRDRRAAANATGGPLPDALLHEPLLDRARTTPDAIAVRTPETALTYRQLADRAGGVAETLTASGLRPGEPVAVWTDKGWEQVVAVLGTLMAGGAYLPVDTAQPPARRDTILADAGVRTVLTQSWLAETDDLPATVSAVAVDLVPAAPATREPRTAPRRDPDDLAYVIYTSGSTGTPKGVMISHRAALNTVQDINRRYAVTDRDRVLGIAGLGFDLSVYDLFGPLAVGATLVLPRADRRGDPSHWAELVRDFGVTVWNSVPGQLHMLCDWLRSEPPADDGTLRLALISGDWIPVALPDQARALLPGLEIISLGGATEGSIWSIAHPIGEVDTDRPSIPYGTPLTNQTFAVLDRHLRPRPEWVPGELFIGGAGVALGYLGDEARTAERFLTDPRTGQRLYRTGDLGRYLPDGTIEFLGREDAQIKIRGYRVELAEVEAAVQAHPAVAAGAVVVDDSAAGGRRLAAFVETARRDGDRRAAPGARQAREAAADAVREASAAVDGARLADFLAALDEVALDGMTRVLAGSAVFEDGAARTADEVGTALRATPRHRHIVRRWLRALAARDRLTHRDTDDTYSGLVAVSGPDTERRWRLAADLEHEVGWSSELLTVMRTCAERLPELVAGDVGIRDLLFPGAATDAADAAYRDNLAIRHLNRAVVAALREIAASHTGEERLRILEVGGGVGGTTGELVPVLAEYGVDYLFTDPSAFFLNEARERFADHTWVRYQRFDVDQDLRGQHLPPNTFDVVVCANTLHAAADADAAVGRLRELLVPGGQLVFVENTRDENLPLLVSMEFLEVAGRPWTDVREHTGQSFLTHPQWRELLGRHTASDVTSLPEGQDALARTGQEVFLATMKDDRHHVPTGELARTAATRLPEYMLPAVWQVVDTLPRTANGKTDRARLVDWLPRESAPVVVDERPRDELENSLADLWSELLAVEGVTRNDDFFDLGGDSLLVARMVGRLRERVPRAADLEWEVVLRHMLRRPTVAGLAGFLRSLADPKDAPAPGAVRTDPVIHLHGARSDDEPTTVLVHAGTATIMPYRALITEIRRRSPGLAEVVGVEVPDLNGFLAAPPQGLIEQLAADYARALTADGRSRFHVVGYCLGGLIATEVARNLAESGAEVESLTVISSHSPRFRLDDELLAEYSFAVMMGIDPAELGFPDDQYRVAAAADAVLASSPGILPDGGLAALPEEFEDVAGRFRSLAEVPRATRIARMCEAVPASAGSYEPDHMSRLFLAFRQSVFAITRYTAEPYAGDITFLRHDGAYPFPGSKDAVTTYWEELTLGDLDIVDIGGDHYSCLSVEHAPGILKTLGELTRGAITR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05500 | Phenyloxazoline synthase mycobactin synthetase protein B | MSDEAVVEARTAEGDAGRRGPHTAPAVRDAVARALDLAPQELDDDRDLFELGLDSLLLMSLVGAWRREGSTVTFQDLTRVPTLAAWTALLARAPHGDAPAAARPAPVPRQADRSVPRQADRATERSAPQQAERSAPRRSVRQADRQQNRQADGAAEPFPLATMQHAYWIGRQDGQPLGGVAAHFYVELDGREVDPARLDAALRALVHRHGMLRAVFDEEGRQRYGATGAPLTVHDLRARTPEEADSALESLRERNTHARGDVAGGEVFRAALCLLPDGRTRLQIDLDMMAGDALSLRVLLSDLRRFYACPDDPPPVLGLDYRRYLAEHDARRRAERERDAVWWRERLHELPRGPRLPTTVDPLTPVGAGDTALTRSRRLHHWLGPDDKAALIKAAGRHGLTPAAALATAFAETVAAWSDSRRFLLNLPLFDREMFSPEVAHLVGDFSSSVLLDADLGAPLPFARQARRLQERLQEGISHGAYGGVEVLRDLARAEGAPVLAPVVYTSAIGLGEIFEQDVQKSFGRPSWIISQGPQVYLDAQVTELDGGLLLNWDVRDGVFEAGVPDAAFDAYRRLITCLRTDPDAWDRPVDGLLAPGVLARRAVAALPPAPVPHRALHTRFFELAETEPDRTAVVRTTGAPLTYGQLADTARRIAALLGDHGVGEGDTVAVTLPKGDGQIGAVLGILAAGAAYAPVGVEQPAVRRRRIHSVAGAAAVLTDRAHADLCADAAAPAPVLLVEDAPAAGPAPVVLPDPGLPAYVLFTSGSTGEPKGVEVPHRAVVNTVEAMAEQLGLGPDDRTLAISALDFDLATWDIFAPLSLGGQVVAVGQEHRRDAHHWAELVRTHGVTLVQCVPALLDLLMAAGEDAAGGEGLGTSPRMVLLGGDWVGLDQPARLRALVPGCRFVALGGMTEAAVHSTVFEVTETDPAWKSVPYGVPLRnMRARVVDGRGRDCPDMVPGELWIGGPGVASGYRADPARTAERFVEYDGERWYRSGDLARYRPDGVLEFLGRADHQVKIGGHRIELGEVESALESDPAVRHAVATVLDTPVRRLAAAVSSRDGAAPEPDAVRDRAAERLPAHMVPERVLVLDALPLTENGKLDRAAVRRALTEAAGHATARASAPEGPVETAVAAEWSDLLAVDRVGRESSFFLLGGDSLVATRMIGRLRAAGFPDARVADLFARPVLRHFCETLRAGTADGREQEPPAPALVPDPDHAHEPFPLTDVQAAYHTGRDPRFALGGVGTWHYTEFDGTDVDLDRLERAWNTLVRRHGMLRAVVEDGHQRVLPDVPPVRIPVREATAADAPEALAELRARLSQQVRDPARWPLFAVEAVRHPDDGDGHGDGDGTVRTRVGVGLDYLVLDALSITTLYAELNALYADPDHQLPPVDVTFRDYLTRLPADPASVDRARAHWQARLAELPPPPALPYDRDPATLDAPVFTRRRLTLSAEDWQAVKRRAARHGLTPSTVLLALYGEILAAWSGTDAVTVTLTLFNRRDVHPHIHRVLGDFTSLSLAGHRREGASWLAAALALQHRQAEDLDHADVPIDWLLREFGRRTGTVDAAAPVVFTSAVGVGDATLARAGTGLPEKVWGISQSPQVCLDNQVTEESGGLVVTWDAVEELFAEGVLDAMFDAHARLLRHLVTGDWEAPLPDPLPAAQHDRRAAVASGAALEPVAPRLLHEAFFAHAAGRADRTALVTTAGEELSYGALAERALRTAAALADAGVGPGDLVAVTLPKGPDQIAAVLGVVAAGAAYVPLGLEQPAARLARVRAAARFRVVVGEWPDTGDGTAPRALSFARTQRSEPWRSPRETSPEALAYVIFTSGSTGRPKGVEISHAAAWNTVADISARHGIGAGDRVLALSALDFDLSVYDLFGLLAAGGSLLLPTEDQRREPARWPDLVDRYGVTVWNTVPALLDLLLDADEQGTGGLRGLRTALVSGDWIGLDLPGRLRARTARPCAFVAMGGATEAAIWSNTLTVTDVDPRWASIPYGRPLTGQHYRVVDRDGRDCPDWAPGELWIGGAGLARGYLAEPERTAEKFVVRDGRRWYRTGDLGRFRGDGLLEFLGRLDTQLKIAGHRVEAGEIEAALEAHPAVARAAVVAVGERTAKRLVAFAVPLATPATATEPPTADDLLGHLADRVPAYAVPSRIALLPALPLTANGKVDRKALTDTAGPAPVPAGAEPPRGGTETALAELWREHLPEPVRDRNANFFTLGGGSLAALRLLTAIERRLGAAVPVRRFFAAPTVAALAADITRTLAAHGTAYETGEL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05528 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H838 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05529 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H460 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05530 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H23 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05531 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H157 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05539 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H838 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05540 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H460 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05541 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H23 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05542 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H157 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05547 | Phylloseptin-PHa | FLSLIPAAISAVSALANHF | Skin secretions, Orange-legged Leaf Frog, South America | Membrane disruption | MTT cell viability assay | NCI-H157 | Lung cancer | IC50 : 14.10 μM |
| dbacp05549 | Phylloseptin-PHa | FLSLIPAAISAVSALANHF | Northern orange-legged leaf frog | Disruption of the membrane | MTT assay, Lactate dehydrogenase (LDH) assay | NCI-H157 | Non-small-cell Lung cancer | LD50 : < 5 µM |
| dbacp05554 | Phylloseptin-PTa | FLSLIPKIAGGIAALAKHL | Skin secretions, the Brown-bellied Leaf Frog, South America | Membrane disruption | MTT Cell viability assay | NCI-H157 | Lung cancer | IC50 : 6.73 μM |
| dbacp05555 | Picturin 1BN | GIFKDTLKKVVAAVLTTVADNIHPK | Norepinephrine-stimulated skin secretion, the Giant Gladiator Treefrog, the Rusty Treefrog, Trinidad, South America | Cell membrane penetration | Not specified | A549 | Lung carcinoma | LC50 : 7 - 14 µM |
| dbacp05558 | Picturin 2BN | GLMDMLKKVGKVALTVAKSALLP | Norepinephrine-stimulated skin secretion, the Giant Gladiator Treefrog, the Rusty Treefrog, Trinidad, South America | Cell membrane penetration | Not specified | A549 | Lung carcinoma | LC50 : 7 - 14 µM |
| dbacp05569 | Piscidin-4 | FIHHIIGGLFSAGKAIHRLIRRRRR | Nile tilapia | Necrosis | Adenosine triphosphate (ATP) assay | A549 | Non-small cell Lung cancer (NSCLC) | IC50 : 1.922 – 27.62 µM |
| dbacp05570 | Piscidin-4 | FIHHIIGGLFSAGKAIHRLIRRRRR | Nile tilapia | Necrosis | Adenosine triphosphate (ATP) assay | NCI-H661 | Non-small cell Lung cancer (NSCLC) | IC50 : 3.769 – 14.17 µM |
| dbacp05571 | Piscidin-4 | FIHHIIGGLFSAGKAIHRLIRRRRR | Nile tilapia | Necrosis | Adenosine triphosphate (ATP) assay | NCI-H1975 | Non-small cell Lung cancer (NSCLC) | IC50 : 1.241 – 5.472 µM |
| dbacp05572 | Piscidin-4 | FIHHIIGGLFSAGKAIHRLIRRRRR | Nile tilapia | Necrosis | Adenosine triphosphate (ATP) assay | HCC827 | Non-small cell Lung cancer (NSCLC) | IC50 :10.61 – 18.52 µM |
| dbacp05578 | Pleurocidin | GWGSFFKKAAHVGKHVGKAALTHYL | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | A549 | Non-small cell lung adenocarcinoma | IC50 : 300.8 µM |
| dbacp05583 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH5 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | A549 | Non-small cell lung adenocarcinoma | IC50 : 42.1 µM |
| dbacp05601 | Polysaccharide deacetylase | MSSEGFGLPKESWRWPETAWRGHVDAVRAGRRLVPDRWPGGARVAVALSFDSDHETIPLRDGETSPGRLAQGEYGARAGAPRILRLLERYGVPATFFMPAVSALLHPEEARAYTRDGHELAVHGWIHERnMLLDREEERELTARALDTLTTVTGQRPVGIRTPSWDFSDSTLDIMLELGFAYDSSLMADDEPYEIVAGGRSTGLVEIPVDWIRDDAPYFTMDRYGSVRPHSRPRGVGEIWRDEFDAAYHDGGVFQLTLHPHVIGHRSRLVVLRELLDHIASHQDVWFATHAQLADAARSMLPASGPDRP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05606 | Polysaccharide deacetylase | MITLVRRAAALCVLGAALTACGTTAAEVAPRPAPSAPAPSSSASRTPTPTLAPGPGGLTPVFEHGPRTDGTNHGEQDGTRDGKLIALTFDADMTADQGPRAASGERFDNPQLIAALRELKVPATVFMTGRWAEEYPDEARSIGRDRKFEIANHSYSHYAYTDDCYGLPTVAEDDMRADLERAYTAFEKAGVPNPMPYFRFPGGCYDKAALKELSATGVTAVQWDVVSGDAFATDADAVTRQVLDGARPGSVVVMHCTRSAAPVTEEVVRAVVPELRSRGYRFVKVSDLVGAANGRA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05611 | Polysaccharide deacetylase family protein | MPVLMYHAVAAGPNDATRALSVTPQAFAEQMAAVADRGRTPIGTAELAAAWRSGRPLPRRPVLITFDDGYAGVHRHALPVLARHGFPATLFVSTGWLRGPHDTGGAPDTMLDWAQVRELAAAGVEIGGHSHTHPQLDQVGEERLRHELIHSKEIVADQLGVVPASFAYPYGYSDRRVRRAVRETGYAQALAVGNGLARRAQGPYALRRVTVRRSTGTEEFARLVEGRAIARTFALDRALTKGYAVLRRTRQARRKVLGAGA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05616 | Polysaccharide deacetylase family protein | MYHSVGDRSDDPYRITVTPDRLEAQLRWLRRRGLRGVPVAELLAARAGGDGGDLVGLTFDDGYADFVEHALPCLRRWGCGATLFVLPGRLAGDNAWDPLGPRKPLLSADGIRHAAAEGVEIGSHGLTHVDLTTADDAVLTAETAGSRALLAELTGTPVTGFCYPYGTVDARAADAVRAAGYTYACAIDPGPLTGPYALPRVHVGQRDTSVRLLLKTRLHRLRRRASAGV | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05621 | Polysaccharide deacetylase family protein | MDDPPAWIAEFTVTPKEFAAHLDAIVGSGRTPVTIGVLADHLAGRAPLPPRPVLLTFDDGFADLPGPTAEALAERSLPATAYLTTGAIVPGGRSLLPPAPMMTLAAVAGLERSGMEIGSHTVTHAQLDTLPGTDLAYELRTSKAVLEDALGHPVRHLAYPHGYNSAKVRSWSARAGYETATAVRHALSSERDERYRIARLIVRRGHTVADVESWLAGGGVRTAPYRDGPKTVAWRWYRRGRAMVRGPEFAG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05630 | Prepilin peptidase | MGPGLGVDLDLLVVLVAALWGAGAGALLPRAVYRFAAPSGEAWRERCPGEHPVRGWLGRARCAQCTGERQAYGPGAGLLAAVTAVVCVALAGATGARPEVAVWLLLAPVGVLLAAVDLRVRRLPDPLTLPLAGAALVLLGLTALVPEHAGEWTTALLGSLALGAGYLVLFLINPAGMGFGDVKLALGAGAVLGWYGWPTLILGTFAGFLLGAFYGGVLLVTRRAGRKTAIPFGPFLIAGAFLGLLVGAFTA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05637 | Proline iminopeptidase | MGLYPEIEPYDHGMLDVGDGNHVYWETCGNPHGKPAVVLHGGPGSRATPGHRRYFDPAAYRIVLLDQRGAGRSRPRASAHDTDMGVNTTAHLMADLERLRAHLGIERWLVWGVSFGSFLGLRYAQTHPGVVTELVLTGVATGSNREVDLLTRGLGKLFPEAYEQLLAGLPPDEREGNHAAAYHRLLESPDAAVRERAARAWTDWETATIPAPPRSVARYEDPAFRLGFARTVTHYWGNDHFLGDGNDEGVVLRDAPLLKGVPGTLVQGSLDFGNLLGTVWRLHHAWPDSELVLVDEAGHDAGAVGDEVLVAATDRYARGAA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05642 | Proteasome accessory factor PafA2 | MGIETEYGISVPGHPNANAMLTSSQIVNAYAAAMHRARRARWDFEEENPLRDARGFDLARETADSSQLTDEDIGLANVILTNGARLYVDHAHPEYSAPEVTNPRDAVLWDKAGERIMAEAAERAAQLPGAQPIHLYKNNTDNKGASYGTHENYLMKRETAFSDIVRHLTPFFVSRQVFTGAGRVGIGQDGHEHGFQLSQRADYFEVEVGLETTLKRPIINTRDEPHADAEKWRRLHVIIGDANLSEISTYLKLGTTALVLSMIEDGFIAVDLAVDQPVRTLHQVSHDPSLKHLVTLRSGRTLTAVQLQMEYYELARKYVEERYGADADDQTKDVLGRWEDTLNRLENDPMSLAGELDWVAKRELMEGYRRRDNLDWDAPRLHLVDLQYADVRPTKGLYNRLVDRGRIKRLLDENEVERARTKPPEDTRAYFRGRCLEQYADDVAAASWDSVIFDLPGRDSLQRVPTLEPLRGTRNHVKELLDRCRTADDLVRVLSGG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05647 | Proteasome subunit beta | MEANTRSTGRLPAAFLTPGSSSFMDFLGEHQPEILPGNRQLPPVQGAIEAPHGTTIVAVTFPGGVVLAGDRRATMGnMIAQRDVEKVFPADEYSAVGIAGTAGLAVEMVKLFQLELEHFEKVEGAQLSLEGKANRLSTMIRSNLGMAMQGLAVVPLFAGYDVDRGRGRIFSYDVTGGRSEELNFATTGSGSIFARGAMKKLFHDELTEEQATTLVVQALYDAADDDSATGGPDVARRIYPIITVITEDGFRRLGEDECSALARSVLERRLEQPDGPRAALL | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05676 | Ps-1Pb | IKIPSFFRNILKKVGKEAVSLIAGALKQS | Merlin's dwarf gray frog | Immunomodulatory properties | Cytotoxicity assays, CellTiter-Glo Luminescent cell viability assay | A549 | Lung adenocarcinoma | LC50 : < 12 μM |
| dbacp05679 | Ps-2Pa | GIFPIFAKLLGKVIKVASSLISKGRTE | Merlin's dwarf gray frog | Immunomodulatory properties | Cytotoxicity assays, CellTiter-Glo Luminescent cell viability assay | A549 | Lung adenocarcinoma | LC50 : < 12 μM |
| dbacp05694 | PST13-RK | KKKFPWWWPFKKK | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 90 µg/ml |
| dbacp05706 | PTP-7a | FLGALFHALSKLL | Synthetic peptide | Inducing cell membrane damage | MTT/MTS assay | A-549 | Lung cancer | IC50 : 28 µM |
| dbacp05707 | PTP-7b | FLGALFKALSHLL | Synthetic peptide | Inducing cell membrane damage | MTT/MTS assay | A-549 | Lung cancer | IC50 : 32 µM |
| dbacp05708 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µg/ml |
| dbacp05713 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µg/ml |
| dbacp05718 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 13.71 µg/ml |
| dbacp05723 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.09 µg/ml |
| dbacp05728 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 13.94 µg/ml |
| dbacp05733 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 8.01 µg/ml |
| dbacp05738 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 24.58 µg/ml |
| dbacp05772 | Putative ATP-grasp-modified RiPP | MFAHSDRLPSGTPLPNGISTPTPWGLRRMAPYPALAPSYARVELDPATQTGRYFDASGAVLEMPGHGTSTGTRPATNTGNSSDGAGPGGNGGGDQDSGNDTDQ | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05793 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 843.40 µM |
| dbacp05796 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 843.40 µM |
| dbacp05800 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Lung cancer | IC50 : 872.70 µM |
| dbacp05804 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 283.90 µM |
| dbacp05808 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Lung cancer | IC50 : 104.10 µM |
| dbacp05812 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Lung cancer | IC50 : 109.30 µM |
| dbacp05816 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Lung cancer | IC50 : 588.20 µM |
| dbacp05821 | R8 | CALRRRRRRRR | Not found | Cell membrane disintegration | SPR assay | A549 | Human lung adenocarcinoma | Not found |
| dbacp05877 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 5.90 µM |
| dbacp05881 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Lung cancer | IC50 : 15.44 µM |
| dbacp05885 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 5.79 µM |
| dbacp05889 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Lung cancer | IC50 : 16.14 µM |
| dbacp05893 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Lung cancer | IC50 : 20.19 µM |
| dbacp05897 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Lung cancer | IC50 : 79.50 µM |
| dbacp05901 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung | IC50 : 5.90 µM |
| dbacp05906 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung cancer | IC50 : 5.90 µM |
| dbacp05932 | Release factor glutamine methyltransferase | MNLLLAEVAQAAQRLADAGVPSPRTDAEELAAHLHGVKRGELHAVPDADFDARYWEVVARREAREPLQHITGRAYFRYLELQVGPGVFVPRPETESVVGWAIDAVRAMDVVEPCIVDLCSGSGAIALALAQEVPRSRVHAVELSEDALVWTRKnMEGSRVDLRQGDALTAFPDLDGQVDLVVSNPPYIPLTEWEYVAPEARDHDPQLALFSGEDGLDLIRGLERTAHRLLRPGGVVVVEHADTQGGQVPWIFADERGWADAADHPDLNNRPRFATARKALP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05935 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp05948 | RGD-La | RGDLLRHVVKILEKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | 47.26Inhibition ratio at 50 µg/ml |
| dbacp05957 | RGD-Las | RGDLLRHVVKILSKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | 52.50 Inhibition ratio at 50 µg/ml |
| dbacp05979 | rRNA methyltransferase | MNRPVPVPPLADVLRAALAELVDGLPPRQAGRAVERLIGHYRGDTPTDAPILRDRADVVAYAAYRMPATFAAVRSALDAFADAVPGWAPGSHVDVGGGTGAATWAVGDTWAGPRQVTVLDWAEPALALGREIAAAHPALRDVRWQRSRIGAALTVEDTDLVTVSYVLNELTSADRAALVDAAASAARAVVIVEAGTPDGYARVIEARDRLVAAGFHVAAPCPHSAACPIVPGTDWCHFAARVSRSSLHRQVKGGSLAYEDEKFSYVAATRLPVSPAPSRVVRHPLIRKGQVLLDLCEPDEQLRRRTVTKRHGDLYKAARDAVWGDAWPDAANPPTE | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp05984 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 58.18 µM |
| dbacp05988 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Lung cancer | IC50 : 179.00 µM |
| dbacp05992 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 792.60 µM |
| dbacp05996 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Lung cancer | IC50 : 278.30 µM |
| dbacp06000 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Lung cancer | IC50 : 316.90 µM |
| dbacp06004 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Lung cancer | IC50 : 1185.00 µM |
| dbacp06008 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9 | Human Lung cancer | Not found |
| dbacp06010 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | A549 | Human lung cancer | Not found |
| dbacp06012 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | OECM-1 | Human lung cancer | Not found |
| dbacp06017 | S9 family peptidase | MGEPVRTLSYGSWPSPVDAALAAAHDGRPDEVGFVGDEVWWTAPRPAEGGRRTLVRRHADGTEEAVLPAPWNVRSRVIEYGGRSWAAVTTDAGPLVVFVNFADQRLYSFAPGGDAPRPLTPLSAVGGGLRWIEPDPRPEHGEVWCVLEEFTGEGPTDLRRVLAAVPLDGSAADDRDAVRELTAERHRFVTGPRVSPDGSRAAWLAWDHPRMPWDGTELIVADIGPEGTFRDARAVAGGPEESIAQADWAPDGSLLYASDRTGWWNLYRDGRPLHAREEEFGGPLWKLGQRWFAPLDSGLIAVLHGRGAAVLGVLDPETGEVVDAAGPWTEFAPALAAHGERIAGVGAGAHSGFEVVELDARTGRARVIGAPYEDATDPAYYPPSRIRTFTGPGGRDIHAHLHPPHHPGCRAPDGELPPYVVWAHGGPTSRSPLVLDLEIAYFTSRGIGVAEVNYGGSSGYGREYRNRLRGQWGVVDVEDCAAVALALAEEGTADPRRLAVRGGSAGGWTTAASLATTDVYACGAISYPVLDLAGWGAGETHDFESQYLESLIGPRAEVPDRYTERSPAEHAESVTAPFLLLQGLDDVICPPAQCERFLARMAGRGVPHAYLTFEGEGHGFRRAETMVRALEAELSLYAQVFGFTPPGVAALELTR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06019 | Saha-CATH3 | KRMGIFHLFWAGLRKLGNLIKNKIQQGIENFLG | Tasmanian devil | Pore formation on cell membrane | Not specified | A549 | Lung cancer | MIC : 500 μg/mL |
| dbacp06020 | Saha-CATH5 | KRIGLIRLIGKILRGLRRLG | Tasmanian devil | Pore formation on cell membrane | Not specified | A549 | Lung cancer | MIC : 500 μg/mL |
| dbacp06021 | SALF | Ac-ECKFTVKPYLKRFQVYYKGRMWCPNH2 | Giant tiger prawn | Regulate apoptosis related death receptor/NF-κB signaling pathway | MTT assay | HeLa | Human lung cancer | MIC : 100 µg/ml |
| dbacp06039 | Sec-independent protein translocase protein TatA | MFGRLGAPEIILILVVIILLFGAKKLPDMARSLGKSARILKSEAKAMKGENKSDDSAPADPPNPEQSAAQRTIQASPGDVTSSRPVAEPTDTTKR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06044 | Sec-independent protein translocase protein TatA | MLRNGLEPWHLLIVAIVFLVLFGSKKLPDMARSLGKSARILKSEAAAMKSDGGPAAERASGGGPAAPAPAATQPSGSAPAGDRDRARDR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06050 | Sec-independent protein translocase protein TatB | MFNDIGALELVTLVVLAVLVFGPDKLPKVIQDVTRTIRKIREFSDSAKQDIRDELGPEFKDFEFEDLNPKTFIRKQLDNDELGLKELRSGFDLKKEMAEVTDAVHGRDTEASSASSAAASSSGGRIDMSKKADLSKRPEKAEKPAADDRPPFDVDAT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06056 | Sec-independent protein translocase protein TatC | MLKPARSKEKDPEGRMPLAEHLRELRNRLAKALLAIVVVTVVAAFFYRDIINFLTDPILESVGCEKSFEELAEAKAGSEPCAQITINGLLGPFTLALKVSLTAGIVLASPVWLYQLWAFVAPGLHRSEKKYAYAFVATGAPLFLVGAYFAYAVLPTSAKVLIEFTPSDVDNLLPLDELLDLVTRMVVVFGLSFELPLLLVMLNLTGVLSGKRMLGWWRAMIMGITLFAAIATPSTDPLTMLMLAGPIWVLYFAAVTIALLNDRRKSRREALEPDDDEASDLDLTPEDVGEVEPVTTARALPEQATRDRVNGYDDVT | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06095 | Signal peptidase I | MDIETQPTERDRSSRSSGSEQPSDPAGPEERSRSALAGRIADWVPGGRITVTLLVLLLFLLLVSTFVLKPFQIPSGSMERGLRIGDRVLVNKLAYRFDGRPQRGDVVVFDGTGLFGHGDYIKRVVGVGGDHVVCCDREGRIRVNGRSVDESAFLYPGDRPSTVGFDVVVPDGTLFVLGDHRSGSSDSRDHLGSPGGGMIPVDRLIGRADWIVWPFGHATHLDRPDAYADVPDAEAGGVSGAAGGREASAVSGPAGEREAGGDSGAAGERAAGEDSGAAGGGVRRAESVDG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06100 | Signal peptidase I | MGSRGKPRGAPSSPAENLLPTGSRRTAAPSGGRSRAERRKLQRKVKRRRRRGAVKEIPLLVGVAVLIALVLKTFLVQAFVIPSGSMEQTIQIGDRVLVDKLTPWFGSEPQRGDVVVFRDPGGWLAGEQTTKQDDPVVVKQVKEGLAFIGLLPSDDEKDLIKRVVGVGGDKVKCCDTQGRVTVNGVPLTEDYLYPGDTPSRTPFEVTVPEGRLWVMGDHRSNSADSRAHQETDFGTVSEDEVVGRAMVIAWPFGHWTTLDEPKTYASVSDSVSGSTAAPRLSHRVAPYDPNAMIQLPIPAELPLVMGVVGLRRVRRGRWQRVRSWRGGCSGWRTVRTRRRGEPRTPRGDGRPGPGRSPGLRVRLRLRNRGRQGDRRTERRDPARGSGRDASRDAHPGQEAALLLEGAADPDRYRAGSRPADQDVPGPGVLDPVVLDGEHPADR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06105 | Signal peptidase I | MGGESTTRTAPRGGGAKNTPVGSRRGQRLSGLAVALGMVLFLGGFVWGAVVYRPYTVPTGSMTPTIAAGDRVLAERVSGSDVRRGDVVVFKDAAWADAPMVKRVVAVGGDTVSCCQKGKLQVNGKVIDEPYLPAGTPAEISDFQTVTVPEGRLFLLGDERDNSVDSTAHLTDAAGGTVSRGAVDARVDAVVWPMNGMLERPTGFETLGGLSSPGPLWTVVALVTGGAVLILGGAAYGPVAKRAEASRARRGTEAAGGR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06110 | Signal peptidase I | MGGTPPATPTPAKKQRSFWKELPILIGIALVLALLIKTFLVQAFSIPSSSMENTLQIGDRVLVDKLTPWFGSEPDRGEVVVFHDPDDWLAGEPTPDPNALQTVLSWIGLMPSADEKDLIKRVIGVGGDTVECNKTGPLKVNGKALNEPYVYAGNTPCSEDEQGGQFKVTVPEGKIWVMGDHRQNSRDSRYNQSDKNGGMVPVDEVVGRAIVVAWPMNRWGTLPVPETFDQDGLQARASAAALSVAPQGLAVAGVVPVVWWRRRRRAVSVETR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06115 | Signal recognition particle protein | MFDTLSDRLSATFKNLRGKGRLSEADIDATAREIRIALLEADVALPVVRAFIKKVKERSMGAEVSKALNPAQQVLKVVNEELVGILGGETRRLRFAKQPPTVIMLAGLQGAGKTTLAGKLGRWLKEQGHSPLLVACDLQRPNAVNQLSVVAERAGVAVYAPEPGNGVGDPVKVAKDSIEFARTKVHDLVIVDTAGRLGIDQELMQQAADIRDAVSPDEVLFVVDAMIGQDAVNTAEAFRDGVGFDGVVLSKLDGDARGGAALSIASVTGKPIMFASNGEKLEDFDAFHPDRMASRILDMGDLLTLIEQAEKTFSQEEAEKMASKLASKKGQDFTLDDFLAQMEQVRKMGSISKLLGMLPGMGQMKDQINNLDERDVDRTAAIIKSMTPGERQEPTIINGSRRARIAKGSGVDVSAVKNLIERFFEARKMMSRMAQGGGMPGMPGMPGMGGGPGRQKKQQKKAKGKQRSGNPMKRKQQEQEEAARRAAAAQGGGALGLPQQGGQDFELPEEFKKFMG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06129 | SmacN7(R)8 | AVPIAQKGGGRRRRRRRRGC | SMAC | Inducing apoptosis | Not specified | H460 | Lung cancer | Not found |
| dbacp06143 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | HEL | Lung cancer | Not found |
| dbacp06151 | SsrA-binding protein | MAKEKGRKLIAQNKKARHDYQILDTYEAGLVLSGTEVKSLRQGRASLADGFVQLDGHEAWLHNVHVPEYSQGTWTNHSARRKRKLLLHRVEIDKLEAKSQETGHTIVPLALYFKDGRAKIEIALARGKKEYDKRQTLREKQDRREAERTISAIRRKQRA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06166 | Sungsanpin | GFGSKPIDSFGLSWL | Marine **Streptomyces species** | Cell invasion | Cell invasion assay | A549 | Lung cancer | MIC : 5 μM |
| dbacp06167 | Sungsanpin | GFGSKPIDSFGLSWL | Marine **Streptomyces species** | Cell invasion | Cell invasion assay | A549 | Lung cancer | MIC : 50 μM |
| dbacp06168 | Sungsanpin | GFGSKPIDSFGLSWL | Marine **Streptomyces species** | Cell invasion | Cell invasion assay | A549 | Lung cancer | MIC : 50 μM |
| dbacp06169 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | Not found |
| dbacp06173 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µM |
| dbacp06177 | Synthetic peptide | KWKKLLKKPPPLLKKLLKKL | Synthetic peptide | Not specified | MTT/MTS assay | Calu-6 | Lung cancer | 35% survival rate at 10 µM |
| dbacp06178 | Synthetic peptide | KWKKLLKKPPPLLKKLLKKL | Synthetic peptide | Not specified | MTT/MTS assay | Calu-6 | Lung cancer | 0% survival rate at 100 µM |
| dbacp06183 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | H157 | Non-small cell Lung cancer | IC50 : 2.79 μM |
| dbacp06253 | Temporin-La | LLRHVVKILEKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | 45.62 inhibition ratio at 50 µg/ml |
| dbacp06262 | Temporin-Las | LLRHVVKILSKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | 50.64 inhibition ratio at 50 µg/ml |
| dbacp06267 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | NCI-H157 | Lung cancer | TI : 10μM |
| dbacp06268 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | U251MG | Lung cancer | TI : 10μM |
| dbacp06269 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | PC-3 | Lung cancer | TI : 10μM |
| dbacp06270 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | MDA-MB-435s | Lung cancer | TI : 10μM |
| dbacp06283 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | NCI-H157 | Lung cancer | TI : approx. 10μM |
| dbacp06291 | Tetrahydrofolate synthase | MSDNPGENGQPDPSDPLDSFDEIIDAETTRDPDLAVIEAGSRTLRTQGGPPEADVPGRPEDPETDAALRAVETELATRWGETKLEPSVTRIAALMDVLGDPQRSYPSIHITGTNGKTSTARMIEALLGAFELRTGRYTSPHVQSITERISLDGAPMSAERFIETYQDIKPYVEMVDAQQEYRLSFFEVLTGMAYAAFADAPVDVAVVEVGMGGSWDATNVIDGDVAVVTPIDLDHTDRLGETPGEIATEKSGIVKQDATVILAQQPVDAAQVMLKKAVDVNATVAREGLEFGVVARQVAVGGQLATLRGLGGEYDEVYLPLHGAHQAHNAAVALAAVEAFFGVGAQRPEPLDLDTVRKAFAAVASPGRMEVVRRSPTVVLDAAHNPAGARVTAEAVGEAFQFSRLIGVVGASGDKNVRGLLEAFEPVFAEVVVTQNSSHRAMDADELAGVAVEVFGEDRVQVEPRLPDALEAAITLAEEEGEFAGGGVLVTGSVITVGEARLLMGKG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06299 | Tetratricopeptide repeat protein | MPRGAPARGSAHRYGDGPRFTQCPRPPGVPGREVAYCDLVDQDWEERVTAAWAAIDDYADDGAAEFRAVIDALADELPADSPLGLFERACAWDSTGHSDRAVPLYREALERGLGEVSHHKGRRAKIQLASSLRNTGHPEEGVLLLSPELVSTSDELDDAVRATLALCLSAMGRDREGLSLVLGALAPHLPRYQRSMAAYARQLVEPEDPED | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06312 | TOMM leader peptide-binding protein | MHDEQHHGPGLGGSDGLWDEALRGLGDALDAKVVANRGWDLSWERLQWEKASADGEDLVSVRVYDDEVVVGPRWVPGTDSGCASCAEVRERTTAEHPLATALDTPRAVPRAARPLLPLLLAAAAANLADHPLGPGELYAVGAQYVRRHRVPRSFFCPACADHGSVAADDWRPEPLELPAEPLSSKDPTRGAGGAHLVEPGALRERLLDARYGPIQVIMRESDVPFAMSMCLAPDAAAPGHGRAGTFAEADPVGIIETYERLGSFPFDTPLLLERSHREVAAHALDPVTLGEHTEKQLEHPDCQVLPYTPDTPMDWVWGHDLATGEPLLVPAEAGFYQYEQRFKLSRHAARAARVEARRARAAGHRPAPGTLRKYFHDSSSGCAAGSSLTEAALHSLLELAERDAFLLSWHRREPLPRIADASITDPESRSLIDLIRTRGFDVHVLVARQDIDLPIVWVLVVNRQNPFPASYSSGGSGADPDTAIRGALREVAQLVTNKMQWNREEAEQMLDDPWKLVELEQHPQLYTLPEKLARVTEVLGGPQTTVQDAFPGWPQVLRRASGGTVRGALDHVRALYAAAGLDRIVLVNQTTREHADAGISVAKAVVPGILPMCFGHAQQRLKNLPRLVAALAGTPQENREIPYDPHPFP | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06317 | TOMM leader peptide-binding protein | MHPMVKPALRRGWRDLNTVQFGMTPAHALTLAPVDTATGGFLELLNGTRGPALLREEGHRMDLPEGHVDRVVDRLAGAGLLDDSRGGGPAAEALREKKDVLDRLRPDLATLSLTTSAPGDAIRHLAARRALRVGVRGAGRVGAALAGLLSGAGVGEVDVRDGGCVEPWDVAPGGLPARSVGDRRDAAARRVVRAAAPGGPPRRSPAAPPDGSDPGLSLVVVAPRDDVAVHTPDPASVESLMASGTPHLYAGVVEGTGVVGPLVLPGETGCAGCLYADRTDRDPAWPRLVAQWRSGRPRPVPPCDLTLAATVAGLAAAHALAFLDGGTPAGTGVRWEVSLPALRWHARPVAAHPACPCGAAAEGKAEGKQEHIAEDGAGGATMAGQGPPSAARHGVGPTRPAGTWRAHV | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06344 | Trigger factor | MKSAVETLNPTRVRLTVEVPFEELKDSLDAAYKKINQQVTVKGFRKGKIPARVIDQRFGRGAVLEEAVNDALPKFYTDAVNEAELNPLGQPEVDITELKDGETLNFTAEVDIRPTVEIPDYSGIEVEVDAVEVSDEDVEKSVEQLRERFASTSPVERAAQDGDVLTLDLQAKVDGEVLEDGVADGVSYTIGSGELLDGIDEAVKGLEAGGEATFASELKGGSAAGKEAEVTVKVSQVAARELPELDDDFAQLASEFDTLEELQADSRKRLAnMKQYDQATQAQERVLDKLLELVEIPVPEKLLEDEINTRKHNLEHHQLGQMGLDLEKYLELQGKTAEEFETETREAAVKGIKTQFVLDELVKQENLNVSQEELTEHLMRRASSSGMSPDQFAQAVVEQGQVPLLVGEVARGKALAAVVEKATVKDTNGEIVDLDDEEDEEPETVEAAATESADAEQADEKADDKADDKAGKAEEKTEG | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06349 | Tritrpticin | VRRFPWWWPFLRR | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 200 µg/ml |
| dbacp06356 | Trp operon leader peptide | MSPERRRFENQRSRSPAQDYGVGTGAHGRAQRMRRAAHSGARPGWGTLPAMFAHPIQNWWWTAHPAAH | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06358 | TsAP-1 | FLSLIPSLVGGSISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | HI-57 | Lung cancer | IC50 : 55.9 µM |
| dbacp06359 | TsAP-1 | FLSLIPSLVGGSISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | H-838 | Lung cancer | IC50 : 52.5 µM |
| dbacp06360 | TsAP-2 | FLGMIPGLIGGLISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | HI-57 | Lung cancer | IC50 : 4.1 µM |
| dbacp06361 | TsAP-2 | FLGMIPGLIGGLISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | H-838 | Lung cancer | IC50 : 11.0 µM |
| dbacp06368 | TsAP-S1 | FLSLIPKLVKKIIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | HI-57 | Lung cancer | IC50 : 1.5 µM |
| dbacp06369 | TsAP-S1 | FLSLIPKLVKKIIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | H-838 | Lung cancer | IC50 : 1.6 µM |
| dbacp06376 | TsAP-S2 | FLGMIPKLIKKLIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | HI-57 | Lung cancer | IC50 : 0.83 µM |
| dbacp06377 | TsAP-S2 | FLGMIPKLIKKLIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | H-838 | Lung cancer | IC50 : 1.6 µM |
| dbacp06397 | Type 2 lantipeptide synthetase LanM | MSDVQVATDARPATGPTAAADAHVVTEPQVAVEDFLPFYRNRIPRQVVVDRLRGPLSQAAAPEHAGTLVDQVWEDLVTAVEGHSLRVLIGEFHEFRQSRGLPATAGSDEAISRFRRHIEDPDNCRELLGRYDVLRRRLTVVLDRFLDAYDDLFTAFRDDRPRLVERGLLTDGGDTLASLITTGGDPHNDNRRVVGVRLAGGGRLVFKPRTLAADDFVRDLYAVVDPYLAHSLGGCVPESLSVGDHGWQSFVTPRAMTGPDQPARYFYRFGALCALFGAIGASDLHDENLLAAGEHPCVIDTEMMLRPGSGTGDGSLEQRLNNHVEASVASTMLVPNVRPESPIDVIMAGVGVSGEQVSGKMKKSALQDGGTDALRLRWEPIVYQHKENVPRLGDEKLASVRFYRDIVAGYTDALGAVRERRAIEEVIGRYAELPVRCLIRSTMVYGRFLDAATQPRYLRDAGESERFLGLLKQFPRQLAPEARAFAGEAERVAMDTGNVPYFTGRAGTTELATHTDRLPGAHPSSPADAARAGLALHAAQSDRYHRFVLEECFGELAEAAPDVMSAQSVFAPVLDTPAGEPWWPHIARILQDIQVTYSDADGVQCGWVGGVGPDRGVPTLLPGNYLSFHDNGGIVTFLQDAAEHDPRFAELYRRADRGLSALLQVYDEAQLRAPESVFTGAASMMLTRPRRQDRAWTARLLERVPERIEAGTLEKDLANGPAGLLMAVLARLEAGQDRLMDEEQLGRLCDLVLGQAATPLDRAWYDVAHGDVGMWWAVSRIGRYLGDAALSGEAADRLTERLSAGELPPVPGWCNGSAGVLLVSAEILTSAGRPEVLTGGRLAELLDGATSSRGDRPVDLSVCHGSSGVVQSLIATSRLLEDRSLLGRAAEYREQTARAAGARGFHTGCPGRTSLLGYMFGWSGIGHTDLMLDEALDGRAPAFVPVALTAAGAPEEPAPPRRPGANVRASAAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06402 | Type 2 lantipeptide synthetase LanM | MRSAINYYPEFDDTEIEETITPLAAFDDEVRAVVSREPQQPAVLPSRPGVVKDWTARAEEYPFQQVVRDIAAGAADGDPLAAFPGLFADRDDALTELLDRAEARIRELYTRPLVAAVNHAREQGSLLGETPRERYRYFVDEAVRGSVASAGGLDFPVLRNLTPVVLAGTVDSVVELCSRLVADRAAIRDTFGIAVEDRLVSFGRPQGDTHHHGRAVCILAFESGTRLVYKPRDVSCEAGFAVLADEFNAAFGTRLHAVTALARDGYGYVEYVETEDVSAISERFLYESGELAAVLYLLNARDMHFENIVPTRRGPVPVDLETVLHPERIHVGPVPEADGNAYGTIGRSVYGVGILPLVMAGRRGDQGGHVDLGFLGGPGRGASPFKQMSFDEPYTDRIRLSLKAQEVSARRTVVGERTEEEILRLGRSMADGFTRTYRAVLAAPGTWTALLRKAADGLRIRYVHNPTALYSQTLRMVTGPSALDDTDTYLALLKRIAIASKTSDRTLIASELRQLAERDVPYFTVSATGTRVCDGDGREVGAAFGSSPLDLALDKAAGLGETDLGEQLRLIRSAFTAQFPDNHLTPARPTEAPSGGGADSGERAALTSLARELTDGLVATSLPDRFAHLPRTWIGPLASAEADRPWPPGVLGYDLYTGRTGIALTLAAAGRVLDDERCLAVARQIFSTTGEILASHRYETRSLQQAGYAGYTGMSGILFCLSAAGRLIGEEAWVSAAQGAVPLVLEQIRAVPVDELPLDVISGLAGVLNCFAAVADPTGSGVAAPEGREAVTEVALLLTRALGRDGALARSVLDQSGFAHGISGVVHALGRAHPLLPAEHRAPVGTALTDLVRRLDTFYDPAERNWSSQLSRQGSFATGWCHGATSVALALSGAAGVLGHETVAARRDQAVENTLRLGFGRNLTWCHGDLGNHGALRFIAGPDGSPLHDEVRQKERQWLRPEVMRRKLADPDSRYAHTNSLMVGSAGLALHLLNRIDPGLRLCPLTLTVEGR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06433 | UDP-N-acetylmuramate--L-alanine ligase | MAPGLPTAMDRPHFIGIGGAGMSGIAKVLAQRGAAVAGSDAKESATAGALRALGATVHIGHAAGHLADDASCVVVSSAIREDNPELARAAELGIPVVHRSDALAALMNGLRPLAVAGTHGKTTTTSMLAVSLSELGLNPSYAIGGDLDEPGSNALHGSGEIFVAEADESDRSFHKYAPEVAIVLNVELDHHANYASMDEIYESFETFADRIVPGGTLVIAADHEGARELTRRLAGTVRTVTYGESEDADVRILSVVPQGLKSEVTVVLDGAELTFGVSVPGRHYAHNAVAALAAGAALGVPAAELAAALAAYTGVKRRLQLKGEAAGVQVVDSYAHHPTEMTADLEAMRAAVGDARILVLFQPHLFSRTQELGKEMGQALALADASVVLDIYPAREDPIPGITSDLIVEAARAAGADVTPVHDKDAASAAVAGMAKAGDLVLTMGAGDVTDLGPRILDELSSQANQ | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06438 | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase | MTYPGPPRPVRISATPLAELADQLGVTAPDSSAGVTGITHDSRAVRPGDLYAALPGARVHGADFATQAAGLGAAAVLTDPAGAERVSAAGLPALVVDDPRARMGELAATIYGHPGRDLLQIGITGTSGKTTTAYLVEGGLRTEKSTGLIGTVEMRIGDERIKSERTTPEATDLQALFSVMRERGTEAVAMEVSSHALVLGRVDACVFDVAVFTNLSPEHMEFHSGMEDYFQAKAQLFTPARSRLGVVNVDDEYGRRLAKEATVPVVTYSAEGHPDADWRADEVEVGPLDSTFTVLGPKGERIAAKSPLAGPFNVANTLAAIVSLAAAGLDPQTAADGVAAVPGVPGRLERVDEGQPFFAVVDYAHKTDAVESVLRALRKVTEGKLHAVLGCGGDRDTTKREPMGAAVARFADTAVLTSDNPRSEDPLAILAVMLQGAASVPAHERGEVQVFEDRAAAIAAAVARAEPGDTVVVAGKGHEQGQDIAGVVRPFDDREVLREAIQRSKA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06443 | UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase | MITLSLAEIADVVGGRMHDIPDASAQVTGPVVRDSREAGPGSLFVAFVGERVDGHDFAPAVVGAGAVAVLGSRPVGVPAIVVDDVQAALGALARHVVRRLGTTLVALTGSAGKTSTKDLIAQVLRRKAPTVFTPGSLNNEIGLPLTALTATGETRFLVLEMGARGIGHIRYLCELTPPRIGLVLNVGSAHIGEFGGREQIAQAKGELVEALPPAGEGGTAVLNADDPLVRAMASRTTAKVLLFGESGEADVRAENVRLTDSGQPSFSLHTPSGASDVTMRLYGEHHVSNALAAAAVAHELGMSADEIATALSEADSLSRWRMEVTERPDGVTVVNDAYNANPESMKAALRALVAIGGASRARGGRTWAVLGEMAELGDEALAEHDAVGRLAVRLNVSKLVAVGGREAQWLQLGAYNEGSWGEESVHVSDAQAAVDLLRSELRPGDVVLVKASRSVGLESVATALLETGTEGEVAAR | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06448 | UDP-N-acetylmuramoylalanine--D-glutamate ligase | MPSEFSGKHVTVAGLGVSGVPAAKVLHGLGAHVTVVNDGADERARTQAAELEALGVTVRLGDGTASDSGSAAGLPEGTELIVTAPGWKPTKPLFTAAEQAGVPVWGDVELAWRLRGHGGRKAAPWLAVTGTNGKTTTVQMLASILAAAGLRTAAVGNIGVSLLDAVTGDTEYDVLAVELSSYQLHWAPSLRAHSAVVLNLAADHLDWHGSMEAYAADKGRVYEGNQVACVYNAADRATEDLVRAADVEEGCRAVGFTLGTPGPSQLGVVEGLLVDRAFVEDRHKNAQELAEVSDVNPPAPHNIANALAAAALARAYGVPAAAVRDGLRAFTPDAHRIAHVADVDGVAYVDDSKATNTHAAEASLAAYEPIVWIAGGLAKGATFDELVAGAAKRLRGAVLIGADRALIREALARHAPEVPVVDLDRTDTGAMPQAVREARRLAEPGDTVLLAPACASMDMFTNYNKRGDAFAEAVRELGA | Streptomyces sp. VN1 | Not specified | Cytotoxicity assay | U87MG | Lung cancer | IC50 : 50 µM |
| dbacp06495 | Vibi E | GIPCAESCVWIPCTVTALIGCGCSNKVCYN | Alpine violet, Viola biflora | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp06497 | Vibi G | GTFPCGESCVFIPCLTSAIGCSCKSKVCYKN | Alpine violet, Viola biflora | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp06498 | Vibi H | GLLPCAESCVYIPCLTTVIGCSCKSKVCYKN | Alpine violet, Viola biflora | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp06499 | Vibi H | GLLPCAESCVYIPCLTTVIGCSCKSKVCYKN | Alpine violet, Viola biflora | Cell membrane disintegration | Not specified | Not found | Lung cancer | Not found |
| dbacp06607 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of either cancer or bacterial cell membrane integrity | Not specified | Not specified | Lung cancer | IC50 : 10−5 to 10−6 M |
| dbacp06669 | Crabrolin | FLPLILRKIVTAL | European hornet (Vespa crabro) | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 27.71 μM |
| dbacp06674 | Crabrolin-4R | FLPRILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 11.40 μM |
| dbacp06679 | Crabrolin-4K | FLPKILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 22.55 μM |
| dbacp06684 | Crabrolin-TR | FLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 4.637 μM |
| dbacp06689 | Crabrolin-FR | RLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 31.51 μM |
| dbacp06694 | Crabrolin-AR | RLPRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 41.31 μM |
| dbacp06699 | Crabrolin-PR | RLRRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | H-838 | Lung Cancer | IC50 = 32.32 μM |
| dbacp06723 | L14 | ALWKSILKNAGKALNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-838 | Lung Cancer | IC50 = 64.4 µM |
| dbacp06724 | L14 | ALWKSILKNAGKALNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 20.1 µM |
| dbacp06725 | 14V | ALWKSILKNAGKAVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-838 | Lung Cancer | IC50 = 7.0 µM |
| dbacp06726 | 14V | ALWKSILKNAGKAVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 4.1 µM |
| dbacp06727 | 14G | ALWKSILKNAGKAGLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-838 | Lung Cancer | IC50 = 48.7 µM |
| dbacp06728 | 14G | ALWKSILKNAGKAGLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 31.7 µM |
| dbacp06729 | L2V | ALWKSILKNVGKVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-838 | Lung Cancer | IC50 = 2.2 µM |
| dbacp06730 | L2V | ALWKSILKNVGKVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 0.6 µM |
| dbacp06731 | 14V5K | ALWKKILKNAGKAVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-838 | Lung Cancer | IC50 = 8.1 µM |
| dbacp06732 | 14V5K | ALWKKILKNAGKAVLNEINQIVQ | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 6.1 µM |
| dbacp06733 | 14VL23 | ALWKSILKNAGKAVLNEINQIV | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-838 | Lung Cancer | IC50 = 5.7 µM |
| dbacp06734 | 14VL23 | ALWKSILKNAGKAVLNEINQIV | Dermaseptin-SS1- Analog | Membrane Permeabilization | MTT assay | H-460 | Lung Cancer | IC50 = 16.4 µM |
| dbacp06748 | M1-20 | grrrqrrkkrlgpfsidllikslsdnmtdl | Synthetic | Inhibits FOXM1 transcriptional activities | CCK-8 assay | A-549 | Lung Cancer | IC50 = 32.47 µM |
| dbacp06749 | mPNC-NLS | QETFSDLWKLLVQRKRQKLMP | Synthetic | p53-mediated apoptosis | MTT assay | A-549 | Lung Cancer | IC50 = 44.9 μM |
| dbacp06751 | mPNC-NLS | QETFSDLWKLLVQRKRQKLMP | Synthetic | p53-mediated apoptosis | Cytotoxicity assay | A-549 | Lung Cancer | IC50 = 45 μM |
| dbacp06768 | M1-21 | rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF | Synthetic | FOXM1 inhibitor | Cell Viability assay | A-549 | Lung Cancer | IC50 = 22.00 µM |
| dbacp06775 | PMAP-NC | RIIDRLWLVRRPQKPKFVLVWVL | Synthetic Analgog of PMAP-24 | Membrane permeabilization | MTT assay | A-549 | Lung Cancer | IC50 = 7.1 μM |
| dbacp06776 | MP1-Q12K | IDWKKLLDAAKLIL | Analog of Polybia MP1 | Not available | MTT assay | A-549 | Lung Cancer | IC50 = 12.5 μM |
| dbacp06798 | Test peptide | YSFGL | Neuropep Peptide | Not available | MTT assay | A-549 | Lung Cancer | IC50 = 26.417±0.660 µM |
| dbacp06799 | Test peptide | YSFGL | Neuropep Peptide | Not available | MTT assay | MDA-MB-231 | Lung Cancer | IC50 = 39.047±0.770 µM |
| dbacp06801 | A11 | EYVQTVKSSKG | Annexin A1 | Targeting PD-L2 | Biotin Pull Down assay | H-460 | Lung Cancer | Not Available |
| dbacp06859 | ALA-A2 | KLWCKSSQVPQSR | Alpha-Lactalbumin | Not available | MTT assay | A-549 | Lung Cancer | ~50% cell viability |
| dbacp06903 | CIGB-300 | GRKKRRQRRRPPQ-X-CWMSPRHLGTC | Synthetic | Cell Penetration | Crystal Violet assay | NCI-H-460 | Lung Cancer | IC50 = 30 ± 5.3 µM |
| dbacp06912 | mtp1 | DGDWDAWTRETS | Synthetic | Disrupts transcription | MTS assay | A-549 | Lung Cancer | 17.4% decrease in cell viability at 10 μM |
| dbacp06913 | AC-P19M | FAKKLAKLKKKLAKLAKKR | Synthetic analogue of AC-P19 | Inhibition of cell signalling | WST-8 assay | A-549 | Lung Cancer | IC50 = 9.84 µM |
| dbacp06914 | AC-P19M | FAKKLAKLKKKLAKLAKKR | Synthetic analogue of AC-P19 | Inhibition of cell signalling | WST-8 assay | H-460 | Lung Cancer | IC50 = 6.29 µM |
| dbacp06915 | AC-P19 | FAKKLAKLKKKLAKLALAL | Synthetic | Inhibition of cell signalling | WST-8 assay | A-549 | Lung Cancer | IC50 = 52.14 µM |
| dbacp06916 | AC-P19 | FAKKLAKLKKKLAKLALAL | Synthetic | Inhibition of cell signalling | WST-8 assay | H-460 | Lung Cancer | IC50 = 49.08 µM |
| dbacp06920 | HAZ | GVKFAKRFWRFAKKAFKRFEK | Synthetic | Cell membrane destabilization | MTT assay | A-549 | Lung Cancer | IC50 = 5.44 μM |
| dbacp06921 | Ocellatin-3N | GIFDVLKNLAKGVITSLAS | Leptodactylus nesiotus | Not available | CellTiter-Glo assay | A-549 | Lung Cancer | LC50 = 35 ± 1 μM |
| dbacp06942 | HTDT-6-2-3-2 | GPLGAGP | Enteromorpha prolifera | Apoptosis inducing | CCK-8 assay | NCI-H-460 | Lung Cancer | IC50 = 0.3686 ± 0.0935 mg/mL |
| dbacp06944 | HTDT-6-2-3-2 | GPLGAGP | Enteromorpha prolifera | Apoptosis inducing | CCK-8 assay | A-549 | Lung Cancer | IC50 = 0.9867 ± 0.0857 mg/mL |
| dbacp06979 | GV1001 | EARPALLTSRLRFIPK | Human telomerase reverse transcriptase (hTERT) | Inhibition of angiogenesis | Cell Viability assay | A-549 | Lung Cancer | Graph Fig 2A |
| dbacp06980 | Ponericin-W1 (11-25), At1 | KLLPSVVGLFKKKKQ | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 > 100 µM |
| dbacp06982 | Ponericin-W1 (11-25) [P4K | KLLKKVVKLFKKKKK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 >100 µM |
| dbacp06984 | Ponericin-W1 (11-25) [P4K | KLLKKVVKLFKKLLK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 4.3 µM |
| dbacp06986 | At4 | KLLKKLLKLLKKLLK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 7.2 µM |
| dbacp06988 | At5 | KIIKKIIKIIKKIIK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 3.6 µM |
| dbacp06990 | At6 | KVVKKVVKVVKKVVK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 > 100 µM |
| dbacp06992 | At7 | KIIKKIKKKIKKIIK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 10.3 µM |
| dbacp06994 | At8 | KLLKKLKKKLKKLLK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 13.4 µM |
| dbacp06996 | At9 | KVVKKVKKKVKKVVK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 100 µM |
| dbacp06998 | At10 | IKKIIKIIKKIIKKI | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 4.4 µM |
| dbacp07000 | At11 | IIIKKIKKKIKKIII | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 7.9 µM |
| dbacp07002 | At12 | KIIIKIKKKIKIIIK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 14.0 µM |
| dbacp07010 | ST101 | vaeareelerlearlgqargelkkwkmrrnqfwlklqr | Synthetic | Prevents C/EBPβ dimerization, induces degradation | Annexin V/ PI staining assay | A-549 | Lung Cancer | mean EC50 value of 2.1 ± 0.4 μmol/L |
| dbacp07017 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 5.55 ± 0.13 μM |
| dbacp07018 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | H-358 | Non Small Cell Lung Cancer (NSCLC) | IC50 = 4.00 ± 0.20 μM |
| dbacp07019 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | H-1975 | Non Small Cell Lung Cancer (NSCLC) | IC50 between 4.0 and 5.5 μM |
| dbacp07020 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | HCC-827 | Lung Adenocarcinoma | IC50 between 4.0 and 5.5 μM |
| dbacp07025 | [G10a]-SHa | FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-549 | Lung Cancer | IC50 = 14.52 ± 1.44 µM |
| dbacp07032 | [G10a]2-SHa | FLSGIVGMLaKLFKFLKaLMFLSGIVG | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-549 | Lung Cancer | IC50 = 3.79 ± 1.61 µM |
| dbacp07039 | [G10a]3-SHa | FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-549 | Lung Cancer | IC50 = 3.74 ± 3.46 µM |
| dbacp07045 | Jeff-[G10a]2-SHa | FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-549 | Lung Cancer | IC50 = 70.71 ± 5.39 µM |
| dbacp07052 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 16.38 μM |
| dbacp07054 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 17.40 μM |
| dbacp07057 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 3.07 μM |
| dbacp07059 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 2.78 μM |
| dbacp07062 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 22.67 μM |
| dbacp07064 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 24.03 μM |
| dbacp07067 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 0.51 μM |
| dbacp07069 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 3.29 μM |
| dbacp07072 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 35.28 μM |
| dbacp07074 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 27.76 μM |
| dbacp07077 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 5.28 μM |
| dbacp07079 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 2.94 μM |
| dbacp07082 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 193.4 μM |
| dbacp07084 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 71.18 μM |
| dbacp07097 | K2F6K2 | KKFFFFFFKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 1146.23 ± 346.83 μg/mL |
| dbacp07098 | K3F6K3 | KKKFFFFFFKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 123.10 ± 35.19 μg/mL |
| dbacp07099 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 62.64 ± 9.55 μg/mL |
| dbacp07100 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | AnnexinV-FITC/PI double staining assay | A-549 | Lung Cancer | apoptotic cells (early and late) increased from 9.59 ± 1.00% to 43.03 ± 2.13% |
| dbacp07101 | K4F8K4 | KKKKFFFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 571.87 ± 66.23 μg/mL |
| dbacp07102 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | H-460 | Lung Cancer | IC50 = 6.27 µM |
| dbacp07107 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | H-157 | Non-small cell lung cancer | IC50 = 24 μM |
| dbacp07116 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | A-549 | Lung Cancer | IC50 = 6.99 ± 0.63 µg/ml |
| dbacp07121 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | A-549 | Lung Cancer | IC50 = 4.92 ± 0.84 µg/ml |
| dbacp07244 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | NF-κB inhibition enhances cisplatin synergy | Sulforhodamine B assay | NCI-H-460 | Lung Cancer | IC50 = 287.9 μM |
| dbacp07245 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | NF-κB inhibition enhances cisplatin synergy | Sulforhodamine B assay | A-549 | Lung Cancer | IC50 = 44.6 μM |
| dbacp07260 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 10.11 μM |
| dbacp07261 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 6.143 μM |
| dbacp07264 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 1.796 μM |
| dbacp07265 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 1.546 μM |
| dbacp07268 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 186.1 μM |
| dbacp07269 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 88.28 μM |
| dbacp07272 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-838 | Lung Cancer | IC50 = 180.8 μM |
| dbacp07273 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | H-157 | Lung Cancer | IC50 = 427.3 μM |
| dbacp07312 | B1OS-L | FLPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | H-838 | Lung Cancer | IC50 = 3.976 µM |
| dbacp07317 | B1OS-D-L | FlPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | H-838 | Lung Cancer | IC50 = 2.553 µM |
| dbacp07336 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | NCI-H23 | Lung Cancer | IC50 = 4.96 ± 0.94 μM |
| dbacp07337 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | H-157 | Lung Cancer | IC50 = 15.18 ± 2.98 μM |
| dbacp07338 | Temporin-HLa | FFPLIFGALSSILPKIL | Hylarana latouchii | Membrane disruption | MTT assay | H-460 | Lung Cancer | IC50 = 1.64 ± 0.41 μM |
| dbacp07339 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | A-549 | Lung Cancer | IC50 = 4.5 µM |
| dbacp07362 | Pal-N-Ter-TAT | Pal-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ | Analogue of N-terminal fragment of the VDAC1 protein | Mitochondrial targeting, VDAC1-HKII dissociation | MTT assay | A-549 | Lung Cancer | IC50 = 44.98 μM |
| dbacp07369 | Piscidin 3 | FIHHIFRGIVHAGRSIGRFLTG | Morone chrysops x Morone saxatilis | Cu²⁺-mediated membrane lipid oxidation | MTT assay | A-549 | Lung Cancer | IC50 = 21.6 µM |
| dbacp07370 | Piscidin 3 | FIHHIFRGIVHAGRSIGRFLTG | Morone chrysops x Morone saxatilis | Cu²⁺-mediated membrane lipid oxidation | MTT assay | A-549 | Lung Cancer | IC50 = 2.99 µM |
| dbacp07375 | Brevinin-2DYd | GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC | Rana dybowskii | Not Available | MTT assay | A-549 | Lung Cancer | IC50 = 2.975 µg/ml |
| dbacp07379 | Ranatuerin-2Lb | GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC | Rana luteiventris | Not Available | MTT assay | A-549 | Lung Cancer | IC50 = 15.32 µM |
| dbacp07383 | Odorranain-C1 | GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC | Odorrana grahami | Not Available | MTT assay | A-549 | Lung Cancer | IC50 = 27.31 µM |
| dbacp07387 | Brevinin-2DYb | GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC | Rana dybowskii | Not Available | MTT assay | A-549 | Lung Cancer | IC50 = 24.01 µM |
| dbacp07391 | Ranatuerin-2 | GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP | Rana catesbeiana | Not Available | MTT assay | A-549 | Lung Cancer | IC50 > 128 µM |
| dbacp07395 | 17BIPHE2 | GBKRLVQRLKDBLRNLV | Derivative of LL-37 | ERK-mediated apoptosis and mitochondrial disruption | MTT assay | A-549 | Lung Cancer | IC50 = 34.33 µmol |
| dbacp07396 | 17BIPHE2 | GBKRLVQRLKDBLRNLV | Derivative of LL-37 | ERK-mediated apoptosis and mitochondrial disruption | MTT assay | NCI-H-1975 | Lung Cancer | IC50 = 71.42 µmol/L |
| dbacp07402 | Pep | GKLRLIKKLWVKKWKKKGWKA | Synthetic | Membrane disruption induces necrotic death | MTT assay | A-549 | Lung Cancer | IC50 = 4 µM |
| dbacp07409 | Dermaseptin-TO | ALWKDLLKNVGIAAGKAALNKVTDMVNQ | Phyllomedusa tomopterna | Membrane disruption induces cell death | MTT assay | H-157 | Lung Cancer | Graph Figure-7 |
| dbacp07438 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 16.37 µM |
| dbacp07442 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 30.19 µM |
| dbacp07446 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 9.899 µM |
| dbacp07450 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 10.51 µM |
| dbacp07454 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 12.11 µM |
| dbacp07458 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 12.55 µM |
| dbacp07462 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 12.48 µM |
| dbacp07466 | Tachyplesin | KWCFRVCYRGICYIRRCR | Horseshoe crab | Fas activation drives apoptosis/necroptosis | MTT assay | A-549 | Lung Cancer | IC50 = 35 µg/ml |
| dbacp07467 | Tachyplesin | KWCFRVCYRGICYIRRCR | Horseshoe crab | Fas activation drives apoptosis/necroptosis | MTT assay | H-460 | Lung Cancer | IC50 = 25 µg/ml |
| dbacp07503 | Brevinin-1Ha | FALGAVTCLIRTKCKVLPKLF | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | H-157 | Lung Cancer | IC50 = 278.9 µM |
| dbacp07507 | Brevinin-1HY | FALGAVTKVLYKLFCLITRKC | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | H-157 | Lung Cancer | IC50 = 2.811 µM |
| dbacp07512 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | H-157 | Lung Cancer | IC50 = 1.55 μM |
| dbacp07516 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | LDH leakage assay | H-157 | Lung Cancer | 80% LDH release at 10−4 M |
| dbacp07517 | LL-37 Analogue 2 | LKRIVQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 33.7 µg/mL |
| dbacp07518 | LL-37 Analogue 3 | AKRIVQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 29.8 µg/mL |
| dbacp07519 | LL-37 Analogue 4 | FΚRIVQRILDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 3.9 µg/mL |
| dbacp07520 | LL-37 Analogue 5 | FKSARIVQRILDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 10.7 µg/mL |
| dbacp07521 | LL-37 Analogue 6 | FKRIVQRIRDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 56 µg/mL |
| dbacp07522 | LL-37 Analogue 7 | FKRIVQRIRDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 12.5 µg/mL |
| dbacp07523 | LL-37 Analogue 8 | FKRIVQKIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 145 µg/mL |
| dbacp07524 | LL-37 Analogue 9 | FKRIVQLIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 18.9 µg/mL |
| dbacp07525 | LL-37 Analogue 10 | FKRIVQLIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 13.9 µg/mL |
| dbacp07526 | LL-37 Analogue 11 | FKRIVQRIKDLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 75 µg/mL |
| dbacp07527 | LL-37 Analogue 12 | FKRIVQRIKDLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 45.5 µg/mL |
| dbacp07528 | LL-37 Analogue 13 | FKRIVQIIKKFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 20.0 µg/mL |
| dbacp07529 | LL-37 Analogue 14 | FKRIVQIIKKFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 12.9 µg/mL |
| dbacp07530 | LL-37 Analogue 15 | FKRIVQLLKKLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 12.8 µg/mL |
| dbacp07531 | LL-37 Analogue 16 | FKRIVQLLKKLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 9.8 µg/mL |
| dbacp07532 | LL-37 Analogue 17 | FKRILQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 19.2 µg/mL |
| dbacp07533 | LL-37 Analogue 18 | FKRILQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 29.2 µg/mL |
| dbacp07550 | NMANF2 | KAIGLVIPEIDGKLDGGAQRV | Staphylococcus hominis strain MANF2 | GAPDH-like protein disrupts survival | MTT assay | A-549 | Lung Cancer | IC50 = 46.6 µg/mL |
| dbacp07644 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | H-460 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07645 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | H-292 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07646 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | NCI-H23 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07681 | Longicalycinin A | FYPFG | Dianthus superbus | Cyclization enhances apoptosis via lysosomes | MTT assay | DLA cell line | Lung Cancer | CTC50 = 2.62 µM |
| dbacp07851 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | H-157 | Lung Cancer | IC50 = 25.51 µM |
| dbacp07856 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | H-157 | Lung Cancer | IC50 = 9.88 µM |
| dbacp07860 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | A-549 | Lung Cancer | Not Available |
| dbacp07866 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | A-549 | Lung Cancer | IC50 = 9.6 ± 0.3 µM |
| dbacp07867 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | H-460 | Lung Cancer | IC50 = 8.5 ± 0.4 µM |
| dbacp07868 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | H-1437 | Lung Cancer | IC50 = 13.0 ± 0.2 µM |
| dbacp07872 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | A-549 | Lung Cancer | IC50 = 7.0 ± 0.3 µM |
| dbacp07873 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | H-460 | Lung Cancer | IC50 = 4.9 ± 0.9 µM |
| dbacp07874 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | H-1437 | Lung Cancer | IC50 = 5.3 ± 0.2 µM |
| dbacp07877 | Fi-Histin1-21 | SRSSRAGLQFPVGRIHRLLRK | Fenneropenaeus indicus | Membrane disruption and DNA binding | XTT assay | NCI-H-460 | Lung Cancer | IC50 = 22.670 ± 13.939 μM |
| dbacp07889 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.62 ± 0.12 μM |
| dbacp07892 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.62 ± 0.12 μM |
| dbacp07895 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.89 ± 0.21 μM |
| dbacp07898 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 3.26 ± 0.36 μM |
| dbacp07901 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 2.10 ± 0.32 μM |
| dbacp07904 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 1.00 ± 0.36 μM |
| dbacp07907 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.96 ± 0.33 μM |
| dbacp07910 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 1.85 ± 0.31 μM |
| dbacp07913 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 2.26 ± 0.24 μM |
| dbacp07916 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 3.59 ± 0.12 μM |
| dbacp07919 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 7.35 ± 0.22 μM |
| dbacp07922 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 4.26 ± 0.52 μM |
| dbacp07927 | Phylloseptin-PBa3 | FLSLIPHIVSGVAALANHL | Phyllomedusa burmeisteri | Membrane disruption, apoptosis, selective cytotoxicity | MTT assay | H-838 | Lung Cancer | Cell viability ~ 65% at 10-5 M |
| dbacp07952 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | H-157 | Lung Cancer | IC50 = 58.18 µM |
| dbacp07956 | DP-2 | GRKKRRQRRRGALWKSLLKNVGKA | Synthetic | DRS-DU-1 induces selective tumor cytotoxicity | MTT assay | H-157 | Lung Cancer | IC50 = 3.21 μM |
| dbacp07985 | R-C16 | RGWFRAMRSIARFIARERLREHL | R-Lycosin-I | Fatty-acid modification enhances peptide apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 ~ 5 µM |
| dbacp07989 | K5, 17-DPS3 | ALWKKILKNAGKAALNKINQIVQ | Analogue of Dermaseptin-PS3 | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | H-157 | Lung Cancer | IC50 = 18.20 μM |
| dbacp07991 | L10, 11-DPS3 | ALWKDILKNLLKAALNEINQIVQ | Analogue of Dermaseptin-PS3 | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | H-157 | Lung Cancer | IC50 = 0.12 μM |
| dbacp07995 | [G10a]SHa | FLSGIVGMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 =24.3 ± 0.8 µM |
| dbacp07998 | [G10a]SHa-BCTP | FLSGIVGMLaKLFLFKQYAELW | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08001 | [G4a]SHa | FLSaIVGMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08004 | [G7a]SHa | FLSGIVaMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08007 | [G4,7a]SHa | FLSaIVaMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 = 37.3 ± 3.5 µM |
| dbacp08010 | [G4,7,10a]SHa | FLSaIVaMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08013 | [G7,10a]SHa | FLSGIVaMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | NCI-H-460 | Lung Cancer | IC50 >100 µM |
| dbacp08015 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 11.9 μM |
| dbacp08016 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | H-460 | Lung Cancer | IC50 = 5.19 μM |
| dbacp08017 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | PG-BE1 | Lung Cancer | IC50 = 31.3 μM |
| dbacp08038 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | A-549 | Lung Cancer | IC50 = 9.921 ± 0.82 mg/ml |
| dbacp08039 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | H-460 | Lung Cancer | IC50 = 9.083 ± 1.22 mg/ml |
| dbacp08042 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | PC-9 | Lung Cancer | IC50 = 7.921 ± 1.19 mg/ml |
| dbacp08058 | TAT-327 | RKKRRQRRREFLDCFQKF | Peptide-327 | Peptide 327 blocks Eps8–EGFR | CCK-8 assay | A-549 | Lung Cancer | EC50 = 55.42 ± 0.84 μM |
| dbacp08064 | Temporin-PE | FLPIVAKLLSGLL | Pelophylax kl. esculentus | Modulates membrane interactions | MTT assay | NCI-H-157 | Lung Cancer | IC50 = 34.56 μM |
| dbacp08068 | temporin-PEa | FLYIVAKLLSGLL | Synthetic analog of Temporin-PE | Modulates membrane interactions | MTT assay | NCI-H-157 | Lung Cancer | IC50 = 3.398 μM |
| dbacp08072 | temporin-PEb | FLPIVAKLLSGLLGRKKRRQRRR | Synthetic analog of Temporin-PE | Modulates membrane interactions | MTT assay | NCI-H-157 | Lung Cancer | IC50 = 3.464 μM |
| dbacp08083 | Peptide 3a | YD | Synthetic | Inhibit COX-2 enzyme | MTT assay | A-549 | Lung Cancer | IC50 = 5.7 ± 0.04 µM |
| dbacp08085 | Peptide 3b | YD | Synthetic | Inhibit COX-2 enzyme | MTT assay | A-549 | Lung Cancer | IC50 = 5.8 ± 0.02 µM |
| dbacp08088 | PTP-7S | EENFLGALFKALSKLL | PTP-7 | Not Available | MTT assay | A-549 | Lung Cancer | 65% cell viability at 10 µΜ |
| dbacp08142 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | H-1299 | Lung Cancer | 80% cytotoxicity 10 μM concentration |
| dbacp08178 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | A-549 | Lung Cancer | Not Available |
| dbacp08179 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | NCI-H69 | Lung Cancer | Not Available |
| dbacp08265 | HR | HVLSRAPR | Fraction identified from Tr1 | Not Available | MTT assay | A-549 | Lung Cancer | 15% inhibition at 500 μg/mL |
| dbacp08303 | ATRA1-R3W2 - HYD | RRWKRFFKRWKGGVIGVTFPF | Synthetic | Not Available | Cytotoxicity assay | H-358 | Lung Cancer | LD50 ~24.5 μM |
| dbacp08305 | MAD1 | KRWHWWRRHWVVW | Synthetic | Not Available | MTT assay | A-549 | Lung Cancer | IC50 = 36.2 μM |
| dbacp08307 | DAP1 | LWKRWVGVWRKWL | Synthetic | Not Available | MTT assay | A-549 | Lung Cancer | IC50 = 11.9 μM |
| dbacp08320 | Sample Peptide 2 from US011339203B2 | FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | NCI-H2444 | Lung Cancer | Cell Viability = 0.6% at 25 μM |
| dbacp08321 | Sample Peptide 2 from US011339203B2 | FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | A-549 | Lung Cancer | Cell Viability = 1.4% at 25 μM |
| dbacp08327 | Sample Peptide 1 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | NCI-H2444 | Lung Cancer | Cell Viability = 6.8% at 25 μM |
| dbacp08328 | Sample Peptide 1 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | HCC-827 | Lung Cancer | Cell Viability = 11.8% at 25 μM |
| dbacp08329 | Sample Peptide 1 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | NCI-H446 | Lung Cancer | Cell Viability = 0.5% at 25 μM |
| dbacp08332 | Sample Peptide 2 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRRKKRRQRRR | Synthetic | Not Available | CCK-8 / WST-8 | NCI-H2444 | Lung Cancer | Cell Viability = 3.6% at 25 μM |
| dbacp08333 | Sample Peptide 2 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRRKKRRQRRR | Synthetic | Not Available | CCK-8 / WST-8 | HCC-827 | Lung Cancer | Cell Viability = 4.9% at 25 μM |
| dbacp08334 | Sample Peptide 2 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRRKKRRQRRR | Synthetic | Not Available | CCK-8 / WST-8 | A-549 | Lung Cancer | Cell Viability = 9.1% at 25 μM |
| dbacp08335 | Sample Peptide 3 from EP3604345B1 | MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | NCI-H2444 | Lung Cancer | Cell Viability = 87.7% at 25 μM |
| dbacp08336 | Sample Peptide 3 from EP3604345B1 | MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | HCC-827 | Lung Cancer | Cell Viability = 120.6% at 25 μM |
| dbacp08337 | Sample Peptide 3 from EP3604345B1 | MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | NCI-H446 | Lung Cancer | Cell Viability = 56.7% at 25 μM |
| dbacp08340 | Sample Peptide 4 from EP3604345B1 | PWWWPPVVVQQQMILLIGAARKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | HCC-827 | Lung Cancer | Cell Viability = 102.6% at 25 μM |
| dbacp08341 | Sample Peptide 5 from EP3604345B1 | KKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | HCC-827 | Lung Cancer | Cell Viability = 106.5% at 25 μM |
| dbacp08343 | Phakellistatin 18 | PIPYPIF | Marine Sponge Phakellia fusca | Not Available | Cytotoxicity assay | A-549 | Lung Cancer | IC50 = 72.42 µM |
| dbacp08345 | P18-1 | PIPYPIF | Analogue of Phakellistatin 18 | Not Available | Cytotoxicity assay | A-549 | Lung Cancer | IC50 = 67.53 µM |
| dbacp08347 | P18-2 | PIPRPIF | Analogue of Phakellistatin 18 | Not Available | Cytotoxicity assay | A-549 | Lung Cancer | IC50 = 79.71 µM |
| dbacp08351 | Seq ID No. 15 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVTSVIK | Synthetic | Not Available | Tetrazolium-based assay | HOP-062 | Lung Cancer | Cell viability ~ 50% at 20 μM |
| dbacp08352 | Seq ID No. 15 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVTSVIK | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability < 25% at 20 μM |
| dbacp08353 | Seq ID No. 15 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVTSVIK | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability < 50% at 20 μM |
| dbacp08354 | Seq ID No. 16 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKSVIK | Synthetic | Not Available | Tetrazolium-based assay | HOP-062 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08355 | Seq ID No. 16 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKSVIK | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08356 | Seq ID No. 16 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKSVIK | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08357 | Seq ID No. 17 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKKVIK | Synthetic | Not Available | Tetrazolium-based assay | HOP-062 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08358 | Seq ID No. 17 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKKVIK | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08359 | Seq ID No. 17 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKKVIK | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08360 | Seq ID No. 26 from patent ID US202000079827A1 | RRWVRRVRRVWRRVVRVVRRWVRR | Synthetic | Not Available | Tetrazolium-based assay | H-460 | Lung Cancer | Cell viability < 50% at 20 μM |
| dbacp08361 | Seq ID No. 26 from patent ID US202000079827A1 | RRWVRRVRRVWRRVVRVVRRWVRR | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08362 | Seq ID No. 34 from patent ID US202000079827A1 | RRWvRRvRRvWRRvvRvvRRWvRR | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability < 25% at 20 μM |
| dbacp08363 | Seq ID No. 34 from patent ID US202000079827A1 | RRWvRRvRRvWRRvvRvvRRWvRR | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08372 | IDP-NS02 | RQRRNDLRSSFLTLRDH | Synthetic | Not Available | AlamarBlue assay | NCI-H524 | Lung Cancer | EC50 ~ 5 μM |
| dbacp08390 | IDP-LLCb01 | RRRRRRRSKAPKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 5 μM |
| dbacp08391 | IDP-LLCb01 | RRRRRRRSKAPKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 2.5 μM |
| dbacp08392 | IDP-LLCb01 | RRRRRRRSKAPKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 5 μM |
| dbacp08393 | IDP-LLCb02 | RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 7.5 μM |
| dbacp08394 | IDP-LLCb02 | RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 10 μM |
| dbacp08395 | IDP-LLCb02 | RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 15 μM |
| dbacp08396 | IDP-Lb01 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 22.5 μM |
| dbacp08397 | IDP-Lb01 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 12.5 μM |
| dbacp08398 | IDP-Lb01 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 22.5 μM |
| dbacp08399 | IDP-Lb02 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 22.5 μM |
| dbacp08400 | IDP-Lb02 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 7.5 μM |
| dbacp08401 | IDP-Lb02 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 15 μM |
| dbacp08402 | IDP-Lb03 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 22.5 μM |
| dbacp08403 | IDP-Lb03 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 5 μM |
| dbacp08404 | IDP-Lb03 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 15 μM |
| dbacp08405 | IDP-Lb04 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 > 30 μM |
| dbacp08406 | IDP-Lb04 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 12.5 μM |
| dbacp08407 | IDP-Lb04 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 > 30 μM |
| dbacp08408 | IDP-Lb05 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 10 μM |
| dbacp08409 | IDP-Lb05 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 7.5 μM |
| dbacp08410 | IDP-Lb05 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 12.5 μM |
| dbacp08411 | IDP-Lb06 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 12.5 μM |
| dbacp08412 | IDP-Lb06 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 7.5 μM |
| dbacp08413 | IDP-Lb06 | SKAPKVVILSKALEYL | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 12.5 μM |
| dbacp08414 | IDP-La05 | RRNDLRSRFLALRDQVP | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H187 | Lung Cancer | EC50 ~ 22.5 μM |
| dbacp08415 | IDP-La05 | RRNDLRSRFLALRDQVP | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H82 | Lung Cancer | EC50 ~ 15 μM |
| dbacp08416 | IDP-La05 | RRNDLRSRFLALRDQVP | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | NCl-H510A | Lung Cancer | EC50 ~ 10 μM |
| dbacp08433 | Alpha-gliadin peptide p31-43 | LGQQQPFPPQQPY | Synthetic | Not Available | MTT assay | A-549 | Lung Cancer | 9.4% growth inhibition at 70 μg/mL |
| dbacp08434 | Alpha-gliadin peptide p31-43 | LGQQQPFPPQQPY | Synthetic | Not Available | MTT assay | NCI-H1975 | Lung Cancer | 36.3% growth inhibition at 70 μg/mL |
| dbacp08436 | Alpha-gliadin peptide p31-43 | LGQQQPFPPQQPY | Synthetic | Not Available | TUNEL assay | A-549 | Lung Cancer | Mean apoptotic rate = 36% at 200 μg/mL |